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Viral encephalitis is a serious and important human and animal health problem, as
exemplified by West Nile encephalitis and HIV-related dementia. There is a need
for better understanding of the pathogenesis of virus encephalitis. Experimentally,
Semliki Forest virus (SFV) is an excellent mouse model of viral encephalitis and
virus-induced demyelination. SFV is an alphavirus of the Togaviridae. In mice it is
neuroinvasive and neurotropic. Following infection of susceptible mouse strains,
clearance of infectious brain virus is coincident with inflammatory cell infiltration
and is followed by demyelination. There is some existing evidence to suggest that
CNS demyelination observed following SFV infection has an immune aetiology and
based on transient depletion studies that CD8+ T-cells are likely to be the main
effectors of this.
This thesis examines the role of acquired immune responses in SFV encephalitis.
The role of components of the acquired immune response in mediating clearance of
infectious virus and virus RNA and in the pathogenesis of demyelination was
examined using mice with genetic deletions affecting components of acquired
immune responses. This included mice deficient in CD4+ and CD8+ T-cell responses
and in specific T-cell mediators IFNy, perforin and Fas. Infectious virus was
determined by plaque assay, the presence of virus RNA by quantitative, real-time
PCR and the neuropathology by standard histopathology and immunohistochemistry.
Analysis of inflammatory infiltrates in the SFV infected CNS demonstrated a rapid
influx of macrophages and NK cells and a >40-fold increase in T-lymphocytes,
predominantly CD8+ cells. Mice lacking CD8+ T-cells showed no difference in their
ability to clear infectious virus from the brain, but had a slower clearance of virus
RNA. Adoptive transfer of CD8+ T-cells to SFV infected SCID mice demonstrated
that CD8+ T-cells mediated the demyelinating lesions. Mice lacking CD4+ T-cells
were unable to generate good antibody responses and were unable to clear infectious
virus. Transfer of anti-SFV hyperimmune (HI) serum to SFV infected SCID mice
lowered virus RNA to levels comparable to those in immunocompetent (BALB/c)
mice. However, antibody alone was not sufficient to eliminate virus RNA and
infectious virus reappeared once antibody levels dropped.
IFNyR"7" mice were found to have slower clearance of virus RNA compared to wild-
type mice but IFNy was not necessary for the development of demyelinating lesions.
A protective role for IFNy was demonstrated in SFV infection; recombinant IFNy
transiently protected SFV infected IFNa/pR"7" mice. Neither perforin nor Fas was
necessary for clearance of infectious virus or viral RNA. SFV infected Fas knock¬
out mice had increased CNS demyelination.
In summary this thesis demonstrates that in SFV infection, CD8+ T-cells are the main
component of the CNS inflammatory response; CD8+ T-cells mediate the lesions of
demyelination; clearance of infectious virus is mediated by antibody but antibody
alone is insufficient to clear all virus RNA; CD8+ T-cells and the IFN-y system
contribute to the elimination of virus RNA. It is likely that both antibody and CD8+
T-cells are required to eliminate SFV infection.
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Chapter 1 Introduction 2
Acquired Immune Response to SFV
Introduction
Semliki Forest virus infection ofmice offers a laboratory model of central nervous
system (CNS) virus infection allowing study ofCNS immune responses. This thesis
examines the role of acquired immune responses in the clearance of SFV and in the
pathogenesis of the neuropathological changes observed following SFV infection.
This chapter will introduce the biology of SFV and alphaviruses, before setting out
the components of the anti-viral immune response. The relatively inaccessible CNS
is targeted by a number of infectious agents, but not always successfully. The CNS
has a variety of immune mechanisms to counter such infections, the mechanisms and
limitations of these defence mechanisms will be discussed. Persistence of viral
infection is a complicated topic, and this chapter sets out to define what is meant by
persistence. A number of viral infections in mice result in CNS persistence. The
issues involved in this will be examined.
Finally, the pathogenesis of SFV will be discussed, especially the known roles of
different components of the immune in clearing SFV from the CNS and in inducing
CNS pathology.
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Alphaviruses
SFV is a member of the genus Alphavirus, which is grouped into 6 antigenic
complexes based on amino acid sequence (Table 1). These 6 complexes share about
45% amino acid identity in divergent structural proteins and about 60% in the more
conserved non-structural proteins (Figure 1). SFV is most closely related to
Chikungunya and Mayaro alphaviruses (Table 1). Alphaviruses have a worldwide
and geographically distinct distribution. SFV is found naturally in sub-Saharan
Africa and is spread by mosquitoes, aides africanns and aides aegypti. The original
isolate was found in the aides abnormalis mosquitoes in the Semliki forest in
Uganda, from which it is named (Smithburn & Haddow, 1944).
The Alphavirus' natural cycle is between mosquitoes and birds or small mammals.
The infection of humans and larger mammals, which does occur and can lead to
severe and fatal disease, is outside the usual transmission cycle of these viruses. The
vertebrate host for SFV is unknown, but infections have been reported in horses,
monkeys and man. SFV was associated with an epidemic of equine encephalitis in
Senegal and death of a laboratory worker was associated with SFV infection; SFV
was isolated from the cerebrospinal fluid (CSF). However, it is unclear if SFV was
the cause of death (Robin, 1974; Willems, 1979).
Other alphaviruses cause important health and economic problems. In the 1985
Venezuelan Equine encephalitis outbreak in Columbia, an estimated 50,000 horses
were infected and up to 8% may have died. More importantly there were an
estimated 75,000 humans infected with 300 fatalities (Rivas, 1997). More recently,
(2005-2006) a Chikungunya virus outbreak has been reported in islands of the Indian
Ocean and in India. It is estimated that over 200,000 people were infected. This
virus causes acute fever, prolonged fatigue and crippling arthritis (WHO, 2006).
SFV infection ofmice represents a model system of alphavirus infection that has
greatly contributed to our understanding of alphavirus pathogenesis and studies
continue to add to the body of knowledge concerning encephalitis and immune
response to CNS viruses.
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SFV Biology
SFV virions have a (+) RNA genome surrounded by an icosahedral capsid which is
enveloped by a lipid bilayer derived from the host cell. The outermost surface of the
virus is almost entirely covered by heterodimers of glycoproteins El and E2,
arranged in inter-connective trimers, which form an outer shell. The trimers are
anchored in the envelope by an E2 cytoplasmic domain that is associated with the
nucleocapsid. The (+) RNA genome is 11 -12 Kb in size with a poly-A tail and a 5'
cap. The 5' two thirds of the genome encode non-structural (ns) proteins and the
structural proteins are encoded in the 3' end (Figure 1).
The cell surface receptor for SFV is unknown. SFV is taken up into endocytic
vesicles. The fusion of the virion and endosome is mediated by the El glycoprotein
(Omar & Koblet, 1988). After fusion, the viral genome is released into the host
cell's cytoplasm and the virus genome (+) RNA functions as an mRNA. NS proteins
are translated as polyproteins. Replicase activity is associated with the ns
polyproteins. Replication occurs via a negative strand intermediate, giving rise to a
full length genomic RNA for incorporation into new virions. A subgenomic message
is translated to give the structural proteins. Envelope glycoproteins are transported to
the cell membrane where they associate with capsid proteins prior to virus budding.
A B
5' m
-fnsPI | nsP2 j nsP3 | nsP4 j—| Capsid j E2 |6K| E1 p
Figure 1. A - Electron microscope pictures of SFV; B - icosahedral reconstruction from cryo-
electron micrographs and C - structure of SFV genome (Mancini, 2000). ns - non-structural; E -
envelope.
Recent advances in biotechnology have seen the development of a virus based
expression system of virus-like particles (VLPs). VLPs mimic virus structure but are
Chapter 1 Introduction 6
Acquired Immune Response to SFV
non-infectious and can express foreign genes. The SFV genome has been modified
to produce this system. The benefit of these viral vectors is that they retain their
natural tropism while allowing a high and transient level of foreign gene expression.
Possible applications of this technology include vaccines, cancer therapy and gene
therapy. VLPs are generated by the co-transfection of cells with three plasmids.
The first codes for SFV replicase and a foreign gene of interest, the second for the
SFV capsid protein and the third for the SFV envelope protein (Smerdou &
Liljestrom, 1999). VLPs are identical to SFV particles, except in their RNA content,
which only contains the replicase gene, linked to the foreign gene transcript. The use
ofVLP encoding green fluorescent protein (GFP) allows the visualisation of infected
cells without the need for immunostaining (Fazakerley, 2006).
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Innate Immune Response
Cytokines
Cytokines are soluble mediators secreted from cells that act in an autocrine and
paracrine manner to increase or decrease expression of membrane proteins (including
cytokine receptors) and induce cellular proliferation and secretion of effector
molecules. The actions of cytokines serve to control infection and induce, sustain or
decrease an inflammatory response and cytokines have both protective and
pathogenic potential (Stoll, 2000). Local production of cytokines has a pivotal
influence on early immune responses. T-cells and macrophages are major producers
of cytokines. Cytokines can be classified based on structural homology, however, it
is more useful to group them based on their effects, such as pro-inflammatory
(interferon y, TNFa, IL-12 and IL-1) and anti-inflammatory (IL-10 and transforming
growth factor [TGF]-(3).
Type I interferons
Type I interferons (IFNs) are cytokines first discovered in the cellular response to
viruses and are the first line of antiviral defence (Isaacs & Lindenmann, 1957). Type
I IFNs are induced by the presence of double stranded (ds) RNA, a required
intermediate ofRNA virus replication. Upon infection, dsRNA can activate cellular
sensors of infection including retinoic acid inducible gene I, melanoma
differentiation-associated gene-5, protein kinase (PK) R and toll-like receptor (TLR)
3. These cellular sensors activate transcription factors, such as nuclear factor (NF)-
kB, activating transcription factor-2 /c-jun and IFN regulatory factor (IRF)-3 through
phosphorylation cascades. These transcription factors bind to the IFN-(3 promoter,
inducing gene expression (Maniatis, 1998). Activated IRF-3 is also initiates
expression of IFN-a4 (Au, 1993) which with IFNp provides the initial wave of the
IFN response. Released IFNs act in both an autocrine and paracrine manner to
induce anti-viral mechanisms by binding to the type-I IFN receptor. Signal
transduction via the signal transducers and activators of transcription (STAT)
Chapter 1 Introduction 8
Acquired Immune Response to SFV
signalling pathway initiates transcription of hundreds of interferon-stimulated genes
including, 2'-5' oligoadenylate synthetase (OAS)/RNaseL which targets and
degrades ssRNA, thereby inhibiting viral replication and PKR, which leads to the
inhibition of protein synthesis (Der, 1998c).
There are many type I IFNs (a and (1 are main types) all of which bear structural
homology and bind a single IFN receptor. They are found on chromosome 9 in
humans and chromosome 4 in mice. There is only one type II IFN - gamma, which
signals through a type II receptor and is found on chromosome 12 in humans and 10
in mice. Type I and II were originally grouped together due to their ability to
interfere with viral infection (Isaacs & Lindenmann, 1957).
Chemokines
These glycoproteins are chemotactic cytokines and augment the immune response by
their potent activity as leukocyte chemoattractants in inflammatory responses and
also by inducing cellular chemotaxis, extravasation and adhesion molecule
expression. There are three subclasses, based on their expression of cysteine
residues; CXC chemokines - which predominantly recruit monocytes; CC chemokine
- which predominantly recruit neutrophils and C chemokine, lymphotactin, that
attracts T-cell precursors to the thymus.
Macrophages
Macrophages are long lived phagocytic cells that phagocytose infected cells, cellular
debris and pathogens. They effectively present antigen to T-cells as well as being an
important source of pro-inflammatory cytokines (IL-1, IL-6 and tumour necrosis
factor [TNF]-a) which can inhibit viral replication and affect the type of T-helper
response that develops (Laskin & Pendino, 1995). As well as releasing pro¬
inflammatory mediators that attract and activate other immune cells they also
produce reactive oxygen species such as hydrogen peroxide which have direct,
chemical anti-microbial functions. An uncontrolled pro-inflammatory macrophage
response has the potential to cause great tissue damage to the host.
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Natural Killer (NK) Cells
NK cells constitute a major component of the innate immune system that has a
crucial role in the early control ofmany virus infections. They are large, granular
lymphocytes with an activating receptor that recognises surface carbohydrate on
'altered cells' and inhibitory receptors that recognizes major histocompatibility
complex (MHC) class I alleles, thereby preventing attack of 'normal' cells.
NK cells are cytotoxic and granules in their cytoplasm contain the cytolytic protein
perforin and proteases known as granzymes, which are released onto target cells and
when endocytosed induce apoptosis. NK cells are activated in response to IFNs or
macrophage-derived cytokines. They serve to non-specifically contain viral
infections while the adaptive immune response is generating antigen-specific
cytotoxic T lymphocytes (CTLs) that can later clear the infection.
Acquired Immune Response
Along with initial clearance and early control of infection, the combined effects of
cytokines and chemokines of the innate immune response is to attract cells of the
specific immune response to the area of infection, increase antigen processing and
presentation and provide the cytokine environment to effect the differentiation of the
T-cell response.
T-cell Response
The T-cell response is comprised of two main subpopulations, CD4+ (helper) and
CD8+ (cytotoxic) T-cells. T-cells recognise antigen presented on cell-surface MHC
molecules. Therefore, T-cells can only detect virus taken up, processed and
presented by antigen presenting cells (APCs) or by an infected cell. CD4+ T-cells
recognise exogenous antigens presented on MHC class II molecules that are
expressed on dendritic cells (DCs), macrophages and B-cells. Upon activation they
secrete essential cytokines and bind cell surface ligands, activate B-cells, CD8+ T-
cells and induce immunoglobulin (Ig) class switching. CD8+T-cells have a strong
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anti-viral role, and recognise endogenous antigen, for example viral peptides, which
are presented in the groove of the MHC class I molecule (which are ubiquitously
expressed on almost all cells).
Helper cells contain two subsets; TH-1 cells that promote cell-mediated immunity
(secrete IFNy and TNFP) and TH-2 cells that promote antibody-mediated immunity
(secrete IL-4, 5, 10 and 13). CD4+ T-cells are essential for the majority of B-cell
responses and the development of B-cell memory (Gray, 1994). A CD8+ T-cell
primary response can develop without CD4+ T cells but the response does not last as
long and CD8^ T-cell recall (memory) is seriously impaired in mice lacking CD4+ T-
cells (Bourgeois 2003).
CD8+ T-cells can recognise early intracellular viral protein production before virus
budding occurs, allowing an early anti-viral response. When CTLs recognise an
infected cell they release lytic granules containing perforin and granzyme directly
onto the infected cell, inducing apoptosis. CD8+ T-cells can also induce cell death by
Fas ligation and can also control further virus infection by IFN-y and TNF-a
secretion.
IFN-y
IFN-y, the only type II interferon, is a potent anti-viral cytokine. IFNy receptors
(IFNyR) are expressed on most nucleated cells. In the CNS, glial and neuronal
expression of IFNyR has been demonstrated in separate studies (Rubio & de Felipe,
1991; Torres, 1995; Robertson, 2000). IFNy is secreted by activated NK cells, TH1
CD4+ cells and CD8^ T-cells, and is consequently expressed later in infection than
type I IFNs (Mokhtarian, 1996). Similarly to type I IFNs, IFNyR predominantly
signals through the STAT pathway which induces gene expression by STAT
homodimers, binding to IFNy activated sites (GAS) elements. Genes solely
upregulated by IFNy include those for class II transactivator (upregulates MHC
class-I and II) and proteins involved in antigen processing and presentation (Der,
1998b). The increased expression of these proteins serves to increase the speed of
the anti-viral response by more efficient presentation of pathogens. As well as its
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antiviral properties IFNy is an important pro-inflammatory role and is a potent
activator ofmacrophages and has a major role in the regulation of the T-helper cell
differentiation (summarised Figure 2).
Fas and Fas ligand
Fas and Fas ligand (FasL) are members of the TNF receptor and TNF families,
respectively. FasL, which is upregulated on CTLs, initiates apoptosis in the target
cell by binding to Fas. Fas is expressed on a variety of cell types, whereas FasL is
expressed predominantly on activated lymphocytes. Fas ligation by FasL initiates a
signalling cascade resulting in binding and activation of caspases. Caspases are a
group of cysteine proteases, enzymes with a crucial cysteine residue that can cleave
other proteins after an aspartic acid residue. Caspases are essential in cells for
apoptosis. Caspase activation eventually leads to DNA degradation, membrane
blebbing, and other hallmarks of apoptosis (summarised Figure 2). This receptor-
ligand pair also plays an important role in the homeostasis of the immune system
known as activation-induced cell death (AICD). AICD is mediated by upregulation
of FasL on activated T-cells which limits potentially damaging accumulation of
cytokine secreting activated T-cells after antigen elimination and also inactivates
potentially autoreactive cells. The importance of this interaction for the maintenance
of lymphocyte homeostasis is demonstrated in the generalized lymphoproliferative
disorder associated with natural loss-of-function mutations of Fas (Jpr) and its ligand
(gld). Mice homozygous for Ipr or gld mutation develop remarkably similar,
progressive non-malignant lymphoproliferative diseases characterized by severe
lymphadenopathy and an autoimmune disease similar to systemic lupus
erythematosus (Watanabe-Fukunaga, 1992; Takahashi, 1994). The importance of
Fas induced-apoptosis in the CTL response is not known, while FasL is expressed on
killer T-cells its role often seems redundant in the immune response to viruses (Kagi,
1995a; Murray, 1998a).
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Perforin and Granzyme
Perforin is secreted in a cytolytic granule with granzyme (A and B) from the CTL
and is then endocytosed by the target cell. The synergistic action of these effectors
activates an apoptotic cascade which eliminates the infected cell, summarised in
Figure 2 (Trapani & Smyth, 2002b). Perforin has a pore-forming capacity in lire cell
membrane, but this is not thought to be its mode of action, as sub-lytic quantities of
perforin increases granzyme delivery far more than other pore forming molecules.
The presence of perforin allows the granzymes to act on the target cell. Granzyme B
is a potent activator of caspase and of caspase independent apoptosis. It directly
activates pro-apoptotic protein which results in the leakage of proapoptotic
mitochondrial mediators (cytochrome C) into the cytosol (Sutton, 2000). Granzyme
A cannot activate caspases directly but mediates its action by direct cleavage of
nuclear proteins, thus facilitating the formation of ssDNA breaks (Beresford, 1999).
The actions of both granzymes are dependent on perforin, because perforin deficient
mice fail to kill virus infected cells in vivo (Kagi, 1995b).
T-regulatory cells
The concept of suppressor T-cells went out of fashion in the 1980s, however several
studies have found that T-cells can suppress immune responses in autoimmune
disorders, demonstrating unequivocally that these cells have a role in inhibiting
immune responses (Penhale, 1975; Fukuma, 1988; Powrie & Mason, 1990).
Furthermore, a role for T-regulatory (T-regs) cells was found in infectious diseases
such as Leishmania major infection (Belkaid, 2002). T-regulatory cells can be
divided into two subsets, firstly naturally occurring T-regs (CD4+CD25+FoxP3+),
which make up a subset of normal T-cells (5%). T-regs develop in the thymus and
when they recognise their MHC/antigen they mediate their action in a cell-contact
dependent manner (Baecher-Allan, 2001; Shevach, 2002). The second subset is
made of inducible T-regs (CD4+CD25+). These develop in response to cytokine
secretion (IL-10 or TGF-p) and then secrete these anti-inflammatory cytokines
(Groux, 1997b; Jonuleit, 2002). It is unclear whether these are a distinct subset from
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normal T-cells or if their suppressor activity represents a stage of development of
normal T-cells. T-regs have been found to play a role in some virus infections such
as hepatitis C and herpes simplex virus (HSV) infection (Rouse, 2006b).
Antibody Response
When a B-cell recognises the antigen for which it has specificity, antigen is taken up
by binding of cell surface immunoglobulin (Ig). Most B-cell antigens require that
the B-cell receives stimulation from a T-helper cell by antigen/MHC II presentation
on the surface of the B-cell. The T-cell provides cell-cell and cytokine signals that
allow B-cells to clonally expand and develop into antibody secreting plasma cells.
B-lymphocytes secrete soluble antibody into the blood and lymph. Antibody can
neutralise virus particles, so preventing binding or entry of the virus into cells, as
well as tagging viruses for phagocytosis by opsonisation. Antibodies bind to viral
antigen present on the host cell surface and can lead to the cell being lysed by the
classical complement pathway or being killed by natural killer cells (Guidotti &
Chisari, 2001).
Large IgM immunoglobulin molecules are produced early in the immune response.
Following class-switching other isotypes are then secreted that have different tissue
specific functions. IgG is the main immunoglobulin isotype elicited following virus
infection and importantly this smaller molecule can cross into the CNS during virus
infections as the permeability of the blood brain barrier (BBB) increases. This
feature allows IgG antibody to extend its actions to the immunospecialised brain
tissue (Parsons & Webb, 1982b; Coutelier, 1988a).
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CNS immune responses
The CNS has long been considered to be an immunoprivileged site. In health few
leukocytes, antigen presenting cells or antibodies are found there. There is also a
very low level ofMHC molecule expression in the normal CNS. Unlike the
peripheral structural lymphoid tissue such as lymph nodes, there is no lymphoid
architecture within the CNS. Along with this apparent lack of immune function,
tight endothelial cell junctions form the BBB which encloses the brain. The BBB
itself has little endocytosis capacity and few adhesion molecules. Suppression or
limitation of the immune response in the CNS might be expected, as neurons are
terminally differentiated and destruction of such cells by an immune response could
have severe effects. Additionally, the brain is enclosed in the rigid bony cranium and
thus any inflammatory swelling could cause great or even fatal damage, in contrast to
inflammatory swelling in almost all other tissues.
Studies of the CNS in different pathological states have revealed its ability to mount
a significant immune response. Resident CNS cells have been shown to produce
chemokines (Owens, 1994) which are pivotal to leukocyte recruitment. Leukocytes
in their activated form can traffic across the BBB into the CNS (Wekerle, 1986) and
activated astrocytes can locally synthesise complement components, as those
synthesised outside the CNS are prevented from crossing the BBB (Levi-Strauss &
Mallat, 1987; Morgan, 1997). Inflammation compromises the BBB increasing its
permeability, allowing some proteins such as particular antibody isotypes to cross
into the CNS. Antibody can also be secreted intrathecally from plasma cells that
have trafficked into the CNS (Parsons & Webb, 1989).
The healthy, uninfected CNS can express TGF-pi and IL-12 (Morgan, 1993; Park &
Shin, 1996). In response to alphavirus infection, IL-la/p, IL-6 and TNFa mRNA
levels rise rapidly in the CNS (Wesselingh, 1994). Both IL-6 and TNFa have
antiviral activity that helps induce an immune response, by attracting circulating
lymphocytes. However, TNFa can have deleterious effects in the CNS affecting
neuronal function, and therefore may play a direct role in the immunopathogenesis of
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some CNS disorders. TNFa has been shown to be directly destructive to
oligodendrocytes and also to mediate demyelination in vitro (Selmaj & Raine, 1988).
There is little evidence of early IFNy production. Neurons can produce IFNy but it is
possible this cytokine is used in a developmental rather than anti-viral capacity
(Neumann, 1997).
The role of chemokines in CNS inflammation has been demonstrated through the use
of various knockout (KO) mice, with deficiencies in lymphocyte recruitment to the
CNS (Mennicken, 1999). Chemokines can be synthesised and secreted by CNS
cells, principally astrocytes and microglial cells, these cells can also respond to
chemokines by way of receptor expression (Asensio & Campbell, 2001). Monocyte
chemoattractant protein (MCP)-l, stromal derived factor -1 and fractaline are
constitutively expressed at low levels in the uninfected CNS. In CNS viral
infections, the chemokine profile (IFN induced protein -10, MCP-1 and Regulated
upon Activation, Normal T-cell Expressed, and Secreted [RANTES]) results in
lymphocyte and monocyte recruitment. Neuronal production of chemokines has
been demonstrated in CNS virus infection, thus neurons can help recruit
inflammatory cells to fight CNS virus infection (Patterson, 2003).
CD8+ T-cell interactions with infected cells are restricted to cells expressing MHC
class I. T-cell binding to their cognate MHC-peptide complex allows initiation of the
perforin-granzyme pathway or a Fas-FasL interaction. It has long been observed that
MHC molecules are only found at a very low level in the healthy CNS (Lassmann,
1991). The ability of cells of the CNS to express MHC molecules has been
demonstrated through experimental infection with neurotropic viruses. Endothelial,
ependymal, meningeal, oligodendrocyte, astrocyte and microglial cells can rapidly
upregulate MHC class I in response to infection. MHC class I proteins can be
detected in neurons and cell surface expression ofMHC class I has also been
observed, however these neurons were electrically silent and hence terminally
damaged (Joly, 1991a; Neumann, 1997; Kimura & Griffin, 2000). MHC I is not
though to be expressed on an infected but otherwise healthy neuron. Expression of
MHC class II molecules is much more limited in the CNS, and only microglia have
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been shown to express this molecule (Morris, 1997; Redwine, 2001). Although
MHC is expressed in the brain, given the constitutive expression of anti¬
inflammatory cytokines, it is likely that the lytic actions ofCTLs are very limited.
The literature supports the view that the CNS can mount an effective immune
response to pathogens, however the CNS is a specialised tissue and consequently,
virus infection and the immune response to it, comes at a cost. Common
pathological features to most viral CNS infection are mononuclear cell infiltration,
perivascular cuffing, astrocytosis and microgliosis. Such features are commonly
seen in the flavivirus encephalitides (Johnson, 1985). Other pathological features are
specific to individual viruses, such as the negri bodies (cytoplasmic inclusions
containing rabies virus antigen) in pyramidal neurons and Purkinje cells during
rabies infection. This is the main morphological change observed in rabies, the
limited inflammatory response and cell destruction belies the invariably fatal
outcome of this disease. Paralytic polio is characterised by atrophy and necrosis of
motor neurons in anterior horn cells of the spinal cord, causing the flaccid paralysis
typical of this disease (Esiri & Kennedy, 1997). A more widespread effect is seen in
HSV encephalitis where there is widespread necrosis of temporal lobes, and acute
swelling and inflammation (Adams & Miller, 1973).
Demyelinating lesions are found in many CNS infections, where loss of the myelin
sheath surrounding axons affects conductance of nerve impulses. Myelination in the
CNS is mediated by oligodendrocytes, and a single oligodendrocyte can myelinate
several axonal internodes (Blakemore, 1982). Therefore the death of a single
oligodendrocyte can affect signal conductance in several axons. There are a number
of possible ways that CNS infection can cause demyelination. The most obvious
example is by direct virus killing of oligodendrocytes, as occurs in progressive
multifocal leukoencephalopathy (Johnson, 1983). Oligodendrocytes can also be
damaged inadvertently by a bystander effect; the immune response to the
oligodendrocyte or adjacent infected cells releases factors resulting in
oligodendrocyte destruction. This is thought to occur in mouse hepatitis virus
(MHV) infection of the CNS (Houtman & Fleming, 1996; Wu, 2000c).
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Severe combined immunodeficiency (SCID) mice, that lack both B- and T-cells, do
not have demyelinating lesions following MHV infection but the transfer ofCD4+ or
CD8+ T-cells to these mice can initiate demyelinating lesions, perhaps through
stimulation ofmacrophages. CD8+ T-cell mediated cytolysis of oligodendrocytes
can occur if oligodendrocytes are infected and express peptide on MHC class I. Data
suggests that this may occur in SFV, as antibody depletion ofCD8+ T-cells abrogates
demyelinating disease in SFV infected mice (Subak-Sharpe, 1993). Indirect damage
to oligodendrocytes by macrophages and pro-inflammatory cytokines can also
damage myelin. Myelin released from damaged axons can be taken up and presented
to activated T-cells which have entered the CNS to control the virus infection. The
presentation of self peptides alongside viral peptides can result 'epitope spreading'
and an autoimmune response (Miller, 1997).
Autoimmune demyelinating disease can also be induced in mice by the injection of
myelin components. This experimental autoimmune encephalitis (EAE) provides a
frequently studied model of Multiple Sclerosis. Demyelination and paralytic
episodes are associated with CD4+ T-cell infiltration into the CNS. Epitope
spreading resulting in diversification of the auto-immune response to other CNS
components can occur in chronic, relapsing-remitting EAE (Lehmann, 1993).
Certain strains of mice are resistant to EAE, however this tolerance can be broken by
alphavirus infection (Mokhtarian & Swoveland, 1987). There are two main schools
of thought as to why SFV infection breaks tolerance to EAE in C57B1/6 mice. The
first hypothesis is that viral infection triggers production of antibodies and
mononuclear cells that cross-react with self-proteins, in a process called molecular
mimicry, resulting in an autoimmune response. However this theory is not supported
by the findings ofMiller et al (1997). Using T-cell proliferation assays, they looked
for cross-reactive responses between Theiler's murine encephalomyelitis virus
(TMEV, another virus that causes immune-mediated demyelination) and myelin
epitopes. A TMEV specific CTL response was detectable within 7 days, but those
involving myelin did not appear until 50 days post-infection. They suggested that the
inflammatory responses in certain hosts have the capacity to lead to chronic, organ-
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specific autoimmune disease. Tolerance to certain CNS antigens may be slowly
broken via epitope spreading, due to a chronic pro-inflammatory response, making
C57B1/6 more susceptible to EAE following CNS viral infection (Miller, 1997).
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Persistence of RNA viruses in the CNS
There are three requirements for a virus to persist, firstly it must infect cells without
causing cytolysis, it must be able to maintain its genome in the cell and lastly it must
be able to avoid detection by the host's immune system (Ahmed, 1997).
In relation to viral infection, persistence is a broad term and encompasses many
meanings. It can be defined as maintenance of the genome only within the host cell,
such as the persistence ofHSV within neurons. Alternatively, in persistent measles
virus infection of neurons the virus exhibits limited replication and there is an
absence of virus particles. Persistence also describes the high infectious burden of
LCMV infection where many cells and tissues are infected and productively produce
virus.
Latency, where there is transcription of a limited number of virus genes and no virus
particles, can only truly occur with DNA viruses. The exact mechanisms of how
viral latency is established and maintained within the cell are not fully understood.
RNA reversiviruses, reverse transcribe their genome to make pro-viral DNA which
can persist in the nucleus, but other RNA viruses cannot persist intra-cellularly in
this manner. The larger DNA genome can also encode other mechanisms to allow
persistence. For example, human cytomegalovirus encodes immunomodulating
proteins that target MHC class I for degradation, prevent MHC I transport to the cell
surface and prevent peptide loading (Campbell, 1999). RNA viruses do persist
intracellularly but use other mechanisms, such as restricted virus replication,
avoidance of the immune response by infection of immunoprivileged sites and
induction of tolerance to achieve this goal (Figure 3).
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Persistence?
Figure 3. Host cell responses to virus, and virus mechanisms to allow persistence. Black arrows
indicate innate immune mechanisms; green arrows indicate adaptive immune mechanisms and red
crosses are points at which viruses can suppress these responses predisposing to persistence.
Deciding what constitutes sterilising immunity (the complete clearance of all
infectious material) is a complicated matter. There are many sensitive techniques for
detecting viruses and each detects different virus products. Infectious virus is
detected by infectivity assay, virus proteins by immunoblotting, virus nucleic acid by
in situ hybridisation and virus genome by polymerase chain reaction (PCR). The
presence of one viral product however does not necessarily indicate active infection.
For example, if virus RNA can still be detected by sensitive techniques such as real¬
time quantitative PCR or nested PCR, this does not necessarily mean that there is still
infectious or even replicating virus present. The RNA detected could be 'junk' RNA
that is non-functional but has yet to be cleared from the CNS, and is not able to
replicate to produce infectious virus particles. On the contrary, during chronic
measles infection, the virus changes to a form that does not produce virus particles
but only replicates non-structural genes within neurons, but the virus does persist.
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The CNS is susceptible to persistent infection for a number of reasons. It is
inaccessible to some immune mediators, few trafficking lymphocytes enter the CNS,
and the BBB restricts the entry of humoral components such as complement or
antibody. The longevity of neurons predisposes these cells to persistent infection, if
the host cell survives for a long time the virus does not need to infect other cells.
Such is the case in varicella-zoster virus infection of trigeminal ganglion cells in
humans which can last 80 years or more (Gilden, 1983). The typical effectors
against virus infection are MHC class I restricted CTLs. The presence of neurons in
the CNS that do not express MHC predisposes the CNS to virus persistence (Joly,
1991b). Selective pressures also protect essential neurons, for example the
destruction of neurons in the area of the brain controlling respiration (respiratory
centre) would be fatal and therefore such cells do not readily undergo apoptosis
(Allsopp & Fazakerley, 2000). The anti-inflammatory cytokine TGF-P is
constitutively expressed in the CNS and is further upregulated in response to
infection (Ranges, 1987; Stitz, 1991; Wesselingh, 1994). Evolutionary balancing of
the potential damage of immune mediators against the benefit of virus clearance
appears to have selected a system which can predispose to virus persistence when the
potential for CNS damage is too great.
Research on neurotropic viruses has provided a wealth of information on host
defence mechanisms, CNS immunity, and chronic viral infection and CNS
pathology. Several viruses can establish persistent infection in the CNS and key
examples of such viruses are discussed below. These viruses have been extensively
researched to delineate the CNS immune response to these viruses, their cellular
tropism and the mechanisms employed that prevent their elimination.
Theiler's Murine Encephalomyelitis virus (TMEV)
TMEV is a single stranded (+) RNA virus of the family Picornciviridae. The TMEV
genome is infectious and about 8Kb in length. TMEV is a natural pathogen of mice
which is transmitted by the faecal-oral route and normally persists as an
asymptomatic infection of the gut. In naturally occurring infections, the virus
occasionally enters the CNS and a persistent infection of spinal cord white matter
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occurs. In laboratory studies, direct intracranial inoculations (IC) are used to study
TMEV persistence. TMEV has been categorised into two subgroups, firstly the
highly neurovirulent GDVII and FA strains; in rare survivors of this infection, the
virus is cleared from the CNS. The second group contains the Daniels and BeAn
TMEV strains which can cause CNS persistence.
In susceptible mouse strains, IC inoculation ofTMEV causes a biphasic disease. The
first phase which lasts for about 2 weeks is characterised by acute encephalitis,
infection of grey and white matter in the brain and spinal cord. In the transition from
acute to persistent infection, there is clearance of infectious virus and virus RNA
from the brain but continued infection in the spinal cord. During the chronic phase
the virus persists in macrophages and glial cells, resulting in a demyelinating disease
of spinal cord white matter tracts. There is debate over which cells in the spinal cord
harbour virus because TMEV is a lytic virus, and infected cells often undergo
apoptosis after infection, making it difficult to identify them. Viral antigen is present
in macrophages, but it is possible that this represents phagocytosed virus particles
rather than infection of phagocytes (Lipton, 1995; Zheng, 2001). Glial cells,
including astrocytes and oligodendrocytes in the spinal cord have also been shown to
be virally infected (Aubert, 1987; Simas & Fazakerley, 1996). All mice infected IC
with avirulent TMEV have acute infection but only susceptible (SJL) mice develop
persistent infection (Lipton, 1975).
The initial wave ofTMEV infection is controlled by massive influx of T-cells and in
resistant mice there is complete viral clearance by post-infection day (PID) 21.
Resistant mice can be made susceptible to demyelinating disease and acute virus
clearance can be abrogated by depletion of T-cell subsets (Rodriguez, 1991; Borrow,
1992b). In susceptible mice, demyelinating lesions are characterised by B and T
lymphocyte infiltration. Direct cytolytic damage to oligodendrocytes is thought to be
partly responsible for demyelination, but the anti-TMEV CD4+ T-cell response is
also involved (Gerety, 1994). The acquired immune response therefore has a
contradictory role; it is essential for virus clearance but in susceptible mice
exacerbates pathological changes when virus persists. SCID mice die from
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overwhelming encephalitis but do not have demyelination, indicating an immune
aetiology for demyelination (Rodriguez, 1996).
MHC I genes are an important determinant of resistance to infection. In part,
resistance maps to the MHC Class I gene H2, in particular to H-2D. The CTL
response of resistant mice is H-2Db restricted and virus is efficiently cleared without
the development of any neuropathological changes. Transgenic expression of TMEV
genes in resistant mice inactivates virus specific CTLs, and following infection in
these mice, virus persists and demyelination occurs (Lin, 2002). Susceptible mice
mount an H-2K restricted response. If the H-2D presentation is inactivated in
resistant mice, the remaining H-2K restricted CTLs are unable to mount an efficient
responses (Azoulay-Cayla, 2001). The reasons for such poor H-2K restricted CTL
response are not known, but it has been suggested that H-2K is poorly expressed in
the CNS, resulting in inefficient CTL mediated virus clearance in the brain (Altintas,
1993).
The genome of the virus itself also plays a role in determining persistence.
Neurovirulent TMEV (GDVII and FA strains) do not persist in mice surviving
infection (Lipton, 1980). Therefore a determinant of persistence is encoded in the
BeAn and DA strains. Recombinant GDVII virus expressing capsid from the DA
virus has the ability to persist (McAllister, 1990; Tangy, 1991). Persistence is linked
to the ability ofDA to infect the white matter and establish a restricted infection of
oligodendrocytes. In contrast, neurovirulent viruses preferentially infects neurons,
leading to more severe disease, but this virus can be fully cleared from the CNS
(Jarousse, 1994).
The cell type that harbours TMEV in persistent infections is still controversial.
Macrophages are infectious, but can only produce few virus particles as they have a
block in (-) strand RNA synthesis (Cash, 1988; Clatch, 1990). TMEV viral RNA is
detectable by in situ hybridization techniques in macrophages late in infection. It has
been demonstrated that the antigen burden is predominantly contained in this cell
type but only a low infectious load (Aubert, 1987). Therefore macrophages may
harbour infection but perhaps have a block in virion assembly accounting for the low
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number of virus particles. However, phagocytosis of infected cells will cause
macrophages to contain viral antigens and this makes true viral infection of
macrophages difficult to identify. Evidence for persistence of virus in myelin or
oligodendrocytes comes from studies on two mouse strains that have mutations in the
genes encoding myelin basic protein and myelin structural protein. These mutations
confer resistance to TMEV infection, indicating that myelin or oligodendrocytes
allow virus to persist (Bihl, 1997). Astrocytes have also been cited as the cell
responsible for TMEV persistence. These cells have been shown to effectively
replicate the virus and produce infectious virions with minimal CNS cytotoxicity
(Zheng, 2001). TMEV persistence requires a combination of host and virus factors,
with a poor host CTL response combined with virus cell tropism for white matter,
resulting in virus persistence.
Mouse Hepatitis virus (MHV)
Mouse hepatitis virus, a natural pathogen of mice, is a member of the Coronaviridae.
MHV is a pleomorphic, single stranded (ss) RNA, enveloped virus with surface
projections. There are many biotypes ofMHV with different cellular tropism and
virulence. The John Howard Mueller (JMH) strain ofMHV and MHV-4 strains are
neurotropic. JMH MHV infection is characterised by a biphasic disease and immune
responses. In acute infection there is encephalomyelitis with demyelination which is
quickly resolved. The second phase of the disease is persistent infection with
demyelination and no infectious virus is detectable in these chronic infections.
During the acute phase ofMHV infection, a rapid influx of T-cells, in particular
CD8+ T-cells, controls the acute infection (Williamson & Stohlman, 1990) and
comprises up to 50% of virus specific T-cells. CD4+ T-cells do not appear to have a
direct anti-viral role but are essential for both the CD8+ T-cell and antibody response.
CD8+ T-cells use both perforin and IFNy to control virus replication. Perforin
preferentially inhibits viral replication in microglia and astrocytes (Lin, 1997). IFNy
controls oligodendroglia infection (Parra, 1999a) and also increases MHC I
expression, an essential function to allow more expression of viral peptides to permit
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CTLs to efficiently clear virus. The cellular immune response is not capable of
achieving sterile immunity and is surpassed by the humoral response as the virus
moves into its persistent phase. Persistence of viral RNA in glial cells has been
reported up to 1 year PI. This is consistent with the ongoing demyelination and
recovery that is observed with infection in these persistently infected mice (Knobler,
1982a).
The retained CD8+ T-cells lose their ex-vivo cytolytic activity in the chronic phase of
infection, while maintaining their IFN-y secretory capacity (Ramakrishna, 2004).
Virus induced TNF-a production decreases, indicating reduced AICD, which might
account for increased CTL numbers. This loss of cytolytic potential could benefit
the host by limiting long-term CNS pathological changes, while contributing to anti¬
viral functions. T-cells may become exhausted or their cytolytic activity down-
regulated in order to prevent immunopathological changes at the cost of allowing
persistent viral infection.
The distinct mechanism that induces cytolytic unresponsiveness has yet to be
identified. CD8+ and CD4+ MF1V specific T-cells are retained in the CNS and the
percentage of virus-specific CD8 T-cells (as demonstrated by tetramers) remains
constant (Bergmann, 1999). Myelin loss in the chronic phase of disease is consistent
with an ongoing immune response. The role of virus in retaining CTLs has been
investigated, where the continued presence ofMHV RNA in the spinal cord was
shown to be necessary for the retention of virus specific T-cells (Marten, 2000).
The presence of serum antibody and specific anti-viral plasma cells are delayed in
MHV-4 infection and antibody levels do not rise until infectious virus clears (PID
14-21). In the chronic phase of this infection, antibody titres increase and remain
stable during virus persistence (Tschen, 2002b). Humoral immunity alone is
required for control of persistent virus infection as demonstrated in studies on pMT
mice (that cannot secrete antibody). These mice can control infection in the acute
phase, indicating a redundant role for antibody in the early stages of disease.
Following initial control during acute infection, the virus reactivates in the absence
of antibody to levels similar to those present in the acute phase, indicting that cellular
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immunity is not effective in controlling persistent infection. The transfer of
neutralising antibody prevents the re-activation of virus in pMT mice, further
underlining the importance of humoral immunity in persistent viral infection (Lin,
1999). The specificity of the antibody response changes over the course of the
persistent infection. For example, plasma cells specific for viral proteins S and N
decline; however, serum neutralising antibody titres do not fall as plasma cells have
specificity for other MHV viral antigens (Tschen, 2002a).
MHV is able to rapidly evolve during the course of CNS infection and whether this
ability to change contributes to viral persistence is of interest (Adarni, 1995).
Accumulation of viral quasispecies with deletions in the S protein hypervariable
domain was associated with increased loads of infectious virus in the CNS following
infection of neonatal mice. CTL escape of virus epitopes was demonstrated in
suckling C57B1/6 mice, which could contribute the increased viral loads through
increased viral fitness (Pewe, 1996). Despite these findings, the relevance of
mutations in MHV in infection of naive adult mice to viral persistence appears to be
negligible (Bergmann, 1998).
It is possible that viral persistence is a trade off between effective viral clearance and
limiting immunopathological damage. Virus is neutralised and kept under control by
antibody (and possibly by IFNy) but a low level of infection continues. Balancing
the need to eliminate virus from the CNS but also limit immunopathology may
favour viral persistence.
Lymphocytic Choriomeningitis virus (LCMV)
LCMV is a member of the Arenaviridae Family. It is a non-cytopathic, ambisense,
enveloped RNA virus. LCMV causes asymptomatic, chronic infections of rodents
worldwide. The outcome of transmission of arenaviruses from rodent to humans
varies from asymptomatic infection to severe haemorrhagic disease. In the adult
mouse, the virus replicates in macrophages at the site of entry (often the lung) before
causing widespread infection ofmultiple tissues. There is a biphasic immune
response, with an initial NK cell expansion giving way to a massive CD8+ T-cell
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response. At the peak of the immune response, 50% of all CD8+ T-cells in the spleen
are specific for LCMV (Murali-Krishna, 1998).
Adult mice infected IC with LCMV succumb to a fatal choriomenigitis after 6-8
days. Virus infection stimulates several immune effector mechanisms but virus
clearance is primarily dependent on CTL. If these cells fail to generate or are
deleted, progression from acute to persistent infection occurs. MHC class I
expression is necessary for CTL mediated virus clearance and as noted, neurons
typically do not express MHC. Nevertheless, following LCMV infection, CTLs have
been shown to mediate clearance of infected neurons albeit slower than conventional
MHC expressing cells, but virus clearance still resulted (Oldstone, 1986; Tishon,
1993).
In order to persist, a pathogen must avoid detection and elimination by the immune
system. CTLs are an important means for clearance of virus. One such mechanism
to evade detection is for viral antigen not to be recognised as non-self, and hence not
alert the immune system to its presence. LCMV accomplishes this successfully via
infection of the neonatal rodent. If LCMV infection occurs while the immune
system is still developing, virus is presented as self antigen and virus specific T-cells
are negatively selected and deleted in the thymus and so do not appear in the
periphery (Pircher, 1989). Cells infected with LCMV do not undergo apoptosis and
in the absence of specific immunity the outcome is persistence. Infected neonatal
mice become congenital carriers, and have a neuronal infection in addition to
leptomeninges and choroid plexus infection. Persistently infected mice shed virus in
their body fluids, leading to virus dissemination. Other immune mechanisms are not
affected by this specific tolerance, as shown by rejection of skin grafts and the
presence of high levels of antibody against LCMV in carrier mice (Buchmeier &
Oldstone, 1978). The 'deleted' LCMV-specific CTLs can be reconstituted in a
tolerant mouse resulting in efficient removal of virus (Ahmed, 1987; Jamieson,
1987). It has been suggested that the CTLs rather than being deleted are functionally
impaired and that adoptive transfer clears persistent virus, allowing regeneration of
the specific LCMV-CTL response (Oldstone, 2006).
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Infection of adult mice with LCMV normally resolves after acute infection, however,
persistence can occur after a high dose of inoculum or after infection with certain
LCMV variants. The clone 13 strain produces a generalised immune suppression
and persistent infection, whereas mice infected with the Armstrong strain rapidly
clear infection and are immunocompetent. A mutation in the clone 13
immunosuppression strain was found where a uracil to cytosine transition at position
855 of the S gene, resulted in a phenylalanine to leucine alteration at amino acid 260
of the envelope glycoprotein, thereby altering cell tropism (Ahmed, 1988; Salvato,
1991). The mechanism of immunosuppression was found to be linked to infection of
splenic, antigen presenting cells, which are consequently killed by LCMV specific
CTLs, leading to functional suppression of the LCMV specific CTL response
(Borrow, 1995).
More recent studies with LCMV clone 13 infected mice (Brooks, 2006; Ejrnaes,
2006) have demonstrated that virus persistence is caused by T-cell
immunosuppression mediated by elevated IL-10 levels. IL-10 is an anti¬
inflammatory cytokine which can inhibit a broad spectrum of cellular immune
response, by suppressing the function ofAPCs and T cells, hence inhibiting pro¬
inflammatory cytokine production, co-stimulation, MHC class II expression, and
chemokine secretion (Moore, 1993). In both studies, the in vivo blockade of IL-10
led to resolution of LCMV infection. The infection of IL-10"/" mice with clone 13 led
to the generation of a robust T-cell response which rapidly cleared virus. Both
studies indicated that DCs were the likely source of the IL-10 production, the reason
for this is unclear, preferential infection ofDCs by clone 13 LMCV strain was
suggested or alternatively that DCs are skewed towards a TH-2 subtype after
infection with this strain and thus are induced to secrete IL-10.
Viral persistence has also been examined in mice following acute infection which
were deemed to have cleared all virus by conventional assays. Viral cDNA was
detected in spleen tissue of apparently healthy mice post-infection. It is not known if
this viral DNA has biological activity. It remains possible that low-level protein
expression can occur (Klenerman, 1997). More recently, Ciurea et al (1999)
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demonstrated that mice with an intact immune response which appear to have
resolved an acute viral infection, continued to express low-level infection in the form
of viral genome, viral antigen and replicative virus in peripheral organs. Whether
persistence occurs after acute LCMV infection in order to maintain immunological
memory remains to be answered (Ciurea, 1999a).
Sindbis Virus (SV)
SV, an enveloped (+) RNA, is an alphavirus of the Togaviridae. SV is closely
related to Western equine encephalitis an important cause ofmosquito-borne
encephalitis in the Americas (Weaver, 1997). In the mosquito, SV replicates in a
non-lytic manner and persists (Stevens, 1970). After IC inoculation of mice with
neuroadapted SV, the virus replicates primarily in neurons of the brain and the spinal
cord. Infectious virus is cleared in immunocompetent mice in 6-8 days without the
development of neurological disease (Jackson, 1988). Weanling mice succumb to
fatal encephalitis within 4 days (Griffin, 1976).
The antibody response is crucial to infectious virus clearance. Antibody secreting
plasma cells are found indefinitely in the CNS of immunocompetent mice following
SV infection (Tyor, 1992b). Antibody immunodeficient mice are persistently
infected but the transfer of hyperimmune (HI) serum clears infectious virus. When
passively transferred antibody decays, virus infectivity then returns indicating the
need for permanent antibody secretion to control virus persistence (Levine, 1991;
Levine & Griffin, 1992). The role of T-cells has been examined in mice lacking B-
cells. Infectious virus is cleared from the spinal cord and parts of the brain, but
persists in cortical neurons in the absence of antibody (Kimura & Griffin, 2000;
Binder & Griffin, 2001c). IFNy is necessary for the partial, T-cell mediated
clearance observed. While virus infectivity is effectively cleared by the humoral
immune response, the role of the immune response in the clearance of virus genetic
material is less clear.
SCID mice have persistent infection (of brain and spinal cord) after SV infection,
and despite lacking both humoral and cellular immunity, no neurological deficits are
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seen in these animals following infection. Persistence was not thought to occur in
immunocompetent mice, but using reverse transcriptase PCR, it was discovered that
although infectious virus had been cleared, viral RNA was still present in BALB/c
mice up to 17 months PI (Levine, 1991; Levine & Griffin, 1992). A number of
possible mechanisms could contribute to the restriction of the cytolytic effect.
Soluble factors have been shown to contribute to the establishment of persistent
alphavirus infection in vitro. SFV infected L929 cells pre-treated with IFNa readily
establish a persistent infection rather than a lytic, virus-induced death (Meinkoth &
Kennedy, 1980). Defective interfering (DI) particles, i.e. virus particles that are
missing part of their genome, have been suggested to have a role in the establishment
of virus persistence in vitro. SV treated BHKs normally succumb to infection but a
small fraction survive along with SV DI particles, it was concluded DI particles were
required to establish a persistent infection with wild-type, standard SV virus (Weiss,
1980). Their efficacy in vivo has also been demonstrated; co-administration of SFV
DI particles with virulent SFV4 to mice prevented lethal encephalitis and results in
virus persistence (Atkinson, 1986).
The cellular differentiation state of SV infected cells has also been suggested to be a
determinant in persistence. SV causes a lytic infection in rodent neuroblastoma cells
but persistent infection occurred in neurons grown with nerve growth factor. The
difference between these two cell types included the expression of genes involved in
cellular differentiation (Levine, 1991). The Bcl-2 family are anti- and pro-apoptotic
proteins that regulate cell death by blocking or promoting mitochondrial outer
membrane permeability. Pro-apoptotic proteins are expressed in cells with extended
lifespans, such as neurons. Micro-injection of a vector expressing Bcl-2 into isolated
neurons prevented growth factor withdrawal triggered apoptosis in these cells
(Allsopp, 1993). SV kills non-neuronal cells by inducing apoptosis, for example rat
AT-3 and BHK cells have lytic SV infections. However, when AT-3 cells expressed
recombinant Bcl-2, these cells survived with persistent infection (Levine, 1993). It is
not known how Bcl-2 regulates the lytic potential of SV or ifBcl-2 or an analogue is
expressed in the adult nervous system. Further investigation is required to determine
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if Bcl-2 is upregulated upon virus infection and whether other cellular genes are
involved. Neurons are described as immunoprivileged, as their terminally
differentiated state necessitates a different immune surveillance to other cells in order
to prevent immune mediated apoptosis. Neurons express very low levels MHC and
as noted, are refractory to apoptosis. The preferential infection of these cells by SV,
is in itself a mechanism for viral persistence (Jackson, 1987; Mauerhoff, 1988).
Evolution of the viruses may play a role in determining persistence. SV was isolated
from two groups of persistently infected SCID mice; one group had been treated with
anti-SV HI serum. The neurovirulence of the isolates was then tested in weanling
BALB/c mice. Viral mutants from both groups of mice were neurovirulent, resulting
in 80-100% mortality. All neurovirulent strains contained Gin to His substitution in
the E2 envelope glycoprotein. This change was not antibody-induced as mutants
occurred in both untreated and anti-SV HI serum treated SCID mice (Levine &
Griffin, 1993).
As noted, antibody has been shown to have a role in mediating SV persistence.
Humoral immunity is important for protection against viral infection and
neutralization of extracellular virus, but clearance of virus from infected cells is
thought to be mediated solely by cellular immunity. However, in a SCID mouse
model of persistent alphavirus encephalomyelitis, adoptive transfer of anti-SV HI
serum resulted in clearance of infectious virus and viral RNA positive cells (as
detected by in situ hybridisation) from the nervous system, whereas adoptive transfer
of sensitized T lymphocytes had no effect on viral replication. Three monoclonal
antibodies to two different epitopes on the E2 envelope glycoprotein mediated viral
clearance. Treatment of alphavirus-infected, primary cultured rat neurons with these
monoclonal antibodies to E2 resulted in decreased viral protein synthesis, followed
by gradual termination ofmature infectious virion production. Thus, antibody
appears to mediate clearance of alphavirus infection from neurons by restricting viral
gene expression, and while neurons become persistently infected, no productive virus
is released (Levine, 1991; Levine & Griffin, 1992). It has not been demonstrated if
antibody clears virus from neurons. HI serum prevents the detection of infectious
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virus in SCID mice, but it has not been determined whether this represents sterilising
immunity.
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Pathogenesis of SFV
SFV infection
In natural infection, following peripheral inoculation, normally by a mosquito, SFV
A7(74) infects local cells such as muscle or Langerhans cells before multiplying and
spreading to target tissues. A high titre viraemia is detectable by 24 hr (Fazakerley,
1993). SFV appears to infect endothelial cells of the BBB (Soilu-FIanninen, 1994)
and crosses this barrier to infect cells of the CNS. The BBB is leaky following CNS
infection from about days 3 to 10 post-infection as demonstrated by the presence of
albumin and IgG in the CSF fluid (Parsons & Webb, 1982c). Once in the CNS SFV
is known to predominantly infect neurons and oligodendrocytes (Pathak, 1983).
Neurovirulence and age related virulence
All strains of SFV are neuroinvasive but they differ in their virulence. L10 is
virulent, and in both neonatal and adult mice, perivascular spread of virus from small
foci to large areas of infection occurs, and many neurons die. In adult mice infected
with virulent strains of SFV, virulence is unaffected and the virus becomes
widespread in the CNS, however most infected neurons are not destroyed. Infection
with avirulent SFV A7(74) results in restricted replication in the adult mouse CNS,
with just small, scattered perivascular foci of infection detectable. Adult mice are
able to clear infectious A7(74) virus from the CNS by PID 10. In stark contrast,
mice under 12 days of age die from SFV A7(74) infection, virus replication is
unrestricted in the CNS and like L10, infection is rapidly fatal (Fazakerley, 1993).
This age-related virulence is attributed to the maturity of the cells in the CNS rather
than the immune response, as SFV A7(74) infection is not fatal in immunodeficient
(SCID, nu/nu) adult mice and causes only small foci of infections in their CNS
(Oliver & Fazakerley, 1998). That the adult neuron is refractory to apoptosis is not
surprising, the death of vital virally infected neurons would not benefit the animal if
the neuron is critical for normal brain function. The ability to limit productive
infection is also age-related. In adult mice with A7(74) infection administration of
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gold compounds (which induce smooth membrane production) converts the focal
infection to a fatal pan-encephalitis (Pathak, 1983). The immaturity of neurons in the
developing brain offers cells with the physiological capacity to replicate virus and
produce viral proteins but also the susceptibility to undergo apoptosis.
Immune response to SFV
SFV infection rapidly induces a type IIFN response and the level of IFN a/|3
expression correlates with that of the viraemia (Bradish, 1975). Administration of
IFN a/p induces an antiviral state locally and systemically, which reduces alphavirus
infectivity (Bradish & Titmuss, 1981). MHC expression is induced by IFN in
response to infection and during SFV CNS infection MHC class I and blood vessel-
associated MHC Class II expression correlates with areas of infection (Morris, 1997).
Furthermore, the administration of anti-type I IFN antibodies enhances viral
replication, demonstrating the importance of the anti-viral activity of type I IFN
(Fauconnier, 1969). However, the most compelling evidence for the protective role
of type I IFN in alphavirus infection has come from the use of type I IFN receptor
knockout mice (IFNa/pR""). The type I IFN family is encoded by many genes and is
currently unfeasible to knock out. However, the removal of a receptor subunit results
in an unresponsive type I IFN system (Muller, 1994). IFNa/pR"/_mice inoculated
with SFV succumb to infection within 72hrs. These mice do not die from
panencephalitis as occurs in neonates but from multiple organ failure (Figure 4).
These results demonstrate the important and necessary role of type I IFN in
protection from alphavirus infection (Grieder & Vogel, 1999; Ryman, 2000b;
Breakwell & Fazakerley, 2007a).
Another effect of a defective type I IFN system was that the virus was observed in
many different tissues, such as the exocrine pancreas, a feature not seen in infection
ofwild-type mice. It appears removing the type I IFN system reveals the true
tropism of alphaviruses (Ryman, 2000a).
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Figure 4. Survival time in WT-129 and lFNa/(3-R " mice following SFV infection. Data from
Fazakerley (Breakwell & Fazakerley, 2007b).
The role ofNK cells in alphavirus infection has not been fully examined. It is
thought that NK cells infiltrate the CNS early in infection (Hickey, 1999) as
indicated by an early peak in lymphocytes. As yet. there is no evidence of either a
protective or pathogenic role for NK cells in alphavirus infections (Hirsch. 1981;
Griffin & Hess, 1986). The use of Beige mice (an inbred strain naturally deficient in
NK cells) did not demonstrate any role for NK cells in alphavirus infection
(Fazakerley, 1985).
After peripheral inoculation of alphavirus there is an up-regulation ofMHC class I
expression on epidermal cells and of class II expression, along with co-stimulatory
molecules, on Langerhans cells (Johnston, 1996). Mononuclear cell infiltrates
forming perivascular cuffs (T-cells, B-cells and NK cells) are detectable within the
CNS from about 3 days post-infection with SFV. The sites of these infiltrates
correspond with the areas of infection (Morris, 1997). T-cells of activated
phenotypes, and perhaps other cells, can cross the BBB into the CNS and are aided
by the up-regulation of adhesion molecules. A preliminary study of SFV
encephalitis determined that the ratio ofCD4:CD8 is approximately 1:1 in the
infected CNS (Trefgarne, 1995); blood normally has a ratio of 2:1. The elevated
levels of CD8 T-cells in the CNS suggest they play a role in alphavirus infection.
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Oligodendrocytes, the cells that produce myelin in the CNS, are known to be
inducible for expression ofMHC Class I, and it is possible that infected
oligodendrocytes are targeted by CTL lytic mechanisms, resulting in the
demyelination seen in SFV. T-cells have been shown to be necessary for
demyelination to occur. Nu/nu mice that have no T-cells and no Ig class switching
develop a persistent CNS infection with SFV (Fazakerley & Webb, 1987; Amor,
1996). The exact role of CD4+ and CD8+ T-cells in CNS immune responses are not
known. The only study on the role of T-cells SFV infection was by using antibody
depletion of CD4+ and CD8+ T-cells (Subak-Sharpe, 1993). Depletion of CD8+ T-
cells prevented demyelinating lesions from forming and removal of both CD8+ and
CD4+ subsets completely ablated all pathological changes (Figure 5). This system
however was limited in that antibody mediated CD8+ T-cell depletion was temporary
and by PID 21, CD8+T-cells numbers increased resulting in some demyelination. In
order to examine the role of CD8+ T-cells alone, infections ofCD8+ T-cell knockout
mice or use of CD8+ T-cell adoptive transfer is required. The above evidence
supports an immunopathogenic role for CD8+ T-cells in alphavirus CNS infection
but direct evidence has yet to be shown.
In alphavirus infection, there is clear evidence of immunopathological changes,
which raises the question: does the damage caused by the immune response outweigh
its benefits? One of the best models in which to attempt to answer this question is
SCID mice that are naturally deficient in both B and T cells. SCID mice infected
with avirulent SFV A7(74) - die at about 22 days post-infection, with widespread
infection including cells in skeletal muscle, myocardium, brain and spinal cord. The
cause of death in SCID mice is unknown, but could include a shock-like syndrome or
an excessive build-up of virus in the peripheral organs. In the CNS there is very little
evidence of inflammation or demyelination, and virally-positive cells are
morphologically normal (Amor, 1996). Immunocompetent mice infected with SFV
have inflammation and demyelination in the CNS.
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Figure 5. Histological scores from SFV infected mice depleted ofCD8 and/or CDT T-cells (Subak-
Sharpe, 1993).
CD8+ T-cells also possess non-lytic mechanisms that have an important role in
infections of non-renewable cells. CD8+ T-cells are important producers of IFNy, a
potent anti-viral cytokine. IFNy is produced later in infection than Type IIFN and is
an important mediator ofMHC upregulation and cellular activation. Binder et al
used a SV construct that expressed IFNy, to investigate the antiviral effects of IFNy.
Infection of SCID mice with the SV construct showed reduced brain virus titres and
clearance of infectious virus in the spinal cord, compared to persistent infection in
SCID mice infected with wild-type SV (Binder & Griffin, 200Id). It could be
speculated that the protective potential of CD8+ T-cells in spinal cord appears to
come at the price of causing inflammatory demyelination within the CNS.
Following SFV infection there is a rapid neutralizing IgM response which is detected
by PID 4. This is followed by an IgG2a (PID 6) and a slow rising IgGl response
(PID 8). From PID 4-10, the BBB is leaky enabling antibody to enter the CNS.
Intrathecal antibody production has also been detected. Antibody and plasma cells
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are detectable in the CSF and brain for many months after infection (Parsons &
Webb, 1982f).
The specificity of antibody appears to be mainly against alphavirus envelope proteins
El and E2. E2 forms the most distal part of the envelope heterodimers and so is
most exposed. There are several neutralising antibodies to this protein. Amino acid
changes to E2 affect the efficiency of antibody binding and virulence. The E2
protein is not conserved between different alphaviruses and consequently, antibodies
to the E2 protein are not cross-reactive. El and capsid are more conserved structural
proteins in alphaviruses and so there is cross-reactivity of antibody to El between
alphaviruses. Although El has 7 known epitopes, these are not normally exposed,
therefore anti-El antibody cannot normally bind to virus. Antibody to capsid is also
cross-reactive, but like El, capsid proteins are not exposed under normal
circumstances.
Antibody can clear virus, at least in peripheral (non-CNS) tissues, via the
reticuloendothelial system in a complement-dependent manner (Jahrling, 1983).
Intraperitoneal (IP) transfer of immune serum protects mice that would normally
succumb to infection (Griffin & Johnson, 1977). In immunocompetent mice there is
clearance of infectious virus (as determined by plaque assay); in nu/nu mice (which
only have IgM antibody) there is only peripheral clearance of infectivity, and in
SCID and pMT mice which have no antibody, there is neither peripheral nor CNS
clearance of infectious virus (Figure 6). When neutralising and non-neutralising IgG
was transferred to SCID mice, this reduced brain virus titres and cleared the virus
(Amor, 1996). The mechanism by which this operates with non-neutralising
antibody is not clear but similar results have been reported with SV (Schmaljohn,
1982). However it has not been demonstrated if antibody alone can bring about
'sterilising' immunity i.e. completely clear virus as detected by infectivity assay and
PCR.
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Figure 6. Infectious SFV titres in the blood and CNS of immunocompetent (BALB/c), T-celi
deficient (nu/nu) and B and T-cell deficient (SCID) mice. Each point represents the sampling of a
single animal. The red line indicate mean infectious virus load in the blood, green line represents
mean infectious virus load in the brain (Amor, 1996)
While antibody has been shown to be crucial for viral clearance, other work suggests
that it may also have an immunopathogenic role. The detection of antibodies to
myelin oligodendrocyte glycoprotein and myelin basic protein following SFV
infection led to the suggestion antibodies that these autoantibodies had a role in the
demyelination process (Smith-Norowitz, 2000). Mokhtarian et al observed an
increase in B-cells in the recovery period of SFV infection, when demyelination is
still occurring, and suggested that antibody takes over from CTLs as mediators of
myelin pathology (Mokhtarian, 2003).
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Hypothesis
Different specific immune effector mechanisms or combinations of these are
responsible for control of infectious virus, eradication of virus and the generation of
demyelinating lesions in the brains of SFV infected mice.
Aims
The aim of this thesis is to identify the contributions of different components of the
acquired immune response to the control and eradication of virus and to the
generation of demyelinating lesions in the CNS of SFV infected mice.
Objectives
• Compare virus clearance (infectious virus and virus RNA) in CD8+ T-cell
and MHCII"7" KO mice with wild-type mice
• Transfer immune CD8+ T-cells or immune splenocytes depleted of CD8+ T-
cells to SFV infected SCID mice and assess CNS histological changes and
virus clearance
• Compare the phenotype of immune cells present in the CNS of SFV
infected C57B1/6 mice and BALB/c mice
• Determine if T-regulatory cells are present in the CNS of SFV infected
mice
• Compare virus clearance and CNS histology following SFV infection in
IFNyR"", perforin"7" and Faslpr mice with wild-type mice
• Determine if recombinant IFNy can protect SFV infected IFNa/p "'" mice
• Raise and characterise high titre HI SFV serum
• Perform passive transfer ofHI SFV serum to SFV infected SCID mice
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Examine the ability ofHI SFV serum to clear virus (infectious and RNA)
from selected tissues of SFV infected SCID mice
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Mice
Mice were infected at 4 and 6 weeks of age (summary of strain details in Table 2).
BALB/c, C57B1/6 and WT129 immunocompetent mice were used. Mice with
targeted genetic deletions were also studied: MHC class II"" mice have a mutation in
the Ap complex of the MHC Class II gene, the lack ofMHC II expression results in
near complete elimination ofCD4+ T-cells (Cosgrove, 1991b); Faslpr mice have a
spontaneous mutation in the Tnfrsf6 lpr gene and are deficient in Fas (Gilkeson,
1991); Perforin"" mice have a targeted mutation in the gene encoding perforin 1 and
are deficient in perforin (Kagi, 1994); IFN-y receptor _/" (IFNyR"/") mice have a
targeted mutation in their IFNy receptor and cannot respond to IFNy (Huang, 1993);
the CD8 molecule is encoded by two genes Lyt-2 and Lyt-3, CD8 knockout (CD8a)
mice have disruption in the Lyt-2 gene and as a result do not have CD8+ T-cells
(Fung-Leung, 1991c); SCID mice have a natural mutation in the Prkdc gene, this
mutation causes developmental arrest of B and T-cells resulting in a B and T-cell
deficiency (Bosma, 1983a). SCID mice were on a C.B-17 genetic background;
genetically this is closely related to the BALB/c strain.
All animal experiments were approved by The University of Edinburgh Ethical
Review Committee and carried out under the authority of a Home Office Project
License. All animals were kept in HEPA filtered cages, with environmental
enrichment, 12 hr light dark cycle and food and water ad libitum.
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Name Deficiency Background Source
IFNa/pR7" Disruption in IFNa/(3 receptor WT-129 In house
MHCIF" Do not express MHC Class II, no CD4T T-cells C57B1/6 In house
CD8a Disruption of CD8 Lyt2 gene, no CD8 ' T-cells C57B1/6 Charles
River
Faslpr Do not express functional FAS protein C57B1/6 In house
IFNyR"'" Disruption in IFNy receptor WT-129 In house
Perforin "A Do not make perforin C57B1/6 In house
SCID Mutation in Prkdc, no B- or T-cells CB-17/BALB In house
WT-129 None In house
BALB/c None Harlan
C57B1/6 None In house
Table 2. Summary ofmouse strains and models used.
Tissue sampling
Mice were euthanized by an overdose of CO2 or sampled following perfusion. The
chest cavity was opened to expose the heart, the right atrium snipped and heparin
applied to prevent clotting. Whole blood was collected and separated by
centrifugation, serum collected and stored at -80 °C. Brains were removed and
bisected along the midline. One half of each brain was used for virus titration, the
other half for histology or virus RNA titre. Heart, pancreas and spleen were also
sampled in some experiments. Mice were sacrificed at various days post-inoculation,
details given in results chapter.
Perfusion
Mice were deeply anaesthetised by halothane inhalation. The chest cavity was
opened to expose the heart, the right atrium snipped and heparin applied to prevent
Chapter 2 Materials and Methods 46
Acquired Immune Response to SFV
clotting. An 18-gauge butterfly needle was inserted into the left ventricle and sterile
phosphate buffered saline (sPBS) was slowly perfused through the animal until the
fluid ran clear.
BHK-21 cell tissue culture conditions
Baby hamster kidney (BHK) 21 cells (clone 13 - ECACC No. 85011433) were
maintained in 10% newborn calf serum (NBCS - Invitrogen) and tryptose phosphate
broth (Invitrogen) in Glasgow's Minimal Essential Media (10% GMEM, Gibco)
supplemented with 1% L-glutamine (2 mM, Merck BDH), 100 u/ml penicillin and
100 pg/ml streptomycin (Merck BDH). At confluence, cells were washed with sPBS
and resuspended by 5 min incubation with 5 ml trypsin/EDTA
(ethylenediaminetetraacetic acid, Invitrogen). Cells were transferred to a universal
and pelleted by centrifugation, 5 min at 400 g, and washed in 10% GMEM and
pelleted as before. Cells were resuspended in 10 ml of 10% GMEM and counted on
a haemocytometer by trypan blue (Sigma) exclusion. T175 flasks were reseeded at
3-5xl06 cells in 40 ml of 10% GMEM. Cells were maintained in this fashion until
passage number 30.
Virus and virus titration
The avirulent strain A7(74) of SFV was passaged in BHK-21 cells. Mice were
inoculated IP with 0.1 ml or with 0.02 ml IC of sPBS in 0.75% bovine serum
albumin (sPBSA) containing 5x10 or 1x10 PFU virus, respectively. BHK-21 cells
were used to titrate infectious virus in blood and tissue samples by a standard plaque
assay. The BeAn strain of TMEV strain was used to raise irrelevant sera. Mice were
inoculated IP with 0.1 ml 0.75% PBSA containing 5x103 PFU ofTMEV BeAn. SFV
VLPs expressing GFP were kindly provided by Audrey Graham. Approximately
80,000 SFV-GFP VLPs were inoculated IC in 0.02 ml 0.75% PBSA.
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The estimated weight of a half brain was 0.15 g. Brain tissue was homogenised in
1.35 ml sPBS to make a final volume of 1.5 ml (1:10 weight-volume homogenate).
Other tissues used in plaque assays were diluted to a 1:10 weight-volume
homogenate. Homogenates were diluted in sPBSA to give ten-fold serial dilutions.
6-well plates were seeded with BHK-21 cells at 3xl05 per well in 10% GMEM and
incubated overnight. When monolayers were sub-confluent, media was removed
from the wells and 400 pi of a serial dilution of homogenate/virus was added in
duplicate. Plates were placed on a rotator at room temperature in a sealed humid
box. After 1 hr, 2 ml ofmedia containing GMEM with 2% NBCS, 1% L-glutamine
(2 mM), 100 u/ml penicillin, 100 pg/ml streptomycin, 25 mM HEPES and 13% agar
was added to 6-well plates and incubated for 48 hr at 37°C in a 5% CCE Wells were
fixed with neutral buffered formalin (Sigma) for 1 hr before removing agar plug and
staining with 0.1% toluidine blue (Sigma). Wells with between 2-70 plaques were
counted.
To calculate PFU per ml:
Average no. of plaques
Amount of inoculum x dilution factor
RNA extraction
Half brain samples were submerged in RNAlater (Sigma), an RNA stabilization
reagent which inhibits the activity ofRNases and preserves RNA in tissues. Tissues
were removed from RNAlater and 80-100 mg of tissue cut for homogenisation.
Tissues were homogenised in an RNase treated glass homogeniser or disposable 1.5
ml plastic homogeniser (Anachem). RNA was extracted using the RNeasy Lipid kit
(Qiagen) according to manufacturer's instructions with optional on-column DNase
step. RNA was stored at -80°C in RNase/DNase free distilled water. RNA quantity
was determined by spectrophotometer (NanoDrop" when available) and was
analysed for quantity
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RNA quality assessment
The quality on the RNA was analysed using the Agilent RNA 6000 Nano Assay.
Figure 7. Electropherogram and gel-like image of RNA band from Agilent 2100 Bioanalyser. On
electropherogram two large peaks represent 18S and 28S ribosomal RNA peaks and two bands on gel
image.
The Agilent 2100 Bioanalyser uses a combination ofmicrofluidics, capillary
electrophoresis, and fluorescent dye that binds to nucleic acids to evaluate both RNA
concentration and integrity. Size and mass information is provided by the
fluorescence of RNA molecules as they move through the channels of the chip. The
instrument software automatically compares the peak areas from unknown RNA
samples to the combined area of the six RNA 6000 Tadder RNA peaks to determine
the concentration of the unknown samples. The RNA integrity number (RIN)
software extension tool measures RNA quality and grades it on a quantitative scale
of 1 to 10. The RIN software algorithm was developed from samples including
approximately 1300 total RNA samples from various tissues from three mammalian
species (human, mouse and rat), all with varying levels of integrity. Sample integrity
is determined by the entire electrophoretic trace of the RNA sample, including the
presence or absence of degradation products. This enables interpretation of an
electropherogram, comparison of samples and repeatability of experiments. Using
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this system the RIN of all samples was determined and only those of greater than 7.5
were used.
Plasmid 'standard' preparation
The PCR standard was prepared from a pGEM plasmid containing the SFV structural
genes. This plasmid, pSFV-1 had a size of 8194 bp. pSFV-1 had been previously
transformed into DH5a (Invitrogen) Escherichia coli. The transformed bacteria
were plated onto Luria-Bertani (LB) ampicillin plates (15% agar). Colonies were
picked the next day and grown overnight in 5 ml of LB (amp) on a shaker. Plasmid
DNA was purified with QIAprep miniprep kits (Qiagen).
Linearisation
The construct had previously been confirmed by DNA sequencing but to check
plasmid identity, pSFV-1 was linearised with EcoRI restriction enzyme. 0.5 pg of
plasmid DNA was added to 2 pi EcoRI buffer, 2 pi 10X BSA, 1 pi EcoRI and made
up to 20 pi with nuclease free H20. The plasmid-restriction enzyme mix was heated
in water bath at 37°C for 1 hr and then run on a 1% agarose gel with ethidium
bromide (0.5 pg/ml).
Following confirmation of its identity by the pSFV-1 plasmid was linearised with
Spel. 2 pg plasmid were added to 2 pi buffer 2, 2 pi 10X BSA, 1 pi Spel and made
up to 20 pi volume with nuclease free water FLO. The plasmid-restriction enzyme
mix was heated in water bath at 37°C for 2 hr. Linearised DNA was purified with Jet
Quick (Genomed) and resuspended in 30 pi ofwater pre-heated to 65°C. The
linearised plasmid was then run on a 1% agarose gel with ethidium bromide (0.5
pg/mL).
In vitro transcription
RNA was synthesized from linearised pSFV-1 plasmid using the following reaction
mix:
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Spe 1 cut plasmid 25 pi
10X SP6 buffer 5 pi
rNTP mix (10 mM ATP, CTP & UTP, 5 mM GTP) 5 pi
H20 7.5 pi
Recombinant RNasin Ribonuclease Inhitibor (60 units) 1.5 pi
SP6 RNA polymerase (50 U/pl) 1 pi
Total Volume 50 pi
The reaction mixture was incubated at 37°C for 1 hr and then 65°C for 20 min before
being cleaned up on an RNeasy kit column. RNA was suspended in 30 pi of H20.
To quantify and assess the quality of the RNA, the in vitro transcript was run on a
0.7% agarose gel and quantified by both spectrophotometer and Agilent Bioanalyser.
First strand complementary (c) DNA synthesis
In 0.2 ml thin-walled PGR tubes (Axygen, UK) the following were added: 1 pi Oligo
(dT) 12-18 primer (Invitrogen), 5 pg total RNA, 1 pi 10 mM dNTPs (Promega) and
DNase/RNase free dH20 to make a final volume of 12 pi. An express thermohybaid
cycler (Hybaid, USA) was used to heat samples for 5 min at 65°C, before chilling
tubes on ice for at least 1 min. The following were added to the tubes (on ice); 4 pi
5X first strand buffer (Invitrogen), 2 pi 0.1 M DTT (Invitrogen), 1 pi RNasin
Recombinant Ribonuclease Inhibitor (Promega) and tubes were incubated at 42°C for
2 min. After incubation 1 pi of superscript II RNase-H reverse transcriptase enzyme
(Invitrogen) was added and tubes incubated at 50 min at 42°C. Samples were
inactivated by heating at 70°C for 15 min before storage at -20°C.
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Real Time - quantitative PCR (q-PCR)
The q-PCR protocol used was developed in the Fazakerley laboratory (Fragkoudis,
2002; McKimmie, 2005). Synthesised cDNA diluted 1:5 in nuclease-free water was
amplified with primers targeting a 173 base pair fragment of the El structural gene
of SFV (Table 3) using a Rotor-Gene Version 5 PCR machine (Corbett Research).
PCR reactions were carried out in 0.1 ml PCR tubes (Corbett Research). The final
volume of the reaction mixture was 20 pi which contained: 0.4 pi of both primers
(50 pM) and dNTPs, 2.8 pi MgCl2 (25 mM), 2 pi PCR Buffer, 11.15 pi
DNase/RNase free distilled water, 0.7 pi of 1:100 diluted SYBR Green (Biogene),
0.15 pi Taq Faststart (Roche) and 2 pi sample cDNA. Non template controls
included water instead of sample cDNA. An initial denaturation step of 95°C for 10
min was followed by 40 cycles of: 30 sec at 95°C, 20 sec at 62°C and 20 sec at 72°C.
A standard curve was generated from a series of 10-fold dilutions pSFV-1 of known
concentration. A melt curve was generated following the completion of the PCR
amplification by increasing the temperature of the samples gradually. This results in
the dissociation of the SYBR Green I from the amplicon and a consequent decrease
in fluorescence. The characteristic melting peak of the amplicon allows it be
distinguished from artefacts. Analysis was carried out using rotorgene software.
Samples were normalised against total RNA as measured by the Agilent RNA 6000
Nano Assay and spectrophotometer (NanoDrop 8' for later experiments). In earlier
experiments when the NanoDrop" was not available samples were also checked for
levels of the housekeeping gene (3-actin. cDNA was amplified with (3-actin primers
(Table 3), targeting a 202 bp of (3-actin gene, using the same reaction mixture and
reaction conditions as before. Data from SFV q-PCR was normalised against the
levels of P-actin expressed. In all instances where this calculation was carried out
there was no change in statistical significance between groups. Therefore measuring
the RNA by spectrophotometer and normalising to total RNA was sufficient. The
results of the q-PCR are represented as 'SFV RNA copies/5 pg total RNA'. As a
1/50 dilution of the product of the first strand cDNA synthesis reaction (to which 5
pg total RNA was added) was used per q-PCR reaction, the SFV RNA copies/5 pg
Chapter 2 Materials and Methods 52
Acquired Immune Response to SFV
total RNA was determined by taking the mean SFV RNA copies for a sample run by
q-PCR and multiplying by 50.
Primer Name Primer Sequence
SFV El forward 5'-CGCATCACCTTCTTTTGTG-3'
SFV El reverse 5'-CCAGACCACCCGAGATTTT-3'
P-actin forward 5'-CGTTGACATCCGTAAAGACC-3'
p-actin reverse 5'-CTGGAAGGTGGACAGTGAG-3'
Table 3. Details of nucleotide sequences of primers used.
Production of hyperimmune (HI) serum
Forty BALB/c mice (mixed sex) age 4-6 weeks were inoculated (day 0) with 5xl03
PFU of SFV A7(74) and boosted with repeat inoculations at 14 and 21 days. As a
specificity control, 40 BALB/c mice were inoculated with 5xl03 PFU of BeAn
TMEV strain. Both groups ofmice were sampled at day 28 and sera collected.
Enzyme Linked Immunosorbant Assay (ELISA)
Detection of anti-SFV immunoglobulin
Mice were bled by cardiac puncture. Fleparinised blood was separated by
centrifugation, plasma pooled and stored at -20°. Microtitre plates (4 HBX, Thermo
Electron Corp.) were coated overnight at 4°C with band purified SFV A7(74) diluted
in NaFICCE pH 9.6 buffer at 1:800 dilution. A diluent volume of 100 pi was chosen
as this gave the most consistent results. All samples were assayed in triplicate. Plates
were washed 3 times with PBS and 0.05% Tween 20 (PBST - Sigma) and blocked
with neat CAS block (Sigma) for 10 min at room temperature. Diluent for serum,
secondary antibody and tertiary antibody was 0.8% CAS block and 0.8% rabbit
serum in PBST. Plates were washed as before, diluted serum samples were added
along with relevant controls: no serum; irrelevant serum and immune serum. The
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microtitre plate with sera was incubated at room temperature for 90 minutes and then
washed as before. Horseradish peroxidase (HRP) conjugated secondary antibody (A-
4416 - full details of antibodies in Table 4) was added at a 1:500 dilution and
incubated for 2 hr at room temperature. Plates were then washed as before. Colour
development was observed by adding 100 pi of tetramethyl benzidine (Sigma)
substrate for 15 min, development was stopped with 0.5 M hydrochloric acid and
plates were read at 450 nm on an microplate reader (Model MRX, Dynex
Technologies).
Isotyping of serum
As before, plates were coated with virus and blocked with neat CAS block. Diluent
for serum, secondary antibody and tertiary antibody was 0.8% CAS block and 0.8%
rabbit serum in PBST. Bound test antibodies were detected with secondary
antibodies to individual immunoglobulin isotypes (incubation 30 min). An HRP
conjugated tertiary antibody (A-9917) diluted at 1:5000 was used to detect bound
isotype specific antibodies (A-9917, 15 min at room temperature). The reaction was
developed with TMB as detailed previously.
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Isotype Specificity Dilution Source Cat. Number
Secondary Ab
Gt.IgG [HRP] Mouse IgG 1:500 Sigma A-4416
Gt.IgG Mouse IgM 1:1000 Sigma M-6157
Gt.IgG Mouse IgA 1:1000 Sigma M-6032
Gt.IgG Mouse IgG 1 1:1000 Sigma M-5532
Gt.IgG Mouse IgG2a 1:1000 Sigma M-5657
Gt.IgG Mouse IgG2b 1:1000 Sigma M-5782
Gt.IgG Mouse IgG3 1:1000 Sigma M-5907
Tertiary Ab
Rb.IgG [HRP] Goat IgG 1:5000 Sigma A-9917
Table 4. Antibodies used for ELISA development. Ab - antibody, Gt - Goat, Rb - Rabbit, HRP
- horse radish peroxidase.
Plaque reduction neutralisation assay (PRNA)
A 96 well plate was seeded with 1.5xl04 BHK cells/well in 100 pi of 10% GMEM
and incubated overnight at 37°C in 5% CCA. Two-fold dilutions of sera were made
starting at 1:10 dilution. Sera were diluted in 50 pi 2% GMEM containing 10%
guinea pig complement. Each sample was tested in triplicate. 50 pi of virus (100
PFU/well) were added to sera dilutions and incubated at 37°C in 5% CO2 for 1 hr.
Controls included normal mouse serum, no serum (virus only) and no virus/no sera
control. Media was removed from the BHK monolayer and serum-virus mix (100
>
pi) added and incubated for 48hrs. The monolayer was fixed with neutral buffered
formalin for 1 hr and stained with toluidine blue for 30 min. Monolayers were
washed and wells examined for cytopathic effect. The neutralization titre was taken
as reciprocal of the highest serum dilution that inhibits cytopathic effect.
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After immersion, fixation in 10% neutral buffered formalin for 48 hr, tissues were
processed for paraffin wax embedding. Paraffin embedded slides were soaked in
clearene (Surgipath) for 2 x 7 min, before soaking in 100% ethanol followed by 95%
ethanol for 5 min each. Slides were incubated in 0.1% luxol fast blue (Sigma)
overnight at 50°C in a sealed humid chamber. Slides were rehydrated through a
series of graded alcohols (95, 70, 50 and 30% ethanol) for 1 min each, washed in
dffO, destained briefly in 0.05% lithium carbonate and 70% ethanol, stained in
0.1% Cresyl Violet Acetate (Sigma), dehydrated in ethanol (30%, 50%, 70%, 95%
and 100%) and cleared in clearene for 15 min before mounting in vectamount
(Vector).
Brain sections were scored for inflammation according to the following criteria: 0, no
inflammatory cell infiltrate; 1, a few inflammatory cells; 2, numerous scattered
inflammatory cells with an occasional perivascular cuff; 3, many perivascular cuffs;
4 many perivascular cuffs with extensive perivascular infiltration and large clusters
of inflammatory cells. The extent of demyelination was determined according to the
following scoring system: 0, no demyelination; 1, a small area ofmyelin loss; 2, >1
small area ofmyelin loss; 3, several small areas of myelin loss or a few medium
sized lesions; 4, several medium sized lesions or one or more large lesions. Micro-
cystic change (MCC) was scored as following; 0, no MCC; 1, small area ofMCC; 2,
a few areas ofMCC; 3, several areas ofMCC; 4, many and larger areas ofMCC.
Examples of uninfected and SFV infected brain tissue stained with luxol fast blue are
shown in Figure 8.
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Figure 8. LFB and CFV stained CNS of BALB/c mice. Areas of the cerebellum from uninfected
mice (A, B & C) and infected mice (D, E and F) sampled 14 days after SFV A7(74) infection.
Demyelination (dashed circles - D), microcystic change (arrows - E) and mononuclear cell infiltrates
(arrows - F) are visible. Bars represent - 400 microns D, 200 microns A, 50 microns B & E and 20
microns C & F.
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Immunostaining for SFV proteins
Slides with paraffin tissue sections were soaked in clearene (Surgipath) for 2 x 7 min,
100% ethanol for 5 min, 0.3% H2O2 for 10 min and then passed through an alcohol
gradient 95 - 30% ethanol for 1 min each before equilibrating in 0.85% NaCl for 5
min. Slides were then heated in the microwave in antigen unmasking solution
(Vector) at 750 W for 12 min and allowed to cool in the same solution for 20 min.
Proteinase K was then added, 37°C for 15 min. All incubations were performed in a
humid chamber. To stop the reaction slides were soaked in EDTA/glycine/PBS for 5
min. After two 5 min washes in PBS, 10% normal goat serum (NGS) was added for
30 min to block any reactivity to goat antibodies. After decanting the NGS from the
sections Rabbit anti-SFV, antibody was added (1:400 dilution, in 2% NGS in PBS)
for 1.5 h. Slides were washed three times in PBS for 5 min. Biotinylated Goat anti-
Rabbit IgG (1:500 dilution in 2% NGS in PBS) was then added to slides for 1 h.
Slides were washed as before. Slides were incubated with VECTASTAIN® ABC kit
(Vector Laboratories) for 30 min and again washed. DAB (Diaminobenzidine)
solution (Sigma) was added until the sections turn light brown by eye (approx 20 - 40
sec for SFV staining). This was then washed off in distilled water. Slides were
counterstained briefly with haematoxylin (Vector 'QS') and rinsed in water. Slides
were dehydrated through an alcohol gradient, 30 - 100% Ethanol for 30 sec each,
and soaked in Clearene for 15 min before mounting.
Adoptive transfer of antibody
SCID mice, age 4-6 week, were inoculated IP with 5xl03 PFU SFV A7(74). At 4
days post-infection, SCID mice received a passive transfer of 0.1 ml ofHI SFV
serum; control groups received either 0.1 ml ofTMEV d28 serum or PBS. Passive
transfers were repeated every 3 days until PID 19. At post-infection day 21, 42 and
63 mice were perfused under terminal anesthesia and sampled.
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Isolation of mouse splenocytes
After removal mouse spleens were placed in a bijou bottles containing 5 ml ofRPMI
media (on ice). Spleens were transferred to a petri dish containing 2ml of RPMI
media with 10% foetal calf serum, 1% L-glutamine (2 mM), 100 u/ml penicillin, 100
pg/ml streptomycin and 25 mM HEPES (10% RPMI). Any fat was removed from the
spleens and splenocytes teased out with a scalpel. The cell preparation was
transferred to universals and centrifuged at 400 g for 5min. The supernatant was
removed and the cells resuspended. To lyse erythrocytes, 1 ml of sterile water was
added, followed immediately by 9 ml of PBS with thorough mixing. Debris was
allowed to settle, the cell suspension removed to a universal, without disturbing
debris. Cells were spun as before, supernatant removed and resuspended in 5 ml
10% RPMI.
Isolation of lymphocytes from mouse brain
The mouse was perfused with sPBS. The brain was removed and placed in a bijou
bottle with 1 ml RPMI (on ice). The tissue was cut into small pieces and 500 pi of
Collagenase Type IV (8 mg/ml, Worthington Biochemicals, NJ) and 100 pi of
DNase (lOmg/ml, Sigma) was added, and incubated at 37°C for 30 min. The tissue
was triturated through a 23 gauge needle to make a single cell suspension. The cell
suspension was transferred to a 20 ml universal. The brain homogenate was
centrifuged (5 min 500 g) to pellet the cells. Percoll (Sigma) was diluted with 10X
PBS to make a 90% solution. All subsequent dilutions were made using IX PBS.
The cell pellet was resuspended in 4-5 ml of 30% Percoll and transferred to a 15 ml
conical tube (Falcon), and carefully underlayed with 2 ml of 70% Percoll. The brain
suspension was spun (850 g for 20 min). The top layer ofmyelin debris was pipetted
off. Mononuclear cells, which band at the interface between the 30% and 70%
Percoll layers, were removed and transferred to a universal with 5 volumes 10%
RPMI. Cells were centrifuged (10 min at 680 g) and the supernatant removed and
the cells resuspended in 200 pi of 10% RPMI and counted.
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Separation of splenocytes by MACS
Cells were separated on a LS column using a VarioMACS™ separator according to
the manufacturer's instructions (Miltenyi Biotec). Briefly, two universals containing
3.5xl08 splenocytes were incubated with 350 pL of CD8a Microbeads for 15 min on
ice, washed in sPBSA (0.5% BSA) and magnetically separated on a prepared MACS
column. Flow-through cells were collected and saved. After the column was
removed from the magnet CD8+cells were eluted and collected in a fresh tube.
Flow-through cells were spun down, resuspended in 2.5 ml of sPBSA and passed
through a second freshly prepared column. Flow-through cells were collected and
the column taken off the magnet and CD8+ cells collected in a fresh tube. Both sets
of flow-through cells were pooled and both sets of CD8+ cells were pooled. Cells
were spun down and counted and lxl06 cells aliquots taken for fluorescent-activated
cell sorting (FACS) analysis.
Staining of lymphocytes for FACS analysis
Up to lxlO6 cells were added per FACS tube (Falcon) and pelleted. 25 pi of diluted
antibody (concentration determined by titration prior to use) was added to cells and
incubated for 20 min at 4°C in the dark (Details Table 5). Cells were washed twice
by adding 2 ml PBS (1% foetal calf serum) and spun at 200 g for 5 min, the
supernatant was then poured off and the tubes blotted to remove excess liquid. Cells
were resuspended by tapping. Cells were fixed by addition of 400 pi of 1% Formal
Saline to each tube. Samples were stored in the dark at 4°C. Data were acquired on
a FACSCaliber cytometer (BD Biosciences) and analyzed by using FLOWJO
software (Treestar). Gates were set using previously established forward and side
scatter parameters which were based on mouse mononuclear cells extracted from the
brain of the EAE mouse model (Steve Anderton, University of Edinburgh, Figure 9).
Gates were verified by back-gating to show the position of cells positive for
monocyte markers such as CD45/Macl (macrophages) and CD3/CD4 (CD4+ T-
cells).
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Isotype Specificity Dilution Source Code
Rat IgG2a k Mouse CD4 [PE] 1:400
Rat IgG2a k Mouse CD8 [FITC] 1:100
Rat IgM k Mouse pan-NK [APC] 1:100
Rat lgG2b k Mouse CD45 [FITC] 1:200
Rat IgG2b k Mouse CD1 lb [APC] 1:500
Rat IgG2a k Mouse CD19 [PE] 1:400
RatlgGlA. Mouse CD25 [APC] 1:200
Hamster IgG Mouse CD3e [FITC] 1:200










Table 5. Antibody details and dilutions used for FACS staining. PE - phycoerthrin; FITC
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Figure 9. Examples of gates used to analyse mononuclear cells from the mouse brain. A Forward
and side scatter plot ofmononuclear cells isolated from the brain, gate R1 shows debris and gate R2
was used to select macrophages/microglia; B CD45 expression in macrophages/microglia selected in
gate R2; C low or no expression ofCD45 in gate R1 (debris); D Forward and side scatter plot of
mononuclear cells isolated from the brain, gate R1 shows debris and gate R2 was used to select
lymphocytes; E CD4 expression in lymphocytes selected in gate R2 and F absence ofCD4 staining
in gate R1 (debris). Bars indicate percentage positive cells
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Intracellular staining of lymphocytes for FoxP3
Mouse lymphocytes were intracellularly stained for FoxP3 (Table 5) using the Foxp3
Staining Buffer Set (cat. 00-5523) following the manufacturer's instructions
(eBioscience). Briefly, lxlO6 cells were added to each FACS tube. Cells were
stained for surface molecules CD4, CD8 and CD25 following the Staining of
lymphocytes for FACS analysis protocol. Cells were washed in cold PBS, pelleted,
resuspended and 1 ml of freshly prepared Fixation/Permeabilization working solution
(eBioscience) was added to each sample. Cells were incubated at 4°C for at least 30
min in the dark. Cells were washed twice by adding 2 ml IX Permeabilization buffer
(eBioscience) followed by centrifugation and decanting of supernatant. 50 pi of
diluted fluorochrome conjugated antiFoxp3 antibody or isotype control
(concentration determined by titration prior to use by Steve Anderton) in IX
Permeabilization buffer was added to cells and incubated at 4°C for at least 30
minutes in the dark. Cells were washed with twice with 2 ml IX Permeabilization
buffer before being resuspended in 100 pi volume Flow Cytometry Staining Buffer
(eBioscience). Data were acquired on a FACSCaliber cytometer (BD Biosciences)
and analyzed by using FLOWJO software (Treestar).
Adoptive transfer of lymphocytes
Magnetically sorted splenocytes from PID 7 SFV infected BALB/c mice were
transferred to recipient PID 7 SFV infected SCID mice (Details Table 6). A 1:1 ratio
for cell transfer was used. For example, a mean of 4.5x106 CD8+ splenocytes were
collected from each BALB/c mouse so this number of cells was transferred IP into
each recipient mouse. For IC inoculation a maximum of lxlO6 CD8+ splenocytes in
a maximum volume of 20 pi was transferred into each recipient SCID mouse. At
PID 14 all mice were sampled.
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Group Number of cells and transfer volume
CD8 IP ~ 4.5x106 CD8+cells in 0.3ml sPBSA (x5)
CD8 IC < lxlO6 CD8+cell in 20pL sPBSA (x5)
F/T ~ 4.5xl07 flow-through cells 250p.L sPBSA (x5)
PBS 0.3ml of sPBSA (x5)
Table 6. Details of number, type and volumes ofmagnetically sorted splenocytes adoptively
transferred. CD8 IP - CD8+ selected splenocytes by IP inoculation; CD8 IC - CD8T selected
splenocytes by IC inoculation; F/T - flow-through cells by IP inoculation ; PBS - PBS only
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Introduction
Acquired Immune Response to SFV
Avirulent SFV A7(74) infection causes a transient CNS infection and clearance of
virus is co-incident with the appearance of demyelinating lesion in susceptible mouse
strains (Suckling, 1978; Kelly, 1982). On a BALB/c background, SCID mice,
naturally deficient in B and T cells and nu/nu mice, naturally deficient in T-cells,
cannot clear SFV infection in the CNS but do not develop demyelinating lesions
(Fazakerley, 1983). In the CNS of SCID and nu/nu mice virally positive cells are
morphologically normal, indicating an immune aetiology for demyelination in SFV
infection. Reconstitution of nu/nu mice with splenocytes from immunocompetent
mice restores demyelinating disease (Fazakerley & Webb, 1987), while depletion of
CD8+ T-cells from immunocompetent BALB/c mice prevents the formation of
demyelinating lesions (Subak-Sharpe, 1993).
Virus clearance and pathological changes attributable to T-cells are observed in a
number of CNS viral infections. The pathogenicity of an immune response can
outweigh the benefits, for example the CD8+ T-cell response induced during LCMV
infection causes a fatal choriomenigitis before virus is cleared (Baenziger, 1986b;
Dixon, 1987c). Whereas following TMEV infection, the CD8+ lymphocyte response
in C57B1/6 mice efficiently clears virus with the help of CD4+ T-cells without
pathological changes, the same virus in SJL mice results in a poor immune response,
slow virus clearance and immune mediated demyelinating lesions (Rodriguez, 1991).
It is evident that T-cells can play a role in both the clearance and the pathology of
CNS viral infections.
To elucidate the separate roles of CD4+ and CD8+ T-cells in SFV infection, mice
deficient in either CD4+ or CD8+ lymphocytes were infected with SFV A7(74).
Subsequent CNS neuropathology and ability to clear infectious virus and virus RNA
were compared in immunodeficient mice and wild-type mice. The two strains of
mice used were, mice with a mutation of the CD8 alpha (Lyt-2) chain (CD8a) that do
not have CD8+ lymphocytes and mice with a disruption in the MHC class II A(3 gene
(MHCII7") which do not express MHC class II and have no CD4+ T-cells, both
strains were on a C57B1/6 background (Grusby, 1991; Cosgrove, 1991a).
During the course of investigation into the pathological changes induced by SFV it
was observed that mice on a C57B1/6 genetic background showed little or no
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demyelination or microcystic change in the CNS following infection. To determine
the possible cause of the lack of CNS pathology in C57B1/6 mice, it was investigated
whether cells in the CNS were permissive to infection using SFV virus-like particles
(VLPs) expressing GFP to visualise infected cells.
To get around the minimal demyelination in mice with a C57B1/6 genetic
background, adoptive transfers of CD8+ immune splenocytes to SFV infected SCID
mice on the BALB/c background which is susceptible to demyelination, were
undertaken specifically to analyse the role of CD8+ T-cells in demyelination. To
further examine the cellular immune response in the CNS, the phenotype of
inflammatory cells in the CNS during infection was examined by FACS.
Objectives
• Compare virus clearance (infectious and RNA) in MHOF7" mice with wild-
type mice
• Compare virus clearance (infectious and RNA) in CD8+ T-cell KO mice
with wild-type mice
• Transfer immune CD8+ splenocytes or immune splenocytes depleted of
CD8+ cells to SFV infected SCID mice
• Assess neuropathological changes in brains of SCID mice that receive
immune splenocyte transfers
• Determine virus clearance in SCID mice that receive immune splenocyte
transfers
• Determine if SFV virus-like particles can infect cells in the CNS of
C57B1/6 mice
• Examine the phenotype of cells present in the CNS of SFV infected
C57B1/6 mice
• Compare the phenotype of cells present in the CNS of SFV infected
C57B1/6 mice and BALB/c mice
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• Determine if T-regulatory cells are present in the CNS of SFV infected
mice
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MHC IT ' mice do not clear infectious virus
To examine the role ofCD4+ T-cells in virus clearance, C57B1/6 MHC II"" mice
(n=20) and wild-type C57B1/6 mice (n=20) aged 4-6 weeks (mixed sexes) were
infected with SFV A7(74) and sampled between PID 3 and 21. MHC II"7" mice
showed increased susceptibility to SFV infection, with 30% dying prior to sampling.
The titres of infectious virus in the brains of both mouse strains were examined
between PID 3 and 10 (Figure 10A). Infectious virus was detectable in all (4/4)
MHC IF7"mice at PID 3 and 7 but was not detectable in any mice (0/4) by PID 10.
Virus was detectable in 100% (4/4) C57B1/6 mice at PID 3, 75% (3/4) at PID 7 and
in none (0/4) at PID 10. MHC II"7" mice showed slightly higher (not significant)
levels of infectious virus compared to C57B1/6 mice at PID 3 (Logio 4.5 and 4.3,
respectively) and PID 7 (Logio 5 and 3.5, respectively). Amor et al demonstrated
that in nu/nu mice virus clearance was observed at PID 10 but infectious virus was
once again detected at later time points (Amor, 1996). In order to determine if the
virus clearance observed in MHCII"" mice was enduring, further mice were infected
and sampled at a later time point. A group ofMHCII"" mice (n=10) and wild-type
mice (n=10) were infected and sampled at PID 28 (Figure 10B). 66% (2/3) of
MHCII"7" mice had infectious virus detectable at PID 28 compared with 0% (0/4) of
C57B1/6 mice. During the course of this experiment mouse hepatitis virus (MHV)
was detected in the animal facility and, although unlikely, it is possible that the mice
used in this study were infected. This could have affected the results. The MHV
outbreak precluded any further studies.
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Figure 10. Infectious virus titres in the brains of SFV infected MHCII-/- mice ( ) and C57B1/6 mice
(■) at PID 3-10 (A) and PID 28(B). Horizontal lines indicate the mean of the groups and the dashed
line indicates the limit of detection.
Levels of SFV RNA were determined at days 14, 21 and 28 in SFV infected MHCII
/_ and C57B1/6 mice (Figure 11). At PID 14, the virus RNA levels were similar
(Logio 4.8 and 5.3, respectively). To allow statistical analysis the data from the two
later time points were combined, virus RNA levels were significantly higher in




























Figure 11. SFV RNA copies in the brains ofMHCIF7" mice ( ) and C57BI/6 mice (■), as measured
by q-PCR. Horizontal lines indicate the mean of the groups and dashed line indicates the limit of
detection. * indicates significant difference ( p<0.05). Data were analysed by Mann-Whitney test.
<21 days post-infection is combined data from PID 21 and 28.
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The MHCII"7" mice had no detectable infectious virus at PID 10, which was
unexpected. B-cell responses to most pathogens are CD4 dependent. In the absence
ofCD4+T-cells, immunoglobulin class switching will not occur (Stavnezer, 1996).
Anti-SFV IgG is necessary for infectious virus clearance in the CNS (Amor, 1996)
and mice deficient in MHC II would be expected to have very little IgG and hence be
unable to clear CNS infection. Sera taken at PID 10 were isotyped by an indirect
ELISA to determine their composition (Figure 12). At PID 10 there was a weak IgM
response in the MHCII"" mice compared with C57B1/6 mice and HI SFV serum
(positive control). This was unexpected as an equivalent IgM titre was previously
noted in nu/nu mice compared with wild-type mice (Amor, 1996). However, this
may be explained as only free IgM (not complexed with virus) will be detectable by
ELISA so any infectious virus present in the blood will bind IgM hence reducing the
titre detectable. The only other immunoglobulin isotype detectable above
background ('no serum' and 'no secondary' controls) in MHCII mice was IgG2b.
There was a clear difference between the levels of antibody isotypes detected
between the wild-type and mutant mice, with a higher OD reading in C57B1/6
observed in 4/6 of the immunoglobulin isotypes tested. The lack ofCD4+T-cells in
MHCIF7" mice, as expected does affect isotype switching, but low levels of IgG2b
antibody were present.
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Figure 12. Comparison of antibody isotypes specific for SFV present in PID 10 serum from MHCII"
and C57B1/6 mice. Controls included HI SFV serum, no sera and no secondary antibody (2° Ab).
Bound antibody was detected by ELISA using isotype specific antibodies. Points represent the mean
of three replicates; error bars (where visible) represent SEM.
To determine the role of CD4+ T-cells in the neuropathological changes observed in
the CNS following SFV infection, paraffin embedded sections from MHC II"7" and
C57B1/6 mice were stained with luxol fast blue, counterstained with cresyl violet and
scored for inflammatory, demyelination and microcystic changes; details of
pathology scoring system are given in chapter 2. MHCII"7" and wild-type C57B1/6
mice had low levels of inflammatory infiltrates in the CNS between PID 10-21 but
very few demyelinating lesions or microcystic changes (Figure 13). No significant
differences in pathology (as tested by Mann-Whitney) were observed between
MHCIF7" mice and wild-type mice. Frustratingly mice on the C57B1/6 background
appear to be a poor model in which to study SFV neuropathology. It is therefore not
possible to conclude if CD4+ T-cells are necessary for the development of
demyelination and microcystic changes in the CNS following SFV infection due to
the low incidence of these pathological features on the C57B1/6 genetic background.
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MHC II -/- C57BI/6 MHC II -/- C57BI/6 MHC II -/- C57BI/6
PID 10 PID 14 PID 21
Mouse Strain
Figure 13. Pathological scores in SFV infected C57B1/6 and MHCIF" mice between PID 14 and 21.
Results are the mean scores for at least 12 sections from at least 4 mice. INF - inflammation, DMN -
demyelination and MCC - microcystic change.
Mice lacking CD8+ T-cells have slower clearance of virus RNA
To determine the role of CD8+ T-cells in virus clearance, CD8a mice (n=30) and
wild-type (C57B1/6) mice (n=30) aged 4-6 weeks of mixed sex were infected IP with
SFV A7(74). The amount of infectious virus and virus RNA in the brain were
determined at various time points post-infection. Infectious virus was titred in brain
tissue by a standard plaque assay on BHK-21 cells (Figure 14). CD8a mice cleared
infectious virus at the same rate as immunocompetent wild-type mice (there was no
significant difference by Mann-Whitney test). At PID 3 all (6/6) CD8a mice and all
but one (5/6) wild-type mice had a high virus titre. At PID 7 5/6 CD8a and 5/5 wild-
type mice had detectable virus. At PID 10 infectious virus was not detectable in any
(0/6) CD8a mice or wild-type mice.
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Figure 14. Infectious virus titres in the brains of SFV infected CD8a mice (*) and C57B1/6 mice (■),
as measured by plaque assay. Horizontal lines indicate mean of the groups and the dashed line
indicates the limit of detection.
The levels of SFV virus RNA were determined in CD8a and C57B1/6 mice at various
time-points after infectious virus clearance (PID 14 and 21) by q-PCR (Figure 15).
Virus RNA was detectable in 100% ofCD8a mice at both time points, in 100 % (5/5)
of C57B1/6 mice at PID 14 and 80% (4/5) C57B1/6 at PID 21. Levels of virus RNA
in the CD8a mice were significantly higher than in to C57B1/6 mice at both PID 14




























Figure 15. Titres of SFV RNA in the brains of SFV infected CD8a mice (*) and C57B1/6 mice (■),
as measured by q-PCR. * indicates significant difference (p<0.05). Data were analysed by Mann-
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Whitney test. Horizontal bars indicate the mean of the groups, dashed line indicates the limit of
detection.
To determine if the difference in virus RNA clearance between CD8a and C57B1/6
mice continued beyond 21 days (3 weeks) a second group of CD8a mice (n=12) and
C57B1/6 mice (n=12) were infected (mice aged 4-6 weeks, mixed sexes) and mice
sampled at 6, 9 and 12 weeks (n=4/time-point). All mice had low levels of virus
RNA (near or below the limit of detection) in the brain, as determined by q-PCR
(Figure 16). There was a small decrease in both CD8a (mean virus copies 3.8) and
C57B1/6 mice virus RNA titre (mean virus copies 3.7) from 6 to 12 weeks post¬
infection (mean virus copies 3.6 and 3.5 respectively). CD8a mice had a slightly
higher mean virus RNA load at each time point but there was no significant






















Figure 16. Long term clearance of SFV RNA in the brains ofCD8a mice (■*) and C57B1/6 mice (■),
as measured by q-PCR. Horizontal bars indicate the mean of the groups, dashed line indicates the
limit of detection.
To determine if CD8+ T-cells have a role in inducing SFV neuropathological
changes, paraffin embedded brain sections from CD8a and C57B1/6 mice (PID 14
and 21) were stained with luxol fast blue (myelin stain) and counterstained with
cresyl violet. Sections were scored for inflammation, demyelination and microcystic
change. The wild-type C57B1/6 and the CD8a mice both showed low levels of CNS
inflammation but no obvious demyelination or microcystic change at either time
point (data not shown).
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Adoptive Transfer of SFV immune cells to SFV infected SCID
mice
Subak-Sharpe et cil used rat anti-CD4 and anti-CD8 monoclonal antibodies to
transiently deplete these subsets in BALB/c mice and noted a reduction in
demyelination in CD8+T-cell depleted mice (Subak-Sharpe, 1993). It had been
hoped that studies on the CD8a mice would confirm this finding in a more robust
system, however due to the low incidence ofmicrocystic changes and demyelinating
lesions on the C57B1/6 background it was not possible to determine the role of CD8+
and CD4+ cells in mediating these changes. In an alternative approach it was decided
to utilise SCID mice on a BALB/c background and to examine the role of CD8+ T-
cells in CNS pathology and virus clearance by carrying out adoptive transfers of
immune cells from SFV infected BALB/c mice in to SFV infected SCID mice.
BALB/c (n=15) and SCID mice (n=20) were infected IP with SFV A7(74) and at
PID 7 spleens were sampled from the BALB/c mice. CD8+ cells were positively
selected using a magnetically activated cell sorter (MACS). The CD8+ selected cells
or flow through cells were adoptively transferred to SFV infected SCID mice (5
mice/group) at a 1:1 ratio. For example, a mean of 4.5x106 CD8+ splenocytes were
collected per BALB/c mouse and this number of cells were transferred IP into each
recipient SCID mouse. One group of SCID mice received lxlO6 CD8+ splenocytes
IC and a control group received PBS (n=5/group). SCID mice were sampled at PID







. sp|enocyte adoptive tissue sampling
(BALB/c & SCID) transfer to SCID mice SCID mice
Figure 17. Timeline for raising, and adoptive transfer of immune splenocytes from SFV infected
BALB/c/ mice to SCID mice.
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Purity of cell population separated by MACS
After splenocytes were sampled from the BALB/c mice they were separated on a LS
column using a VarioMACS™ separator according to the manufacturer's
instructions (Miltenyi Biotec). Splenocytes from PID 7 SFV infected BALB/c mice
were isolated, counted and mixed with anti-CD8a microbeads (Miltenyi Biotec).
Stained cells were put through a LS MACS column on a VarioMACS™ cell
separator. Flow-through cells were collected and saved and CD8+ cells eluted from
the column. Flow-through cells were then passed through a second MACS column
and CD8+ cells eluted and pooled with the first population of eluted CD8+ cells.
lxlO6 cells from each population (as well an unseparated control) were stained with
anti-CD4-PE and CD8-FITC and analysed by FACS to assess the cell populations
present (Figure 18). Unseparated splenocytes contained 20% CD4+ T-cells and
10.5% CD8+T-cells. There was a small population of CD4 and CD8 double-positive
cells. Flow-through cells had an increased proportion of CD4+ cells (21%) and a
decreased CD8+ cell population (3.8%). The positively selected cells had a very low
CD4 population (0.6%) and were highly enriched for CD8+ cells (97%).
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Figure 18. CDAand CD8+ staining of splenocytes from SFV infected BALB/c mice at P1D 7 before
(unstained and unseparated) and after (MACS f/through and MACS CD8+) CD8 cell selection on a
MACS. Numbers are events in a quadrant expressed as a percentage of the lymphocyte gate. MACS
f/through - MACS flow-through cells; MACS CD8+ - positively selected CD8+ cells.
SFV infected SCID mice that receive CD8+ splenocytes do not
clear infectious virus or virus RNA
Three groups of SFV infected SCID mice received immune transfers at PID 7. One
group received CD8+ selected splenocytes by IP inoculation (CD8+ IP), a second
group received CD8+ selected splenocytes by IC inoculation (CD8+ IC) and a third
group received flow-through cells by IP inoculation (F/T). A control group received
PBS only. Of the CD8+ IP mice, 3/5 showed hind-limb paralysis and all showed
piloerection, hunched posture and visible weight loss. F/T mice also had
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piloerection, hunched posture, immobility and visible weight loss. CD8+ IC mice
and PBS control mice had ungroomed coats but otherwise, no outward signs of
illness.
Levels of infectious virus were assayed in the heart tissue of the SCID mice at PID
14 (Figure 19). Mice that received CD8+ T-cells (IP or IC) had low infectious virus
titres. A low level (Logio 2.4 - 2.8 pfu/g) of infectious virus was detectable in 40%
(2/5) mice in both groups. F/T mice had no (0/4) infectious virus and 100% (5/5)
mice that received PBS had significantly higher levels of infectious virus than all
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Figure 19. Infectious virus titres at PID 14 in heart tissue of SFV infected SCID mice that received
immune cell adoptive transfers. * indicates significant difference (p<0.05) with all other groups.
Data analysed by Mann-Whitney test. Horizontal lines indicate the mean of the groups and the dashed
line indicates the limit of detection. Column titles represent the immune cells transferred. F/T - flow-
through splenocytes from MACS, PBS - control PBS transfer.
In SCID mice that received adoptive transfers, the number of copies of SFV RNA in
the brain tissue was assayed at PID 14 (Figure 20). The CD8+ IP group had the
highest mean SFV copies (7.8 Logio SFV copies/5 pg RNA), which was significantly
higher than the F/T group, that received splenocytes depleted of CD8+ T-cells
(p=0.0317 data analysed by Mann-Whitney test). There was also a significant
difference in virus RNA levels between the F/T group and the control mice which
received no cell transfers (p=0.0317).
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Figure 20. Levels of SFV RNA at PID 14 in the brains of SFV infected SCID mice that received
immune cell adoptive transfers. * indicates significant difference ( p<0.05). Data analysed by Mann-
Whitney test. Horizontal lines indicate the mean of the groups and the dashed line indicates the limit
of detection. Column titles represent the immune cells transferred. F/T - flow-through splenocytes
from MACS, PBS - control PBS transfer.
To determine if antibody was being secreted in mice that received adoptive transfers,
sera from all groups (CD8+ IP[x3], CD8+ IC [x2], F/T [x3] and PBS [x2]) were tested
for neutralisation activity by plaque reduction neutralisation assay. There was no
protection ofBHK-21 cell monolayers by the sera in any of the groups (data not
shown); the level of neutralising antibody was below lxlO4 pfu neutralised/ml (limit
of detection).
CNS pathology in mice that have received adoptive transfers
PID 14 brain sections from the SCID mice that received adoptive transfers were
fixed and processed for paraffin sectioning. To examine virus spread,
immunostaining for SFV antigen was carried out. The average number of virus-
positive cells per section was determined from 6 brain sections per mouse (Figure
21). The CD8+ IP group had the highest mean number of virus positive cells/brain
section (mean 20 cells/section). This correlated with the virus RNA load in the brain
of the CD8+ IP mice. F/T mice, CD8 IC mice and PBS mice had similar numbers of
SFV+ cells/section. It was unexpected that the CD8+ IP group that received adoptive
transfers should have more virus-positive cells (not significant by Mann-Whitney
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Figure 21. SFV-positive cells per section of brain (detected by immunostaining) at PID 14 in SFV
infected SCID mice that had received immune cells by adoptive transfer. Error bars indicate the SEM.
Column titles represent the immune cells transferred and the method of transfer. F/T - flow-through
splenocytes from MACS, PBS - control PBS transfer.
Histological scoring for inflammation (INF), demyelination (DMN) and microcystic
change (MCC) was also carried out on paraffin sections of the brain stained with
luxol fast blue (myelin stain) and counterstained with cresyl violet (nuclear stain). In
mice that received PBS, some virus infected areas of the brain had swollen nuclei
(Figure 23A) but otherwise, as expected, these sections showed little pathology (0.25
- INF, 0.25 - MCC). In contrast, mice receiving adoptive transfers had
inflammatory infiltrates, microcystic changes and lesions of demyelination. There
was little difference in their mean histological scores (Figure 22) between the 3
groups of SFV infected SCID mice that received splenocytes (CD8+IP, CD8+IC and
F/T). Demyelination although observed infrequently was present in both F/T and
CD8+ mice. An example of a demyelinating lesion from a CD8+ IC mouse is shown
in Figure 23B. The composition of inflammatory infiltrates appeared to differ
between the groups that received CD8+ T-cells and F/T. CD8+ IP mice had more
mononuclear cell infiltrates (dense, round purple cells) whereas the F/T mice had a
greater number of macrophage-like cells (pale purple, elongated and or dumbbell
shaped cells) in inflammatory regions (Figure 23C & D, respectively). Inflammatory
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lesions were present in both CD8+ IP and F/T group which contained microcystic
change, many SFV positive cells and necrotic areas (Figure 23E & F). Conversely,
SFV positive cells were also found in mice without any inflammatory response
(Figure 23G - CD8+ IP, Figure 23H - F/T).
At the group level, INF was significantly greater (p<0.05) in all groups compared to
PBS. The levels ofDMN and MCC was significant in the CD8+IC (p=0.03) and F/T
(p= 0.0286) groups compared to PBS group (data analysed by Mann-Whitney test).
There was much intra-group variation, especially in the mice that received CD8+
cells IP (Table 7). For example, CD8+IP mouse 1 had a high pathological score
(INF 4, DMN 1.8, MCC 3.1) whereas mouse 3 had almost no pathological changes
(INF 0.9, DMN 0, MCC 0.1). This difference could indicate natural variation in
responses to the virus or, more likely, differences in the efficacy of the adoptive
transfers. If few cells were successfully transferred, a low pathological score might
be expected, as observed in the PBS control group.
The experiment was designed to elucidate the role of CD8+ T-cells in demyelination
and the key finding is that CD8+ cells are sufficient to generate these lesions. No
conclusions can be drawn about the role of CD4 T-cells alone. It is possible that
CD4+ T-cells can initiate demyelination, perhaps mediated by macrophages, but as a
sizable CD8+ population was also present in the flow-through, it cannot be excluded
that CD8+ cells were also responsible for the demyelination in this group.
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CD8+ IP CD8+ IC F/T PBS
Group
Figure 22. Mean histological scores at P1D 14 in SFV infected SCID mice that had received immune
cell adoptive transfers. Results are the means scores for at least 12 brain sections from at least 4 mice.
* indicates p<0.05 with all other groups; + indicates significant difference (p<0.05) with CD8 IC and
F/T groups. Data analysed by Mann-Whitney test. INF - inflammation; DMN - demyelination and
MCC - microcystic change.
Group Number INF DMN MCC
CD8+ IP 1 4 1.8 3.1
2 3 1 1.5
3 0.9 0 0.1
4 2.3 1 1.1
5 1.4 0 0.8
CD8+ IC 1 2.3 0.8 18
2 2.6 1.3 1.5
3 2 0.4 0.5
4 2.4 0.5 1.5
5 2.1 1 2
F/T 1 3.6 2 3.1
2 1.4 0.5 0.9
3 2.8 0.6 1
4 3.3 0.8 1.2
PBS 1 0.3 0 0.4
2 0.3 0 0.3
3 0.5 0 0.6
4 0.6 0.1 0.5
5 0.1 0 0.1
Table 7. Individual histological scores for
SFV infected SCID mice at P1D 14 that had
received immune cell adoptive transfers.
Results are the means scores for at least 12
sections. INF - inflammation, DMN -
demyelination and MCC - microcystic
change.
Chapter 3 Role of CD4+ and CD8+ T-cells in SFV infection. 82
Acquired Immune Response to SFV
Figure 23. Pathological changes in SFV infected SCID mice that received immune cell adoptive
transfer. Sections of paraffin embedded brain tissue were inimunostained for SFV antigen (black) and
then stained with luxol fast blue and cresyl violet. A swollen nuclei (arrows) in SFV infected control
mice; B DMN (circle) in cerebellum ofCD8f IC; C mononuclear cell infiltrates in CD8+ IP (circle); D
macrophage (arrows) and mononuclear cell infiltrates in F/T; E necrotic lesions in CD8+ IP; F
necrotic lesions in F/T; G SFV infected cells (arrows) with no inflammatory response in CD8+ IP; H
SFV infected cell (arrow) with no inflammatory response in F/T. CD8+ IC - mice that received CD8+
cells IC; CD8+ IP mice that received CD8+ cells IP; F/T mice that received F/T cells IP; DMN
demyelination. Bar represents: 20 microns A, C, D, G & H; 50 microns E & F, 100 microns B.
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Virus-like particles can successfully infect cells of the CNS in
C57BI/6 mice
Data shown earlier in this chapter demonstrated that mice with a C57B1/6 genetic
background showed little or no demyelination or microcystic change in the CNS
following SFV infection. Other strains of mice (BALB/c, WT-129) typically have
demyelinating lesions from PID 14 to 21 when inoculated IP with SFV. Previous
reports have shown demyelination in C57B1/6 mice; however these mice may have
had a slightly different genetic background due to differences between breeding
stocks or suppliers (Sheahan, 1983; Mokhtarian & Swoveland, 1987). One possible
explanation for the lack of demyelination in C57B1/6 mice would be more efficient
virus clearance from the brain; if C57B1/6 mice have less viral spread in the CNS,
perhaps due to a more efficient immune response, this could limit or prevent
demyelination. Such is the case in TMEV infection where depletion of the protective
response of CD4+ or CD8+ T-cells makes previously resistant C57B1/6 mice
susceptible to demyelinating disease (Rodriguez, 1991). Another possible
explanation for the lack of demyelination would be that C57B1/6 mice lack a receptor
that allows productive CNS infection. SJL mice are resistant to MHV infection of
the CNS whereas BALB/c mice succumb to CNS infection with a few days.
Resistance to MHV in SJL mice has been linked to a polymorphism in the MHV
receptor (MHVR) biliary glycoprotein 1; the virus has 10 to 30-fold less affinity for
biliary glycoprotein lb (MHVR2) than for biliary glycoprotein la (MHVR1) allele
expressed in susceptible BALB/c mice (Boyle, 1987; Ohtsuka & Taguchi, 1997a). If
SFV does not productively or efficiently infect CNS cells or a subpopulation ofCNS
cells, for example oligodendrocytes, in C57B1/6 mice fewer pathological changes
would be expected.
SFV has been detected in the CNS of C57B1/6 by plaque assay; however a high titre
viraemia could contribute to virus detected in the brain. To determine whether
oligodendrocytes in C57B1/6 mice were susceptible to SFV infection, C57B1/6 mice
(n=4) were inoculated IC with approximately 80,000 SFV-GFP VLPs and sampled at
PID 5 and 14. VLPs are structurally identical to virus but they contain a modified
genome which can express foreign genes. The use ofVLPs encoding GFP allows
microscopic visualisation of infected cells without the need for immunostaining. In a
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previous study it was demonstrated that direct IC inoculation of SFV-GFP VLPs into
the BALB/c mouse brain resulted in widespread infection of cells, predominantly
oligodendrocytes in the major white matter tracts of the brain (Fazakerley, 2006).
VLP infected cells (EGFP-positive) were clearly visible at PID 5 and were most
evident along the white matter tracts (Figure 24A and B). Areas of infection were
also visible in areas away from the white matter (Figure 24C). The higher power
image (Figure 24D) clearly shows VLP infection of oligodendrocytes. The cell body
fluoresces brightly as do all the processes extending from the oligodendrocytes,
which are myelinating surrounding axons. A later time point in infection (PID 14)
was also examined to determine if virus was cleared rapidly in C57B1/6 mice (Figure
24E and F). The fluorescence was weaker than at earlier time points, but VLP
infected cells were still visible. This experiment demonstrated that the white matter
tract cells including oligodendrocytes in the CNS ofC57B1/6 mice are permissive for
infection with SFV or SFV-like particles and that resistance of this cell population to
CNS infection is not the reason for the low levels of demyelination observed in this
mouse strain. Most likely these mice differ to BALB/c mice in the quality or
quantity of their immune response.
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Figure 24. SFV-EGFP VLP infections in the CNS of C57B1/6 mice at PID 5 (A-D) and PID 14 (E
and F). C57B1/6 mice were inoculated IC with 80,000 VLP and sampled at PID 5 and 14. Many of
the infected cells (bright green) have the typical morphology of oligodendrocytes (shown by arrow);
characterised by many extending processes. A,B» E and F show infected cells in the white matter
tracts of the corpus callosum (cc) and cingullum (eg), C and D show infected cell in the cortex. Bars
represent 100 microns A. B & E; 50 microns C & E and 20 microns D.
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The phenotype of CNS inflammatory cells in SFV infection
FACS experiment 1
In this chapter the roles ofCD4+ and CD8+ T-cells were examined to elucidate their
contribution, beneficial or damaging, in SFV infection. In order to examine the CNS
cellular inflammatory response to SFV as a whole, the phenotype of lymphocytes
extracted from the CNS of SFV infected mice were analysed by FACS. The kinetics
of lymphocyte entry into the CNS, the magnitude of immune responses and the
quality of the responses in different mouse strains (C57B1/6 mice and BALB/c) were
studied.
For FACS experiment 1, C57B1/6 mice (n=20, age 4-6 weeks, mixed sexes) were
inoculated with 5xl03 pfu SFV A7(74) IP. Five mice were sampled at 3, 6, 8 and 15
days post-infection. These time points were chosen to allow observations prior to
inflammatory infiltration (PID 3), at peak lymphocyte infiltration of the CSF
(Parsons & Webb, 1982i) and after infectious virus has cleared (PID 15). Brains
from perfused animals were treated with collagenase and DNase and disrupted by
trituration through decreasing needle sizes. Mononuclear cells were then prepared
from a 30:70% discontinuous Percoll gradient after centrifugation (see Materials and
Methods for full details). Cells were stained for FACS analysis with antibodies to
CD4 (T helper cell marker), CD8 (cytotoxic T-cell marker), CD 19 (B-cell marker),
CD25 (T-cell subset marker), CD45 (activation marker) and CD1 lb (Macl -
macrophage marker). These markers allow recognition of T-cell subsets (CD4+ and
CD8+) and B-cells (CD19). Infiltrating macrophage (CD1 lb CD45hl) and resident
microglia (CD1 lb CD4510) can be distinguished by their differential expression of
CD45 (Sedgwick, 1991b). An anti-CD25 antibody was included; CD25 is a putative
marker of T-reg cells, but is also an activation marker of T-cells. Cells double-
staining for CD4 and CD25 may represent a regulatory population. It was of
particular interest to observe if T-reg cells were present in this model system of virus
encephalitis. After FACS analysis, cells were presented as the total number of
cells/brain and not as a proportion of the total number of cells. This method was
chosen as the total cell population increases in the inflamed brain, therefore
representing cell populations as a percentage of the total can be misleading. Using
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the total number of cells/brain allows data between days to be compared. This
method does assume that cell isolation efficiencies in all samples are equal.
At PID 3, low levels ofCD4+ and CD8+ cells were detected, but microglia were, as
expected, the most common cell type detected (Figure 25). By PID 6 there was a 3.5-
fold increase in microglial cells, a 20-fold increase in macrophages and a >25-fold
increase in CD4+ and CD8+ T-cells. A detectable population ofCD4+CD25+ T-cells
was present (Figure 25C). The peak of inflammation was at PID 8 when there were
increases in all cell types. The greatest increase was in CD8+ T-cells (10-fold
increase from PID 6 to a mean of 17,100 cells/brain) levels at twice those ofCD4+ T-
cells (mean 7,800 cells/brain). PID 8 was the first day that CD 19+cells were stained,
a mean cell count/ brain of 1,500, which was low compared to other cell types. At
PID 15 there was a decrease in most cell types, macrophages decreased 2.5-fold and
microglia had a 1.3-fold decrease. At PID 15, both CD4+ and CD8+ T-cells had the
same mean cell count/brain (decreases of 2.8-fold and 4-fold, respectively). CD19+
cells were the only population to remain constant at this time point.
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Figure 25. Phenotype and mean number of cells in the CNS of C57BI/6 mice (n=5) infected with
SFV. Cells were surface stained with labelled antibody and analysed by FACSCalibur. A-
Haemocytometer count; B- CD4 and CD8 staining of lymphocytes; C- CD4 and CD25 staining of
lymphocytes; D- Macl and CD45 staining of lymphocytes; E- CD 19 staining of lymphocytes. Error
bars represent the SEM.
Chapter 3 Role of CD4 and CD8 T-cells in SFV infection. 89
Acquired Immune Response to SFV
FACS experiment 2
The earlier studies in this chapter highlighted differences in CNS pathology between
SFV infected BALB/c and C57B1/6 mice. These changes could be related to
differences in immune responses. The phenotype of inflammatory cells isolated from
the CNS of two strains of SFV infected mice were compared by FACS analysis. Pan-
NK marker Dx5 and T-reg cell marker FoxP3 were included in this experiment. NK
cells are lymphocytes of the innate immune system but possess the cytolytic capacity
ofCD8+ T-cells. They can rapidly kill virus infected cells via perforin/granzyme
release and are an important source of cytokines such as IFNy. It is not known if
these cells are important in SFV infection, but an early peak ofwhite blood cells is
detected in the CSF at PID 6 and this could be NK cells (Parsons & Webb, 1982e).
The detection of naturally occurring T-regs is currently defined by the expression of
FoxP3 (Hori, 2003). The Foxp3 gene is a member of the forkhead/winged-helix
family of transcriptional regulators and this gene appears to function as the master
regulator in the development and function of regulatory T cells.
Mice (C57B1/6, n=20 and BALB/c, n=20) were inoculated with 5x103 pfu SFV
A7(74) IP and 5 mice from each group were sampled at 3, 6, 8 and 14 days post¬
infection. Mouse brain lymphocytes were extracted using a neuronal dissociation kit
(Miltenyi Biotec). This resulted in improved tissue homogenisation and increased
cell yield per brain, but also increased the debris collected, which resulted in
increased autofluorescence.
The cell yield per brain in BALB/c mice (as quantified by haemocytometer) was high
at days 3, 6 and 8 but reduced at day 14 (Figure 27B) which was similar to the
kinetics observed in C57B1/6 mice in experiment 1 (Figure 25A). In contrast, the cell
yield for C57B1/6 mice showed the lowest number of cells/brain at PID 8 (
Figure 26A). Cell isolates from different animals were kept separate but samples
from the same time point were processed together as a batch. It is possible that
something happened to the C57B1/6 day 8 samples to reduce the yield during
processing. This could have been disruption ofPercoll layers during separation in the
centrifuge. As a result the cells/brain counts for all C57B1/6 cell types at PID 8 are
most probably low, though their relative percentages at this time point remain correct.
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The CD8a stain did not work in this second experiment so the CD4"CD3+ population
was analysed as a substitute; this population will include the CD8+ T-cells. The CD4"
CD3+ population is unlikely to be exactly the same CD8+ population. However, the
former showed the same dynamics as the CD8+ T-cells in experiment 1 suggesting it
was a reasonable substitute.
Very few cells were detectable at PID 3 in both groups of mice. The exceptions to
this are microglia, which are resident in the CNS, and a small population ofNK cells.
By PID 6 there was an increase in infiltrating cell populations in both mouse strains.
Notably in the C57B1/6 mice between PID 3 and 6 there was a huge increase in
macrophages (70-fold) and a 5-fold increase in NK cells. The BALB/c mice, as in
C57B1/6 mice in experiment 1, had the highest cells/brain count for all cell types at
PID 8. However, the cells/brain counts for C57B1/6 mice in experiment 2 were low
or stable at PID 8, as discussed previously this may have been an artefact.
Interestingly in these mice at this time point, the CD4+ CD25+ population still
increased. At PID 14 in the BALB/c mice, all cell populations contracted except
CD4+ T-cells which remained stable.
T-regs are defined phenotypically as CD4+CD25+ cells that express the FoxP3 gene.
To investigate if such cells are present during viral CNS infections, pooled cells from
5 mice at PID 6, 8 and 14 were stained for CD4 and CD25 followed by intracellular
staining for FoxP3. PID 3 was not used as a CD4+CD25+ population was not
detectable at this early time-point. The dot plot of the FoxP3 staining from PID 8 in
C57B1/6 and BALB/c mice is shown in
Figure 26F and Figure 27F, respectively. A very small percentage of FoxP3 positive
cells were detected, it is not possible to say whether these represent T-reg cells
without a more extensive study and the inclusion of a positive control. The dot plot
from PID 8 is also representative of the results at PID 6 and PID 14.
Taking into account the problems with cell extraction and the anti-CD8 antibody, it
would have been desirable to repeat this study; however an MHV outbreak in the
animal facilities precluded any further animal work.
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Figure 26. Phenotype and mean number of cells/brain in the CNS of C57B1/6 mice (n=5/time point)
infected with SFV. Cells were surface stained with labelled antibody and analysed by FACSCalibur.
A- Haemocytometer count, B- CD3 and CD4 staining of lymphocytes, C- CD4 and CD25 staining of
lymphocytes, D- Macl and CD4 staining of lymphocytes, E- Dx5 staining (pan NK marker) of
lymphocytes, F- Dot plot of isotype control (left) and FoxP3 (right) with CD25 staining of CD4 '
lymphocytes. Error bars represent the SEM
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Figure 27. Phenotype and mean number of cells in the CNS of BALB/c mice (n=5/time point)
infected with SFV. Cells were surface stained with labelled antibody and analysed by FACSCalibur.
A- Haemocytometer count, B- CD3 and CD4 staining of lymphocytes, C- CD4 and CD25 staining of
lymphocytes, D- Macl and CD4 staining of lymphocytes, E- Dx5 staining (pan NK marker) of
lymphocytes, F- Dot plot of isotype control (left) and FoxP3 (right) with CD25 staining of CD4^
lymphocytes. Error bars represent the SEM
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Summary of findings
• Mice lacking CD4+ T-cells are unable to make a complete antibody
response to SFV
• Mice lacking CD4+ T-cells are unable to clear infectious virus or virus
RNA from the brain
• Mice lacking CD8+ T-cells show no difference in their ability to clear
infectious virus from the brain compared to wild-type mice
• Mice lacking CD8+ T-cells are significantly slower at clearing of SFV RNA
from the brain compared to wild-type mice
• CD8+ T-cells are sufficient to mediate the demyelinating lesions observed
in SFV infected SCID mice that receive T-cells by adoptive transfer
• SFV can successfully infect cells in the CNS of C57B1/6 mice
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To investigate the roles of different elements of the immune response in infectious
disease, a multitude of animal models have been studied. In mice these include the
naturally occurring mutations ofSCID and nu/nu to genetically engineered disruption
or insertion of specific genes. The possibilities to investigate the role of a particular
immune mechanism in disease are sometimes numerous. Caution must be used in
comparing results between studies, not only to allow for mouse strain and pathogen
differences, but also to recognise that genetic changes which may be anticipated to
give similar results may not do so. For example, following LCMV infection of p2
microglobulin KO ^rrf7") mice and CD8a mice, CD8a mice survive persistently
infected without brain immunopathology whereas 80% of mice die. This
disparity is due to the haplotype (H-2d) of the P2IT17" mice. In the absence of P2IT1
mice of this haplotype can still present a limited number of epitopes and in the case
of LCMV, a fatal immunopathology develops (Fung-Leung, 1991b; Cook, 1995). In
contrast the CD8a mice have no functional CTLs and do not develop
immunopathology. For the discussion of this chapter, comparison of results is,
where possible, limited to studies using the same mouse strains used in this thesis.
Select examples of other mice have been included, where their inclusion aids
understanding of the T-cell response in viral CNS infection.
The role of CD8+T-cells in CNS viral infections
The role of CD8 T-cells in SFV infection was examined by infecting CD8a mice and
adoptively transferring CD8+ splenocytes from SFV infected immunocompetent
mice to SFV infected SCID mice. The former studied events in the absence of CD8+
T-cells but on otherwise intact adaptive immune system; the latter studied events in
the absence of an adaptive immune system except for the presence of activated CD8+
lymphocytes. The aim of these studies was to address the following questions about
the role of CD8+ T-cells in SFV encephalitis: Are CD8~ T-cells sufficient to clear
virus? Are CD8+ T-cells sufficient to cause neuropathology? Are CD8 T-cells
required to clear virus? Are CD8+ T-cells required to cause neuropathology?
Are CD8+ T-cells sufficient to clear virus? 2/5 mice that received activated CD8+
splenocytes (either IP or IC) had infectious virus in peripheral tissues 14 days post-
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infection compared with 5/5 control SCID mice that received PBS. When RAG17"
mice (which lack B- and T-cells) were inoculated with MHV and received transfers
of immune CD8+ T-cells, infectious virus loads were reduced but not cleared (Wu,
2000a). Further work using expanded MHV CD8+ T cell clones (Yamaguchi, 1991;
Stohlman, 1995) and IC adoptive transfer into infected immunocompetent BALB/c
mice, increased the efficiency of virus clearance, but complete clearance was still not
achieved. In TMEV infection, resistance to persistent infection is associated with,
amongst others, MHC class I genes. It has been demonstrated that CD8+ T-cells
have an important role in virus clearance (Borrow, 1992a), however the transfer of
CD8+ T-cells alone into TMEV infected SCID mice is insufficient to clear virus
infection (Rodriguez, 1996). In SFV infection the CD8+ T-cells had an antiviral
function, but alone were not sufficient to control viral spread. CD8+ T-cells
inoculated directly IC were more effective at clearing CNS virus RNA, but both
groups of mice that received CD8+ T-cells IC had detectable peripheral infectious
virus. The inability ofCD8+ T-cells alone to clear virus is in keeping with the role of
these cells in other neurotropic viruses.
Are CDH T-cells sufficient to cause neuropathology? SFV infected SCID mice that
received CD8+ cells had lesions of demyelinating disease whereas control mice (that
received PBS only) did not. This demonstrates the CD8+T-cells alone are sufficient
mediate demyelination in SFV infection. The number of virus infected cells/brain
section was also highest in the CD8+ IP mice. It is possible that the increase in virus-
positive cells is caused or initiated by CD8+ T-cells. For example, infected cells
lysed by CD8+ T-cells could allow virus release into an antibody free environment,
augmenting viral spread. The increase in virus spread could also account for the high
amount of viral RNA in mice receiving CD8+ cells IP. The increase in pathological
changes observed in CD8+ IP is consistent with previous work by Subak-Sharpe et al
which demonstrated that antibody mediated depletion ofCD8+ T-cells in SFV
infected BALB/c mice abrogated CNS demyelination. (Subak-Sharpe, 1993). The
mechanism of demyelination was not investigated in this thesis but it is likely, given
the propensity of SFV to replicate in oligodendrocytes that demyelination results
from CD8+ T-cell mediated destruction of infected oligodendrocytes.
In another neurotropic virus infection, LCMV, CD8+ T-cells mediate a fatal
immunopathology. When immune CTLs were transferred into LCMV infected,
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irradiated or immunosuppressed wild-type mice, neuropathology and fatal disease
occurred within 4 days. In contrast, transfer of the same cells to uninfected mice had
no effect (Baenziger, 1986a; Dixon, 1987b).
Similarly, the pathogenic potential ofCD8+ T-cells in the CNS has been
demonstrated in MHV infection. CD8T T-cells alone can mediate demyelination as
demonstrated in Rag1mice given CD8+ enriched splenocyte transfers (Wu, 2000b).
Conversely, IC transfer ofCTL clones specific for MHV into BALB/c mice did not
cause visible brain pathology (Stohlman, 1995). This could be due to rapid clearance
of infectious virus from the CNS in this system, whereas CD8+ T-cells administered
IP take longer to track into the brain, allowing further virus spread in the CNS which
makes the infection more difficult to clear and immune pathology more likely. The
balance between immune response and virus persistence is an important determinant
in whether demyelination occurs. This is elegantly demonstrated in TMEV infection
where resistance and susceptibility to CNS virus persistence and CNS demyelination
are genetically determined. In resistant mice (C57B1/6) virus is rapidly cleared by
CD84 T-cells and there is no brain pathology. In susceptible (SJL) mice there is a
slow, weak CD8+ T-cell response (Dethlefs, 1997b). BALB/cByJ mice can be made
susceptible to TMEV infection by irradiation but the transfer of CD8+ T-cells from a
non-irradiated mice (resistant) confers protection (Nicholson, 1996). Both the
strength and the specificity of the CTL response play a part in prevent or initiating
demyelination in TMEV infection.
The work presented in this chapter has shown that CD8+ T-cells alone are sufficient
to produce lesions of demyelination following SFV infection. The adoptive transfer
performed here was a small study and would benefit from increased group numbers,
as it appears not all adoptive transfers were successful, as was evident from the huge
range in pathological changes in the CD8 IP mice (Table 7).
To address the following questions: Are CD8+ T-cells required to clear virus? Are
CD8+ T-cells required to cause neuropathology? Mice lacking CD8+ lymphocytes
(C57B1/6 CD8a mice) were infected with SFV. However, as there were almost no
demyelinating lesions detectable in wild-type C57B1/6, unlike in other strains of
mice (129 and BALB/c), this study was unable to determine if the lack of CD8+ T-
cells had an affect on demyelination. CD8a mice cleared infectious virus at the same
rate as wild-type mice, however the rate of virus RNA clearance was significantly
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slower (CD8a titres were higher at PID 14 and 21). It can be concluded that CD8+ T-
cells are not required for infectious virus clearance but they accelerate the clearance
of virus RNA. The data are consistent with these from another alphavirus, SV,
where CD8a mice also have a delay in virus RNA clearance but not infectious virus
clearance (Kimura & Griffin, 2000). The difference in virus RNA clearance at 2 and
3 weeks between CD8a and wild-type mice did not persist at later time points (6 and
12 weeks PI).
A more prominent protective role for CD8+ T-cells is apparent in MHV infected
CD8a mice. CD8a mice are more susceptible to MHV infection (70% mortality at
PID 12 compared to 20 % in wild-type) and mice surviving to PID 12 are all positive
for infectious virus, whereas wild-type mice clear infection by this time. Similarly to
SFV, MHV infected CD8a mice did not show increased CNS pathology (Lane,
2000). The importance of CD8+ T-cells in reducing MHV infection is corroborated
by delayed virus clearance in mice depleted ofCD8 T-cells (Pearce, 1994) and p2m"/"
mice (Gombold, 1995).
Murray et al examined neuropathology in TMEV infected mice lacking CD8+ T-
cells, on both susceptible (SJL and PLJ) and resistant (C57B1/6) backgrounds. CD8a
mice on a C57B1/6 background developed persistent infection and demyelinating
disease. Susceptible CD8a mice (SJL and PLJ background) showed no difference in
the extent of demyelinating disease however virus titres increased in CD8a SJL mice
but not in PLJ mice (Murray, 1998d). CD8+ T-cells contribute to resistance to
TMEV and either their absence or the increased presence of virus allows
demyelination to occur. In this system, in contrast to SFV, CD8+ T-cells prevent
demyelination by controlling virus; demyelination is enhanced in the absence of
CD8+ T-cells indicating that theses cells are not required to produce these lesions.
LCMV infected CD8a mice also cannot clear infection. CD8a mice have a high
virus titre following IC LCMV infection; however some pathological changes still
occur in the absence of CD8+ T-cells (Fung-Leung, 1991a). This has been attributed
to CD4+ T-cell mediated cytotoxicity via Fas ligation (Zajac, 1996).
The data from the CD8a mice demonstrates a function of the CD8+ T-cells not
evident in the adoptive transfer of CD8+ splenocytes alone. The presence of CD8+ T-
cells aids the reduction of virus RNA in co-operation with the rest of the adaptive
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immune response. The q-PCR allows more subtle changes in virus load to be
observed than are detectable by plaque assay. Changes in infectious virus clearance
and in neuropathology, observed in other neurotropic viruses, were not evident in
SFV infected CD8a mice.
The role of CD4+T-cells in CNS viral infections
MHCII"7" mice were used to compare levels of virus clearance and neuropathology to
C57B1/6 mice. Mice lacking CD4+T-cells appeared to clear infectious virus at the
same rate as wild-type mice, but sampling at a later time point (P1D 28)
demonstrated that infectious virus was still present. As for wild-type C57B1/6 mice,
MHCII"7" mice had few pathological changes in their CNS. B-cell CD4+ T-cell
independent responses to viruses are also known to occur (Markowitz, 1993). This
was not observed in SFV infection where the antibody response was weaker without
CD4+ T-cells present, as demonstrated by the low levels of SFV specific antibody in
the MHC IF7" mice. A primary CD8+ T-cell response can also develop in a CD4
independent manner (Bourgeois, 2002; Janssen, 2003). However, Nu/nu mice which
lack CD4+ and CD8+ T-cells similarly cannot clear infectious virus in the CNS and
do not develop demyelinating disease (Fazakerley & Webb, 1987). This indicates
that the CD8+ T-cell response that develops in MHC IF7" mice is not sufficient to
clear infectious virus. CD4+ T-cells are required directly or indirectly (via antibody
isotype switching) for clearance of SFV.
Unlike in SFV infection, following MHV infection CD4+ T-cells were found to have
a pivotal role in accelerating neuropathology; MHC II"7" mice had significantly less
inflammation and demyelination than C57BT/6 mice. In this model system MHC II"
7" mice had a significant reduction in the number of activated macrophages/microglial
cells in the brain compared to wild-type mice, suggesting a role for CD4+ T-cells in
myelin destruction.
In persistent TMEV infection, CD4+ T-cells protect against neurological deficits and
as with SFV are essential for virus clearance. Murray et al investigated the role of
CD4+ T-cells in both resistant and susceptible MHCII"7" mice following TMEV
infection. Resistant mice lacking CD4+ T-cells had virus persistence and
demyelination during the chronic stages of disease. Susceptible mice lacking CD4+
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T-cells had drastically increased demyelination. Thus both strains ofMHCIF7" mice
had increased neurological deficits (Murray, 1998c).
The flow-through cells adoptively transferred to the SFV infected SCID mice, were
enriched for CD4+T-cells, however they still only amounted to 21% of the cells
present. Histological studies showed many macrophage-like cells present in the CNS
ofmice that received flow-through cells. The role ofmacrophages in viral infection
is not addressed here, but a critical role in both innate immunity and
neurodegeneration has been suggested for macrophages in alphavirus infection
(Carmen, 2006). It is not possible to reach conclusions about the role of CD4+ T-
cells alone in SFV infection from the adoptive transfer study described here. The
inclusion of an adoptive transfer of immune CD4+ positively selected splenocytes to
SFV infected SCID mice would be necessary to determine if CD4+ T-cells alone are
pathogenic. This would also be required to determine whether CD8 T-cells are
required for pathogenesis (since CD4+ T-cells may also mediate demyelination) and
to determine the extent to which CD4+ cells can clear virus in the absence of B-cells,
antibody and CD8+ T-cells.
SFV can productively infect the CNS of C57BI/6 mice
Many of the commercially available KO mice are on the C57B1/6 background. It is
apparent that the virus induced neuropathology in these mice is not the same as that
observed in mice on a BALB/c or WT-129 background (Gates, 1984). Earlier work
with SFV A7(74) infection of C57B1/6 mice conflicts with the results presented here,
as demyelinating lesions were evident in C57B1/6 mice (Mokhtarian & Swoveland,
1987). These differences could be due to subtle changes in the mouse strain due to
different suppliers; additionally different viral stocks may cause different pathology.
Differences in susceptibility to viral CNS infection between mouse strains have been
studied a great deal. As noted C57B1/6 mice are resistant to TMEV infection and
demyelinating disease, whereas SJL/J mice succumb. This difference in
susceptibility has been accounted for by the efficacy of the CTL response and this
resistance is in part genetically determined by the H2 locus (Rodriguez, 1996; Lin,
2002). In MHV infection, allelic differences in the viral receptor can account for
differing susceptibility to infection between SJL mice (resistant) and BALB/c
(Dveksler, 1993; Ohtsuka & Taguchi, 1997b). Using VLPs we inoculated C57B1/6
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mice IC to determine if a productive infection can occur in the oligodendrocytes of
these mice. This was indeed the case, with many VLP cells visible in white matter
tracts in CNS sections at both PID 5 and 14. There was an abundance of virally
infected cells at early time points and lower levels at PID 14, indicating that virus is
not cleared rapidly. It must be noted that immunostaining was not performed for
viral proteins; and so the remaining fluorescence could be from GFP alone. In
conclusion, the oligodendrocytes of C57B1/6 mice can become infected with SFV;
the reason for difference in demyelination compared to BALB/c or 129 mice must
therefore have another explanation, perhaps a more efficient antibody or less
cytolytic effector response.
The phenotype of cells present in the CNS of SFV infected
mice
In order to directly study the magnitude and quality of the cellular immune response
in the CNS, the phenotype of the inflammatory infiltrate in C57B1/6 mice was
investigated by FACS analysis. Microglia are resident in the CNS, and upon
stimulation by trauma, inflammation or infection they up-regulate markers such as
CD4, MHC class I and CD45 (but are still distinguishable from CD45hl
macrophages) and proliferate (Sedgwick, 1991a). The 5-fold increase in microglia
(CD1 lb CD4510) observed between day 3 and day 8, the peak of CNS inflammation
is consistent with this. Very low numbers of macrophages are present in the resting
CNS. At the peak of infection (PID8) there was an approximately 200-fold increase
in macrophage (CD1 lb CD45hl) numbers in the CNS and their subsequent decrease
was equally efficient.
For a specialised tissue lacking lymphoid architecture, the influx of T-cells into the
CNS over the course of infection was impressive. There was an increase of 165-fold
for CD4+ T-cells and 185-fold for CD8+ T-cell, demonstrating that when required,
these cells efficiently enter the CNS. Like the macrophage population their
disappearance was equally rapid. At PID 8 there were twice as many CD8+ T-cells
as CD4+ T-cells, highlighting the importance of these effectors in viral infection.
The B-cell population within the CNS was examined by CD19+ staining. The CD19+
population at PID 8 and 15 was small but stable unlike the other cell populations it
did not contract. Subpopulations of B-cells that mature into antibody secreting
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plasma cells down-regulate CD 19 and these cells would not have been detected in
this study. It has been suggested that antibody secreting plasma cells remain within
the CNS for several months following SFV infection (Parsons & Webb, 1982g). It
would be of interest to stain for this cell type to confirm if plasma cells are indeed
present in the CNS following SFV infection. The presence of antibody secreting
plasma cells has implications for virus persistence and whether persistent virus is
kept under constant control by antibody.
Taking into account the procedural problems of the experiments comparing the
inflammatory cell phenotype in C57B1/6 and BALB/c mice, overall there did not
appear to be any difference in the magnitude or the kinetics of cellular infiltrates
between the mouse strains. The reasons for different SFV induced CNS pathology
between these mice strains may not be related to the immune response or, more
likely, may be due to more subtle immune differences such as the T-cell epitopes
recognised or the cytokine balance.
The phenotyping study allowed investigation of the presence of T-regs and
differences between mouse strains. The presence of T-regs has been observed in
EAE. Following EAE induction there is an accumulation CD4+CD25+ T-cells in the
CNS, which is co-incident with disease resolution. The detected CD4+CD25+ T-cells
secrete IL-10 and resemble peripheral T-regs. CNS derived T-regs could mediate
activity in vitro, as EAE was exacerbated when these cells were depleted and their
transfer to mice with EAE caused disease resolution (McGeachy, 2005).
T-regs have been shown to be present in a number of chronic viral infections.
Patients infected with hepatitis C virus who develop a chronic infection have a
population of specific T-regs that controls the immune response to hepatitis C.
However it is unclear whether these T-regs are the cause or the result of chronic
infection (MacDonald, 2002; Sugimoto, 2003). The presence of T-regs in the model
virus for immunological studies, LCMV, has yielded little information. The
depletion of CD4+CD25+cells has no effect on the LCMV specific immune response
and ex vivo functional studies of these cells has not shown regulatory activity (Rouse,
2006a).
We looked for similar cells in viral encephalitis at PID 6, 8 and 14. A population of
CD4+CD25+ cells was present; however the number of cells positive for FoxP3 (the
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current marker for T-regs) was very low and without further experiments it was not
possible to say whether this indicated the presence of T-reg cells. As mouse strain
affects CNS pathology, it was thought this could be due to a difference in T-regs.
SFV infection resolves rapidly, co-incident with the activation of the adaptive
immune response which induces an effective antibody response that rapidly
neutralises virus. It is possible that T-regs do not have a role in this infection as the
virus is cleared rapidly.
There is more than one sort of T-reg and not all express FoxP3. A number of T-regs
secrete IL-10 and anti-inflammatory cytokines (Groux, 1997a). To further
investigate whether T-regs have a role in controlling the immune response to viral
encephalitis it would be necessary to deplete the CD4+ CD25+ subset from SFV
infected mice and observe the effect of this depletion on the strength and
pathogenicity of the immune response.
The studies here demonstrate that CD4+ T-cells are required for virus clearance.
While virus RNA is cleared at a slower rate in the absence of CD8+ T-cells, virus
clearance is not affected in the long-term. Therefore CD8+ T-cells contribute but are
not required for CNS virus clearance. In contrast CD8+ T-cells are sufficient to
induce demyelination in the CNS following SFV infection, but further investigation
is necessary to if they are required.
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Previous published studies using antibody depletion of T-cell subsets suggest that
CD8+ T-cells have a role in the pathogenesis of demyelinating lesions found in SFV
infection (Subak-Sharpe, 1993) and the studies in chapter 3 confirm that these
immune cells alone are sufficient; however it is not known which specific CD8+ T-
cell mediators cause these lesions.
In general perforin-induced apoptosis is the predominant mechanism for CTL
elimination of virus infected cells (Kagi, 1995e). CTLs specifically recognise a
MFIC-peptide complex on an infected cell and secrete a cytolytic granule containing
perforin and granzymes (A and B); this is then endocytosed by the target cell where
it activates apoptosis eliminating the infected cell (Trapani & Smyth, 2002a). A
second mechanism, the upregulation of FasL on CTLs also allows these cells to
initiate an apoptosis cascade on target cells, by binding to Fas. FasL can be targeted
to virus infected cells after TcR engagement with MHC on infected cells (Lynch,
1995). Neurons protect themselves against perforin mediated lysis by the expression
of FasL which binds to Fas on the attacking CTL and transmits an inhibitory signal,
thereby preventing granule exocytosis (Medana, 2001). Apoptosis in neurons can be
induced if Fas is expressed on the neuron, however this needs to be coincident with
MHC 1 expression, which is thought only to be expressed on damaged neurons
(Medana, 2000; Redwine, 2001). Other cells of the CNS are vulnerable to perforin-
induced damage; in SFV infection demyelination has been proposed to occur as a
result of immune mediated damage of infected oligodendrocytes (Fazakerley &
Walker, 2003).
CTLs also secrete IFNy, which can stimulate release of cytotoxic factors from
macrophages, upregulate MHC expression on many cell types and induce anti-viral
defences within cells (Farrar & Schreiber, 1993). This non-cytolytic mechanism for
virus clearance is of particular interest in the CNS. Terminally differentiated
neurons, which are relatively resistant to apoptosis, can respond to IFNy and this may
be an important mechanism for clearing virus (Neumann, 1997; Allsopp &
Fazakerley, 2000). IFNy can be synthesised by neurons (Olsson, 1994) and been
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shown to be effective in clearing viruses from oligodendrocytes (Parra, 1999b).
IFNy levels peak relatively late in SFV infection (PID 6), whereas type I IFNs (IFN
a and (3) are essential for early virus control (Muller, 1994; Mokhtarian, 1996).
Some anti-viral genes are upregulated by type I or type II IFNs, and some respond to
both.
The role ofCD8+ T-cell mediators, IFNy, perforin and Fas, was examined to see
which specific mediators were crucial for virus clearance and which for generating
the lesions of demyelination. IFNy, perforin and Faslpr KO mice were infected with
SFV and virus clearance (infectious and virus RNA) and neuropathology were
compared to wild-type mice. The ability of IFNy to substitute for the protective type
I (a/(3) IFN response was also studied.
Objectives
• Compare virus clearance and CNS histology following SFV infection in
IFNyR"" mice with wild-type mice
• Determine if recombinant IFNy can protect SFV infected IFNa/p "" mice
• Compare virus clearance and CNS histology in perforin7" mice with wild-
type mice following SFV infection
• Compare virus clearance and CNS histology in Faslpr mice with wild-type
mice following SFV infection
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Results
Mice lacking a functional IFN/ system are slower at clearing
viral RNA in the short term than wild-type mice
To determine the role of IFNy in SFV clearance, IFNyR_/"(129 genetic background)
and wild-type (WT-129) mice aged 4-6 weeks (mixed sex) were infected IP with
SFV A7(74). Inoculate for this experiment was titred at a later date and found to be
lower than originally thought (Iogio2xl02 compared to logio 5xl03 pfu/ml).
Infectious virus in the brain was determined at PID 3 and 7 (Figure 28). The WT-
129 mice had a higher mean titre of infectious virus at both time points however



















Figure 28. Infectious virus measured by plaque assay in SFV infected IFNRy"/_(A) and WT-129(A)
mice at PID 3 and 7. Horizontal bars indicate mean of the group, dashed line indicates the limit of
detection for the assay.
To assess virus clearance at later time points, copies of SFV RNA in the brain were
titred by q-PCR at 2, 3, 4, 12 and 24 weeks PI (Figure 29); infectious virus is
generally not detectable after PID 10. The mean number of virus RNA copies at
each time point was higher for IFNyR"'" mice compared to wild-type' mice. The
difference between the groups was significant at post-infection week (PIW) 2
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(p=0.0286, by Mann-Whitney test). The difference between the group mean of the
mutant and wild-type mice decreased over time (Logio 0.76 at PIW 2 to Logio 0.2 at
PIW 24). This indicates that IFNy has a role in the clearance of viral RNA, as mice
lacking functional IFNy clear virus RNA from the CNS more slowly. The effect is






























Figure 29. SFV RNA copies measured by quantitative PCR in brain tissue at 2 - 24 weeks PI in
IFNyR"'"(A) and WT-129(A) mice infected with SFV A7(74). * indicates significant difference (
p<0.05), data were analysed by Mann-Whitney test. Horizontal bars indicate mean of the group,
dashed line indicates the limit of detection for the assay.
IFNyR'' mice display the same neuropathology as wild-type
mice during SFV infection
To examine CNS histology a stain for myelin (luxol fast blue) and a nuclear
counterstain (cresyl fast violet) were used. Sections (5pm paraffin processed) were
scored coded on a scale of 1 to 4 for inflammation (cell infiltration), demyelination
(loss of luxol fast blue staining) and microcystic change (tissue vacuolation and
destruction) using the criteria described in histological techniques in the materials
and methods chapter.
The scoring of histology sections is quite subjective, and the sections scored only
represent a snapshot of the histological changes in the CNS. There was very little
difference between the mean scores of the two experimental groups (no significant
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difference by Mann-Whitney test,Figure 30). WT-129 mice had a higher mean
inflammation score (2.15) compared to IFNy-R_/"mice but the demyelination and
microcystic change scores were similar. These results show that IFNy is not required
for demyelination, inflammation or microcystic change in SFV infected mice.
INF
Mouse Strain
Figure 30. Pathology scores in SFV infected IFNyR"'" mice and WT-129 mice at PID 14 and 21 (data
combined). Results are the means scores for at least 9 sections from at least 7 mice. Error bars
represent the SEM. INF - inflammation, DMN - demyelination and MCC - microcystic change.
Recombinant IFN/offers some protection to SFV infected
IFNa/j3 receptor knockout mice
There are many type I IFNs, all of which bear structural homology and bind a single
IFN receptor. There is only one type IIIFN, IFNy. IFNs bind to their cognate
receptors and initiate a signalling cascade, involving the JAK family of tyrosine
kinases and STAT family of transcription factors, which leads to the transcriptional
induction of the IFN-stimulated genes (ISGs). This results in transcriptional
shutdown, inhibition of cellular protein synthesis and RNA degradation. ISGs can be
stimulated by Type I or Type II IFNs. ISGs that are preferentially induced by
IFNa/p but not IFNy include 2'5'-oligoadenylate synthetase 1, MxA and MxB
genes. ISGs preferentially induced by IFNy include IFN regulatory factor-1, IFN
inducible protein-30, and class II transactivator. ISGs that are responsive to all IFNs
include MHC Class I genes, STAT 1 and guanylate binding protein (Der, 1998a).
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Type I IFNs are crucial in early virus control during SFV infection as they are
upregulated within hours of infection. IFNy, which is produced by T-lymphocytes
and NK cells, acts later in infection and following SFV infection its levels peak at
PID 6 (Mokhtarian, 1996).
Type IIFN receptor knock-out (IFNa/(3R~") mice have a 100% mortality rate
following infection with SFV highlighting the importance of this innate defence in
anti-viral protection (Muller, 1994) and demonstrating that an intact IFNy system is
insufficient for protection. In contrast, IFNyRv~ mice cleared infectious virus at the
same rate as wild-type mice (Figure 28) and did not show increased mortality,
demonstrating that the type II IFN system is not required for protection. It is
possible that the failure of the IFNy system to protect IFNa/pR"7" mice from SFV is
related to the timing of this response.
To determine ifmice with no functional type I IFN system could be protected by the
early presence of IFNy, SFV infected IFNa/pR_/" mice were given recombinant IFNy.
Two groups ofIFNa/pR"A mice (n=6/group) age 4-6 weeks were infected IP with
5xl03 pfu of SFV A7(74), one infected group also received 104 IU units of
recombinant IFNy (ProSpec-Tany TechnoGene Ltd) in 0.1 ml PBSA (0.1%) 5 hr
post-infection, and every subsequent 24 hr for 6 days. A control (uninfected) group
received recombinant IFNy at the same time as the infected group (Figure 31).
Mice that were infected with SFV but did not receive IFNy were extremely sick at
PID 1 and were euthanised The two other groups of mice were healthy at this time
point. At PID 3 mice that were infected with SFV and had received 3 inoculations of
recombinant IFNy were found dead; uninfected mice that received recombinant IFNy
alone were still healthy at end of the experiment (PID 6). These results indicate that
IFNy offers partial protection against SFV infection, however this was only sufficient
to protect mice for 48 hr longer than mice that did not receive recombinant IFNy.
This experiment could be repeated with different timings and concentrations of
recombinant IFNy to determine if the doses and timing alter the level of protection.
Nevertheless, the data show that IFNy can provide protection against this virus.
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Figure 31. Survival curve showing survival rates of SFV infected IFNa/pR"'" mice and the effects of
recombinant IFNy. IFNa/pR"'" mice were infected with 5x104 PFU of SFV (grey square and blue
triangle) and one group was also given 104 IU units of recombinant IFNy (blue triangle) at 5 hr PI and
every subsequent 24 hr. A third control group ofmice received recombinant IFNy alone (red star).
reelFNy - recombinant IFN y.
Perforin''' mice do not have reduced SFV infectious virus or
virus RNA clearance
To determine the role of perforin in SFV clearance, perforin"7" mice (on a C57B1/6
background) and C57B1/6 mice (n=18) aged 4-6 weeks (mixed sex) were infected IP
with SFV A7(74). Infectious virus and virus RNA titres were assayed and paraffin
sections from the brain were prepared for histological scoring.
Brain sections from mice at PID 14 and 21 were stained with luxol fast blue and
cresyl fast violet and scored for pathological changes (Figure 32). Both groups
showed low levels of inflammation (scores of between 0.7 - 1.1) and almost no
demyelination or microcystic change. There was no significant difference in CNS
pathology, between perforin"7" and wild-type mice (analysed by Mann-Whitney test).
The lack ofmicrocystic change and demyelination confirms the findings on this
genetic background in chapter 3.
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Figure 32. Histological scoring for inflammation, demyelination and microcystic change in the brains
of Perforin" " and C57B1/6 mice. Results are the means scores for at least 9 sections from at least 7
mice. Error bars represent the SEM. INF - inflammation, DMN - demyelination and MCC -
microcystic change.
Infectious brain virus titres were compared in perforin "'" mice (n=8) and C57B1/6
mice (n=8) to examine if perforin has a role in early virus clearance (Figure 33). The
mean virus titres were different between the groups with higher titres at PID 3 and
PID 7 in the perforin"'" mice, however these differences were not significant (p>0.05,
by Mann-Whitney test).
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Figure 33. Infectious virus measured by plaque assay in SFV infected perforin"'" (□) and C57BI/6
(■) mice at PID 3 and 7. Horizontal lines indicate mean of the group, dashed line indicates the limit
of detection.
Brain virus RNA levels were also compared by q-PCR between perforin"" mice
(n=8) and C57B1/6 mice (n=8), after infectious had been cleared at PID 14 and 21
(Figure 34A). Although there was an apparent difference in RNA virus copies at
PIW 2 (sample size too small for Mann-Whitney analysis), this result is
counterintuitive with the greater clearance occurring in the perforin"7" mice. It is
difficult to hypothesise why a lack of perforin might result in greater virus clearance;
however the situation was reversed at PIW 3 where wild-type mice had apparently
lower virus RNA titres. Repeating this experiment with increased numbers ofmice
would be necessary to elucidate if there really are differences between these groups.
If the data from both time points is pooled, thus comparing virus RNA load between
the groups at 2-3 weeks PI, there is no significant different (p= 0.535 , Mann-
Whitney test) between the groups.
Virus RNA clearance was examined over a longer period of time. Perforin"7" mice
(n=10) and C57B1/6 mice (n=10) were infected and virus RNA titred at PIW 6 and
12 (Figure 34B). There was no significant difference in virus titre between the
groups at either time point (as analysed by Mann-Whitney test). The group means at
both time points were on or near the limit of detection of the assay.
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Figure 34. A - Virus RNA load of SFV in SFV infected perforin"'" mice (□) and C57B1/6 (■) mice at
PID 14 and 21. B - Long term clearance of SFV virus RNA from SFV infected perforin"'" (□) and
C57B1/6 (■) mice. Horizontal bars indicate mean of the group, dashed line indicates the limit of
sensitivity for the assay.
FASlpr mice
The third CD8+ T-cell mediator investigated was Fas, which when bound by its
cognate ligand initiates programmed cell death. The role of Fas in neuropathology
and in virus clearance in SFV infection was investigated in mice with a mutation in
their Fas gene (Faslpr, n=30) and C57B1/6 mice (n=30), age 4-6 week (mixed sex).
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Mice lacking Fas showed no significant difference (as analysed by Mann-Whitney
test) from wild-type mice in their clearance of infectious virus , although 50% (2/4)
of the Faslpr mice sampled on PID 7 cleared infectious virus as compared to 25%















Figure 35. Infectious virus measured by plaque assay in SFV infected FASlpi mice (•) and C57B1/6
mice (■) at PID3 and 7. Horizontal lines indicate mean of the group, dashed line indicates the limit
of detection.
Virus RNA levels in SFV infected Faslpr mice at PIW 2 to 4 were quantified by q-
PCR (Figure 36). Virus RNA levels decreased with similar kinetics in both the
mutant and wild-type mice, with no significant difference between the groups (as
analysed by Mann-Whitney test). Consistent with findings in the wild-type mice,
virus RNA was still detectable 4 weeks post-infection in the Faslprmice.
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Figure 36. Clearance of SFV RNA from the CNS of FASlpr mice (•) and C57B1/6 mice (■) at PID
14, 21 and 28. Horizontal bars indicate mean of the group, dashed line indicates the limit of
sensitivity for the assay.
Brain sections from Faslpr mice and C57B1/6 mice were scored for neuropathological
changes at PID 14. High levels of inflammatory infiltrates were present at a (mean
histological score-2.6) in Faslprmice as well as low levels of demyelination (mean
score -1.1) and microcystic change (mean score - 0.9). C57B1/6 mice had a lower
level of inflammation, significantly less demyelination (p=0.03, Mann-Whitney test)
and very little microcystic change. The lack of Fas appears to have increased the
inflammation and demyelination relative to that observed in the C57B1/6 background
strain. This was an unexpected finding as no other knock-out strain (CD8a, MHC II"
and perforin"7") on the C57B1/6 background showed any increase in neuropathology.
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Faslpr C57BI/6
Mouse Strain
Figure 37. Histology scoring for inflammation, demyelination and microcystic change in Faslpr mice
and C57B1/6 mice. Results are the means scores for at least 6 sections from at least 4 mice. *
indicates significant difference (p<0.05), data were analysed by Mann-Whitney test. Error bars
represents the SEM. INF - inflammation, DMN - demyelination and MCC - microcystic change.
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Acquired Immune Response to SFV
• IFNyR7"mice show no difference in their ability to clear infectious virus
from the brain as compared to wild-type mice
• IFNyR"7" mice have slower clearance of SFV RNA from the brain as
compared to wild-type mice
• IFNy is not required for the development of demyelinating brain lesions in
SFV infected mice
• Recombinant IFNy transiently protects SFV infected IFNa/pR"'" mice
• Neither perforin nor Fas are required for clearance of infectious virus or
viral RNA from the brain
• SFV infected Faslpr mice have increased CNS demyelination compared to
wild-type mice
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Acquired Immune Response to SFV
The findings of the previous chapter demonstrated that mice on a C57B1/6
background that lack CD8+ T-cells are significantly slower than controls at clearing
virus RNA from the brain. CD8+ T-cells have previously been shown to be required
for demyelination in the CNS of BALB/c mice (Subak-Sharpe, 1993) and chapter 3
showed that these cells alone provided a sufficient immune response to generate
these immunopathological lesions To separately analyse the role of the CD8+ T-cell
mediators IFNy, perforin and Fas in SFV clearance and CNS pathogenesis, mice
deficient for these effectors were studied.
IFNy is a potent anti-viral cytokine, in other CNS virus infections, such as vesicular
stomatitis (Indiana) virus and measles virus, where it is essential for virus clearance
(Finke, 1995; Komatsu, 1996a; Patterson, 2002a). In the present study during the
first few weeks PI mice lacking a functional IFNy system were slower at clearing
viral RNA from their brain. However, by 3 and 6 months post-infection mice
lacking a functional IFNy system and wild-type mice had low levels of or no virus
RNA detectable above background levels indicating that IFNy was not required to
establish clearance or very low levels of virus RNA. The results in SFV infected
IFNy knockout mice also showed that IFNy is not necessary for the inflammation,
demyelination and microcystic changes observed. This supports data from Keogh et
al, where SFV A7(74) infected IFNyR"7" mice showed increased neuronal necrosis at
PID 7 after which pathological changes were similar to those ofwild-type mice with
no differences observed in the severity of demyelination (Keogh, 2003). In contrast
in a neurovirulent alphavirus infection, neuroadapted SV in C57B1/6 mice, a
pathogenic role for IFNy was evident. Mortality was reduced to 10% in IFNyR"'"
compared to 93% in C57B1/6 mice. The authors suggest that the pathogenic effect of
this cytokine is possibly a result of its regulatory effect skewing towards a TH1
response or recruitment and activation of macrophages that can secrete toxic
mediators and directly damage neurons (Rowell & Griffin, 2002).
The role of IFNy in clearance of alphaviruses was highlighted by the construction of
a recombinant SV expressing IFNy. This virus was inoculated into SCID mice; virus
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was cleared from neurons in the spinal cord and brainstem but not from cortical
neurons, this is a similar pattern of infection as seen in pMT mice. Wild-type mice
typically clear SV, so it can be concluded that antibody is required for clearance and
IFNy alone is insufficient (Binder & Griffin, 2001b).
The absence of IFNy in other CNS infections has more severe consequences than
those seen in SFV infection. TMEV infection of IFNyR7" mice, on a genetic
background normally resistant to virus persistence, results in persistent infection.
IFNy protects neurons against TMEV induced damage (Rodriguez, 2003). MHV
infected IFNyR"/_ mice show increased mortality and clinical signs. A cell specific
effect is also evident, as there is increased MHV antigen in oligodendroglia (Parra,
1999c). The anti-viral state induced by IFNy is not the only function observed in
MHV. MHC upregulation is suboptimal in the absence of IFNy and this deficiency
affects MHC I mediated effector mechanisms, such as perforin mediated lysis
(Bergmann, 2003).
Recombinant IFNy temporarily protected the SFV infected IFNa/pR~Amice, as these
mice lived to PID 3 whereas mice that did not receive the recombinant cytokine
succumbed to infection within 24 hrs. Recombinant IFNy has also been shown to be
protective in measles virus encephalitis. 50% IFNyR7" mice which normally
succumb to fatal measles virus CNS disease, were protected by recombinant cytokine
transfer (Patterson, 2002b). In SFV infection, recombinant IFNy protection was
short-lived and mice receiving IFNy died after 3 days. This was not due to a toxic
effect of the recombinant IFNy, as mice receiving IFNy alone remained healthy until
the end of the experiment at PID 6.
There are many possible reasons why the mice that received IFNy were not fully
protected. IFNy can initiate some but not all of the same response as type I IFNs. It
is likely that in order to induce a fully protective response, many genes associated
with type I IFNs must be upregulated. Administering IFNy alone may not have
induced certain genes required for protection. However, this was a small study with
a single concentration of recombinant IFNy and doses well-spaced out in time. This
dose was similar to that used by others (Clark, 1987). This study was not
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comprehensive enough to conclude that a type I IFN response is required however, it
can be concluded that IFNy can induce a protective response against SFV A7(74).
Perforin is a major effector mechanism ofCD8+ T-cells. Perforin"7" mice infected
with SFV do not have any difference in the rate of infectious virus or virus RNA
clearance. This is in contrast to other CNS virus infections where perforin has been
shown to have an important role in virus clearance and protection. TMEV infected
MHC I"7" or perforin"" mice, on a genetic background resistant to TMEV persistent
infection are susceptible to persistent infection and ongoing demyelination but have
no neurological signs. This indicates that in TMEV infection and CD8+ T-cells,
perforin, are required for virus clearance and for the development of neurological
deficits (Murray, 1998a). Following IC inoculation with LCMV, perforin"7" mice
have milder disease and delayed mortality compared to wild-type mice. Following
IP LCMV infection (which is cleared in wild-type mice) perforin"7" mice cannot clear
virus (Kagi, 1995c). Expression of perforin in the absence of granzyme or Fas,
demonstrates that perforin alone is insufficient to clear LCMV; perforin works
synergistically with both granzyme A/B and Fas (Rode, 2004a).
West Nile virus (WNV) infected mice show CTL dependent virus clearance with
mortality of about 30% in wild-type mice; virus is cleared in surviving mice.
Knocking out perforin increases mortality to 78% and virus persists in mice
surviving infection. WNV differs from the other CNS viruses discussed above due
to the high cytopathic effect ofWNV for neurons (Shrestha, 2006). Removing
perforin allows the full pathogenic potential of the virus to be realised, therefore in
this case the anti-viral benefits of perforin outweigh the risk potential immune
mediated as perforin protects against direct virus mediated injury.
It has been shown that effector mechanisms in CD8+ T-cells work synergistically, for
example MHV infected mice require IFNy for virus clearance and upregulation of
MHC class I. However perforin works with IFNy, leading to more effective
clearance ofMHC I expressing cells (Bergmann, 2003). Therefore knocking out
single CD8 effectors may have a much less deleterious effect than the combined
results of a double knock-out. The use of such double knock-outs would be of
interest in SFV to determine the combined effects of CD8+ T-cell mediators on virus
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clearance and neuropathogenesis. Unfortunately, the perforin"7" mice are on the
C57B1/6 which is not susceptible to SFV induced demyelinating lesions (chapter 3).
To investigate the role of perforin in SFV neuropathogenesis a perforin"" mouse on a
demyelination susceptible background (BALB/c, 129) is required.
C57B1/6 FASlpr mice infected with SFV did not show any deficiencies in virus
clearance (infectious or virus RNA) compared to wild-type mice. However, in mice
lacking Fas demyelinating lesions were observed at PID 14. The control group of
wild-type C57B1/6 mice had no demyelination, neither did the CD8a or perforin"7"
mice on this background.
TMEV infected Faslprand FasLgld KO(C57Bl/6) mice maintain resistance to
persistent CNS infection indicating that the Fas system not essential for TMEV
clearance (Murray, 1998a). LCMV is also cleared without measurable assistance
from Fas/FasL (Kagi, 1995d). As noted previously, the role of Fas may be less
important than other mediators such as IFN or perforin, however with (IP) LCMV
infection, mice deficient in Fas and granzyme A/B did not survive acute infection
whereas mice with perforin and Fas could control virus replication (Rode, 2004b). A
combined role for perforin and Fas in virus clearance is also suggested in MHV
infection (Parra, 2000).
CTL expansion after activation is controlled by AICD which is primarily regulated
by FasL upregulation on activated T-cells. It is possible that in knocking out Fas
expression in SFV infection, anti-SFV CTL populations did not contract and their
increased numbers led to an increased size of the inflammatory infiltrates and the
lesions of demyelination. The increase in CNS pathology observed requires further
investigation to determine whether this is caused by a dysregulation ofAICD
induced by the lack of a functional Fas system. The data presented here
demonstrates as in other CNS virus infections, Fas/FasL is not essential in SFV
clearance. Whether it does have a role that is masked by functional redundancy
remains to be elucidated.
This chapter aimed to examine the roles of IFNy, perforin and Fas in both virus
clearance and in modulating CNS neuropathology. It was shown that IFNy increases
the rate at which SFV RNA is cleared from the CNS and that recombinant IFNy can
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protect in IFNa/p7" mice. However, IFNy is not required for demyelination.
Perforin was not required for virus clearance and its role in the development of
demyelination lesions could not be answered due to the background strain of the
perforin" " mice. Fas was also not required for virus clearance but these studies
highlighted that Fas may have a separate role in modulating CNS pathology by
controlling numbers of activated T-cells.
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Introduction
Acquired Immune Response to SFV
Non-cytolytic mechanisms for virus clearance in the CNS have long been of interest,
as they allow protection of terminally differentiated neurons from both cytolytic and
toxic immune mediators while preventing the spread of the pathogen. The antibody
response is an example of an immune mediator that can mediate its action in a non-
lytic manner, and the importance of antibody in CNS virus clearance has long been
of interest. Immunoglobulin class switching in B-cells is reliant on CD4+ T-cell help
and therefore the role of B-cells cannot be considered in isolation, as they are
dependent on T-cells to attain full functionality.
Previous research in this laboratory (Fragkoudis, 2002) investigated the clearance of
SFV in B-cell deficient (pMT) mice. These mice were unable to clear infectious
virus or reduce virus RNA levels in the brain, demonstrating the importance of B-
cells in virus clearance from this organ. Whereas this can most likely be ascribed to
antibody, the results must be interpreted with more caution since abnormalities in
dendritic and T-cell functions have also been observed in pMT mice. For example,
following MHV infection of pMT mice deficiencies in T-cell virus specific response
were detected (Bergmann, 2001). To focus on the role on antibody alone in SFV
clearance and persistence, the adoptive transfer ofHI serum to SFV infected SCID
mice was investigated. SCID mice are homozygous for the Prkdcsad mutation and
lack both T and B cells due to a defect in V(D)J recombination (Bosma, 1983b).
SCID mice are a good model to study the role of the acquired immune response in
SFV infection. Avirulent SFV (A7(74)) establishes a persistent infection in this
mouse strain (Amor, 1996). Passive transfer of anti-SFV antibody to SFV infected
SCID mice can clear infectious virus from the blood and the brain; IgG is necessary
for this function. A non-neutralising monoclonal antibody (mAb) also was able to
reduce brain virus titres, by mechanisms unknown, but not viraemia in SCID mice.
This work is supported by similar studies on another alphavirus, SV (Levine &
Griffin, 1992). Using passive transfers of antibody to SV infected SCID mice,
Levine et al demonstrated the crucial role of antibody in virus clearance and
suggested a role for antibody in inhibiting virus replication in neurons.
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Neither of these studies (Levine & Griffin, 1992; Amor, 1996) addresses whether
antibody alone can bring about sterilising immunity, the removal of all infectious
virus. Infectious virus, or material capable of giving rise to infectious virus, could be
present in a tissue even when no infectivity is detectable by plaque assay. Firstly, the
infectivity assay does not detect material capable of giving rise to infectious virus
and secondly, virus neutralisation can occur after sampling, during tissue
homogenisation, giving a false impression of virus clearance.
To address these questions the SFV SCID model was used. The intention was to
administer HI SFV serum to reduce brain virus infectivity to zero and then assay
brains for infectivity and virus RNA weeks after the last serum transfer, to allow time
for clearance of transferred antibody. HI SFV serum was given at 4 days PI and
repeat inoculations every 3 days. This ensured a high titre neutralising antibody in
SFV infected SCID mice, as the half-life of passively administered anti-SFV
antibodies is approximately 4 days (Fazakerley, 1985). This system is more
representative of the enduring antibody response seen in immunocompetent mice,
and measures both persistence of infectivity and virus RNA.
Objectives
• Raise high titre HI SFV serum
• Characterise HI SFV serum
• Passive transfer ofHI SFV serum to SFV infected SCID mice
• Examine ability ofHI SFV serum to clear infectious virus from selected
tissues of SFV infected SCID mice
• Examine ability ofHI SFV serum to clear virus RNA from the CNS of SFV
infected SCID mice
• Determine if infectious virus can be detected after treatment with HI SFV
serum
• As a comparison, determine the rate of virus RNA clearance from SFV
infected wild type (BALB/c) mice
Chapter 5 Role of Antibody in Virus Clearance 126
Results
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Antibody Transfer Experiment 1
The first experiment set out to determine the effect of passive intraperitoneal
antibody transfer on virus RNA load in the CNS of SFV infected SCID mice. SCID
mice (n=8) were inoculated with SFV (day 0). From PID 4-19 SCID mice received
six transfers ofHI SFV serum. Mice were perfused and tissues sampled at PID 21.
Time (days)
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Figure 38. Time course of experiment 1 showing times of virus inoculation, antibody transfers and
tissue sampling.
Production of HI SFV serum
The first step was to raise HI SFV serum for the passive transfer experiment. Forty
BALB/c mice (mixed sex) age 4-6 weeks were inoculated (day 0) with 5x103 PFU of
SFV A7(74) and boosted with repeat inoculations at 14 and 21 days. As a specificity
control, 40 BALB/c mice were inoculated with 5xl03 PFU ofTMEV strain BeAn.
At day 28 mice were euthanised and sera were collected from both groups of mice,
pooled and characterized by ELISA. As a positive control, serum was prepared from
BALB/c mice given a single SFV inoculation of SFV and sampled at PID 7 (SFV d7
serum).
ELISA development
In order to characterise the HI sera an ELISA was developed. To determine the
optimum amount of coating antigen required, antigen (sucrose gradient purified
SFV) was diluted 2-fold across a 96-well plate. HI SFV serum (1:100) or TMEV
d28 serum (1:100) or PBS alone was added. Two dilutions of the secondary
antibody (HRP conjugated, anti-mouse IgG) were tested. From this experiment
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optimum dilutions of antigen and secondary antibody were selected (Figure 39).
The antigen clearly dilutes out, showing specificity of the reaction. Conservation of
the coating antigen was an important consideration; the process ofpurification is
difficult and time consuming. Choosing an antigen dilution with the lowest
concentration that would give a clear result was necessary. A dilution of 1:800 for
virus coating, and a dilution of 1:500 for the secondary antibody were chosen as
optimum concentrations.
Reciprocal Antigen Dilution
Figure 39. Titration of coating antigen (band purified SFV) for antibody binding was determined by
EL1SA. Microtitre plate was coated with serial dilutions of antigen. 2° - secondary antibody
dilution. Points represent mean of three replicates.
To determine the isotypes of antibody present in the HI sera, goat antibodies specific
to different mouse immunoglobulins were used and detected with a HRP labelled
(rabbit anti-goat) antibody (Figure 40).
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Specificity of Secondary Antibody
Figure 40. Comparison of antibody isotypes specific for SFV present in HI SFV serum. Controls
included TMEV d28 serum, SFV d7 serum and no sera. Bound antibody was detected by ELISA
using isotype specific antibodies. Points represent the mean of three replicates; error bars (many too
small to be visible) represent SEM.
The high level of anti-SFV IgM observed was expected in SFV d7 serum but not in
HI SFV sera (as class switching should have occurred). IgM is a large pentameric
molecule and is known to be 'sticky', and to bind non-specifically to the microtitre
plates. This can be seen by the high OD reading with not only the HI SFV serum but
also the TMEV d28 serum. The higher OD reading for the HI SFV serum, compared
with controls, suggests however that there is a specific IgM anti-SFV activity in the
HI SFV serum.
The difference in IgG2a levels between HI SFV sera and controls is specific and
would be expected in HI serum (Coutelier, 1988b). The differences in ODs between
the isotypes are not comparable as each isotype will bind to the microtitre plate with
a different efficiency giving a different background value and each isotype specific
antibody will have a different avidity for its target antibody.
Using 2-fold serial dilutions of the HI SFV, SFV d7 and TMEV d28 sera, the IgG2a
response was examined in more detail (Figure 41).
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Reciprocal Serum Dilution
Figure 41. Anti-SFV IgG titres in the HI SFV, d7 SFV and TMEV d28 sera. Serial dilutions of sera
were added to microtitre plate coated with a 1:800 dilution of band purified SFV. Antibody binding
was detected by HRP labelled goat anti-mouse IgG. Each point represents the mean of three
replicates.
TMEV d28 serum contains antibody that binds non-specifically to the microtitre
plate, this signal titrates to zero at a 1/640 serum dilution. The IgG detected in SFV
d7 serum only titrates out after an initial plateau suggesting that between 1/40 and
1/640 the assay is saturated. The d7 serum titrates out at 1/1280 - 1/20100 dilutions,
this would be consistent with a high titre of antibody, perhaps of one specific IgG
subclass, which is saturating the assay. This would be expected, as some class
switching should have occurred by PID 7 but IgG titres would not have peaked
(Amor, 1996). The HI SFV serum has a high OD at low serum dilutions. As the HI
SFV serum is diluted, the OD drops correspondingly, indicating that there is a high
level of IgG in the HI SFV serum and that it is specific for SFV. The combined
ELISA results demonstrate that the HI serum raised is specific to SFV and that it
contains IgM, IgA, IgGl, IgG2a and IgG2b.
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Infectious virus and virus RNA is reduced by HI serum
transfer
For the passive transfer, three groups (n=8) of SCID mice were infected with 5xl03
pfu SFV A7(74). At 4 days post-infection, one group ofmice received a passive
transfer of 0.1 ml ofHI SFV serum; control groups received either 0.1 ml ofTMEV
d28 serum or PBS. Passive transfers were repeated every 3 days until PID 19. At
PID 21 all mice were perfused and tissues sampled. Figure 38 outlines the time
course of experiment 1.
To determine virus infectivity heart and brain tissue were titrated by standard plaque
assay on BHK-21 cells. Virus was below the limit of detection in both brain and
heart tissue in 100% (8/8) of the SCID mice that received HI SFV serum (Figure 42).
Virus was also below the limit of detection in 100% (6/6) immunocompetent
BALB/c mice at the same time point. Mice in control groups that had received either
PBS or TMEV d28 serum had detectable virus in the brain and heart, these titres
were significantly greater than mice that received HI SFV serum and
immunocompetent BALB/c mice (p<0.01 as analysed by Mann-Whitney test, Figure
































Figure 42. Infectious titres at three weeks post-infection in SFV infected BALB/c mouse brain (•)
and heart (o) (n=6); I - SFV infected SCID mice that received HI SFV serum, brain (♦) and heart (0)
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(n=8); II - SFV infected SCID mice that received TMEV d28 serum, brain (T) and heart (V) (n=8)
and III - SFV infected SCID mice that received PBS, brain (#) and heart (+) (n=6). * indicates
significant difference (p<0.01) with control groups (II and III); data were analysed by Mann-Whitney
test. Dotted line indicates the limit of detection of the assay for heart (H) and brain (B). Horizontal
bars indicate the mean of each group.
Levels of virus RNA were measured in the brains of the SFV infected SCID mice
that received HI SFV serum, as well as in infected BALB/c mice and the two control
groups that received TMEV d28 serum or PBS using q-PCR. Virus RNA was
detectable in all groups at 3 weeks post-infection (Figure 43). Mice that had received
HI SFV serum had a significantly lower level of SFV RNA than control groups that
had received PBS (p=0.0007, Mann-Whitney) or TMEV d28 serum (p=0.0016). The





































Figure 43. SFV RNA copies measured by quantitative PCR in brain tissue at 3 weeks post-infection
in SFV infected BALB/c mice (•); I - SFV infected SCID mice that received HI SFV serum (♦); II -
SFV infected SCID mice that received TMEV d28 serum (▼) and III - SFV infected SCID mice that
received PBS (#). There was no significant difference between BALB/c mice and group I; group I
were significantly different to groups II and III; indicates significant difference (p<0.01); data were
analysed by Mann-Whitney test. The dotted line indicates the limit of detection of the assay.
Horizontal bars indicate the means of each group.
Antibody Transfer Experiments 2 and 3
In experiment 1, passive transfer ofHI serum reduced the infectivity titre to
undetectable by 3 weeks (Group I, Figure 42) however virus RNA was still
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detectable in these mice (Group I, Figure 43) and even in BALB/c mice. In both
groups RNA levels were approximately 100-fold greater than in the negative controls
(dotted line, Figure 43). This virus specific RNA could represent 'junk' RNA
incapable of forming infectious virus, but alternatively it could be potentially
infectious genomes. Although the plaque assays at 3 weeks PI did not detect virus
(Figure 42), these mice may still have had antibody in their system. Only virus in
excess of neutralising antibody in the homogenised tissue can be detected by plaque
assay, therefore any remaining infectious virus could be rendered undetectable by
remaining anti-SFV antibody. The same considerations apply to the BALB/c mice.
To determine if anti-SFV HI serum had cleared all infectious virus from the mice and
established a sterile state the experiment was repeated with a longer interval between
the cessation of antibody transfers and sampling.
In experiment 2 HI sera transfers were carried out as before, with 10 mice each
receiving 6 doses ofHI sera every 3 days from 4 days PI. Two mice were again
sampled at day 21. The remaining mice were sampled at day 42 (Figure 44).
Following exactly the same design in a 3rd experiment mice were sampled at 21, 42
and 63 days post-infection (Figure 44). To control for virus contamination, either in
the animal unit or during RNA processing, a control group of uninfected SCID mice
were included in experiment 3. These mice were kept under the same conditions as
the infected mice. For both experiment 2 and 3 it was necessary to produce new
batches ofHI serum. This serum was raised in exactly the same way as in
experiment 1. HI SFV serum from the second experiment will be referred to as HI-
(2) and mice that received this serum R-(2), HI SFV serum from the third experiment
HI-(3) and the recipient mice of this serum R-(3).
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Figure 44. Time course of infection, antibody transfer and tissue sampling for experiments 2 and 3.
The antibody isotypes present in HI-(2) and (3) sera were compared by ELISA
(Figure 45). As for experiment 1 HI serum, high OD values were observed with IgM
but as shown by the TMEV d28 serum and the 'no serum' controls; a considerable
proportion of this was non-specific. For both HI-(2) and HI-(3) the biggest
difference above background was seen in IgGl and IgG2a, which was expected in HI
sera, as class switching should have occurred. The results show that there were
slightly but consistently higher levels of all isotypes in HI-(3).
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Specificity of Secondary Antibody
Figure 45. Comparison of the antibody isotypes specific for SFV in HI-(2) and HI-(3). Controls
included TMEV d28 serum, no sera and no secondary antibody (2° Ab). Serum levels were measured
by ELISA using isotype specific antibodies. Points represent the mean of three replicates, error bars
indicate the SEM.
To determine if recipient SCID mice had detectable anti-SFV antibodies at the time
of sampling, sera were tested by ELISA (Figure 46). Three weeks after the last HI-
sera transfer (PID 42) both R-(2) and R-(3) mice, had significantly increased levels
of anti-SFV IgG (p<0.05) compared with uninfected mice. At PID 42, the R-(3)
mice had higher levels of anti-SFV antibody (mean OD - 0.41) compared to R-(2)
mice (mean OD - 0.26). Furthermore, the R-(3) mice sampled at PID 63 had
marginally higher levels of antibody than the R-(2) mice sampled at PID 42. These
differences correlate with the higher titres of antibodies in the HI-(3) sera than in the
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Serum Sample
Figure 46. Anti-SFV IgG levels in the sera of SCID mice receiving HI serum. HI serum and serum
from uninfected mice were included for comparison. No sera and no secondary antibody (2°) controls
were included. R-(2) and (3) indicates sera from SFV infected SCID mice that received HI-(2) and
-(3) respectively. Horizontal bars indicate the mean of each group. No 2°- no secondary antibody.
Each point indicates the mean of three replicates, * indicates significant difference (p<0.05); data
were analysed by Mann-Whitney test.
To determine if the sera from the sampled R-(2) and R-(3) mice had neutralising
activity, a plaque neutralisation reduction assay (PRNA) was carried out to determine
the neutralisation titre (NT). The NT of the HI SFV sera were also determined
(Table 8, Figure 47). Consistent with the ELISA, HI-(2) serum had a lower NT than
HI-(3), 1.29xl06 pfu/ml serum compared to 1.54x107 pfu/ml serum. Similarly, all R-
(2) mice had a lower mean NT than R-(3) mice at PID 42, five serum samples from
each group were tested.
Serum NT/ml serum
Table 8. NT for HI sera (HI) and sera from
recipient mice (R) at PID 42. Expressed as
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Figure 47. The NT of sera HI-(2) and (3) (A) and R-(2) PID 42 and R-(3) PID 42 (B and C) were
determined by PRNA. Each dilution was tested in duplicate or triplicate in 2-fold serial dilutions
starting at 1/10. Stained monolayers (dark wells) indicate inhibition of cytopathic effect
(neutralisation of virus by anti-sera). The NT of the sera was determined against 100 pfu of SFV
(constant virus - varying antibody assay). The reciprocal of the highest dilution that inhibited
cytopathic effect was designated the NT titre.
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Passive transfer of antibody does not remove all virus from
the CNS
In SFV infected SCID mice that had received HI SFV serum, infectious virus titres in the
brain were determined by plaque assay. In experiment 2, to verify that a CNS infection
had been established, two mice were sampled at PID 4 prior to the first inoculation ofHI
SFV serum and their brains titrated to determine the titre of infectious virus. As expected
these mice had a high titre of brain virus (Figure 48A). Of the six mice sampled at PID
42, three weeks after the last HI SFV serum transfer, 100% (6/6) were positive for
infectious virus, with virus titres ranging from 2.2 - 6.1 loglO pfu/g brain. In experiment
3, mice again tested positive for infectious virus at PID 4, prior to the HI SFV serum
transfer, and no (0/5) mice were positive for virus at PID 21. At PID 42 (0/6) and at PID
63 (2/3), mice had infectious virus in the brain (Figure 48B). A non-infected control
group was included to check for any possible cross contamination, none (0/6) of these
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Figure 48. Virus infectivity titres in the brains of SFV infected SCID that received HI SFV serum
(♦). Titres were measured by plaque assay in BHK-21 cells. A - Experiment 2, mice that received
HI-(2); B - Experiment 3, mice that received HI-(3), includes uninfected control mice(«). * indicates
significant difference (p<0.05) with days 21, 42 and control groups; data were analysed by Mann-
Whitney test. Horizontal bars indicate group means, dashed line indicates limit of detection, i
indicates number and time points of passive transfer of HI-(2) and HI-(3).
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Using q-PCR, the number of copies of SFV RNA was quantified in the brains of
SFV infected SCID mice that had received HI-(2) or HI-(3) sera (Figure 49). In
experiment 2, at days 21 and 42 all (8/8) mice had virus RNA levels above the limit
of detection. The virus RNA load increased slightly from PID 21 to PID 42, from a
mean of 6.0 to 6.4 logio SFV copies, when the mice were no longer being given HI
SFV serum. As clearly shown in these two experiments, at least some of the RNA
remaining in the brains after passive transfer of antibody is capable of perpetuating
the infection. The experiment was repeated and the time of sampling was extended.
SFV infected SCID mice were given transfer ofHI-(3) and sampled at PID 4, 21, 42
and 63 (Figure 44). In experiment 3 a high virus RNA load was detectable at PID 4
in the brain of a single mouse tested (7.0 Logio) confirming the establishment of a
CNS infection. The HI-(3) serum transfer reduced the virus RNA copies from 7.0
Logio at day 4 to 5.5 Logio copies at day 21. By PID 42 the virus RNA load had
decreased further (mean 4.4 Logio) this reduction was significant (p= 0.0173). By
PID 63 however the virus RNA load had increased significantly (p=0.0238) relative
to PID 42. Samples from the control group of uninfected SCID mice were below the
limit of detection for the assay and significantly lower than all of the virus infected
mice.
Chapter 5 Role of Antibody in Virus Clearance 139
Acquired Immune Response to SFV
HK2)




































♦ ♦ » ♦
♦ ♦
♦ «v»
4 21 42 63 control
Days Post Infection
Figure 49. Titres of SFV RNA in the brains of SFV infected SCID mice that received HI SFV serum
(♦), as measured by q-PCR. A - experiment 2, mice that received HI-(2); B - experiment 3, mice that
received HI-(3), includes uninfected control (•) mice. * indicates significant difference (p<0.05); data
were analysed by Mann-Whitney test. Horizontal bars indicate the means of each group, dashed line
indicates the limit of detection for the assay. 4- indicates number and time points of passive transfer of
antibodies HI-(2) and HI-(3)
Virus RNA is still detectable 12 weeks post-infection in wild
type mice
All 3 passive antibody transfer experiments demonstrated that there could be no
infectious virus detectable by plaque assay but high levels of virus RNA in the brain.
That virus infectivity was undetectable could be due to the presence of neutralising
antibody and also that remaining virus material is RNA in the form of virus
replication complexes. As a comparison, the rate of clearance of infectious SFV (by
plaque assay) and viral RNA (by q- PCR) from the CNS of immunocompetent
(BALB/c) mice was analysed. 15 BALB/c mice, age 4-6 weeks (mixed sex) were
infected IP with SFV A7(74). Three mice per group were sampled from weeks 1 to
12 at three week intervals.
In brain tissue, infectious virus was detectable in 66% (2/3) of mice at day 7 only and
at no other time point (difference not significant by Mann-Whitney test, Figure 50A).
This is consistent with previous data that shows clearance of infectious virus from
the blood at PID 3 and from the brain at PID 7. At one week post-infection 7 Logio
copies of virus RNA were detectable by q-PCR in SFV infected BALB/c mice. This
quickly dropped (4.5 Logio copies virus RNA, difference not significant by Mann-
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Whitney test) by 3 weeks post-infection and changed little at later time points. The
limit of detection for this assay was 3.7 Logio copies virus RNA; virus RNA was
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Figure 50. Clearance of infectious virus and virus RNA in SFV infected BALB/c mice (■). A
infectious virus levels as measured by plaque assay. B virus RNA levels as measured by q-PCR.
Dashed line indicates the limit of detection, horizontal bars indicate group mean.
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Summary of findings
Acquired Immune Response to SFV
Immunocompetent mice slowly clear SFV RNA from the brain but it was
not established whether sterilising immunity is achieved
HI SFV serum transfer to SFV infected SCID mice clears infectious virus
from the brain
HI SFV serum transfer to SFV infected SCID mice lowers virus RNA
levels to those comparable with infected immunocompetent (BALB/c) mice
HI SFV serum transfers are not sufficient to bring about sterilising
immunity in SFV infected SCID mice
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Acquired Immune Response to SFV
Virus infection of the CNS poses a challenge for the immune response. Generally, in
virus infected tissues complete clearance of virus requires destruction of virus
infected cells by cytotoxic T-cells or apoptosis induction. However this action
within the CNS is potentially dangerous as many CNS cells are vital. Limiting the
spread of the pathogen by cytotoxicity is not compatible with protecting vital
terminally differentiated neurons against cytolytic and toxic immune mediators. The
propensity to dampen immune responses, combined with the limited magnitude of
the immune response in the CNS offers the opportunity for virus persistence. As a
result the CNS has highly specialised immune responses and is generally considered
an immunosuppressive environment. Antibody can mediate its action via non-
cytolytic mechanisms and has been shown in several neurotropic viruses to be crucial
in protection in both the natural course of disease and via adoptive transfers.
However, it is not known if antibody alone is sufficient to bring about sterilising
immunity in the CNS following SFV infection or if virus can become persistent in
the absence of other aspects of the adaptive immune response.
The role of antibody in CNS virus clearance was examined using HI serum transfers
to SFV infected SCID mice. Infectious virus was detected by plaque assay and virus
RNA copies by q-PCR. Although single transfers of serum have been shown to be
effective in clearing infectious virus in SFV (Fazakerley & Webb, 1987) and SV
infection (Griffin & Johnson, 1977; Hirsch, 1979), a series ofHI serum transfer over
several weeks was undertaken as this was considered more representative of the
consistently raised titre of neutralising antibody which occurs in immunocompetent
mice.
Following HI SFV serum transfer, infectious virus was not detectable by plaque
assay and virus RNA levels were decreased to levels comparable to an
immunocompetent mouse. Passive antibody transfers have been shown to mediate
virus clearance and confer protection against other neurotropic viruses. In TMEV
infection, although T-cells are essential for clearance of virus and for prevention of
demyelination lesions (Rodriguez, 1996; Kang, 2005), antibody transfer confers
partial protection against CNS infection of SCID and nu/nu mice. The passive
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transfer of antibody to TMEV infected SCID mice was found to prevent virus spread
into the grey matter in the CNS, that can cause irreversible damage and death, and
limits virus to white matter areas (Fujinami, 1989; Njenga, 1997). Antibody transfer
following rabies virus infection also protects, in both susceptible strains of mice and
young mice that would normally succumb to infection (Schumacher, 1989). In vitro
mAb was able to inhibit rabies virus transcription and spread in neurons by unknown
mechanisms (Dietzschold, 1992a). This phenomenon has also been reported in vitro
infections of neuronal cultures with SV (discussed below) (Despres, 1995). SV is
closely related to SFV, and similarly HI serum transfers have been shown to be
effective in the clearance of infectious virus and virus RNA, whereas transfer of T-
cells has no effect on viral replication (Levine, 1991; Binder & Griffin, 200 le).
In experiment 3 following the passive transfer of antibody, no infectious virus was
detectable at PID 21 or 42, but by PID 63, six weeks after the last HI serum transfer,
virus infectivity was again detectable. Two weeks ofHI serum treatment was
insufficient to clear all virus from the CNS and the virus RNA detectable at 21 and
42 days PI was not 'junk' RNA but represented infectious genomes. This confirms
observations with SV where virus recrudescence occurred after transfers ofHI serum
and purified mAb to E2 (Levine & Griffin, 1992). This effect was dose dependent.
When a high level ofmAb was given to SV infected SCID mice, there was no virus
reactivation but virus RNA was still detectable by southern hybridisation. It was not
determined whether mAb was still present and suppressing infectious SV at this time.
Virus persistence in the face of a neutralising antibody response is seen with other
neurotropic viruses. During the acute phase ofMHV infection, CD8+ T-cells clear
the virus infection but in pMT mice virus reactivation occurs after initial virus
clearance (Lin, 1999). T-cells appear to be down-regulated after the acute phase,
perhaps to limit cytotoxicity in the CNS; antibody is essential for controlling late
virus levels (Ramakrishna, 2002). A single passive transfer of anti-MHV antibody
prevents reactivation of infectious virus within the CNS of pMT mice, however
immunologic control is not maintained and as antibody titres decline, infectious virus
reactivates. The antibody response must be maintained in order to keep infectious
MHV below detection.
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As with SV, the time it took for infectious virus to become detectable following
withdrawal of passive antibody correlated with the amount of anti-SFV IgG and the
NT of the HI SFV serum. HI-(3) serum had both a higher NT and detectable anti-
SFV IgG than HI-(2) serum and took 6 weeks after the last HI serum transfer for
virus to rebound in SFV infected SCID mice. It appears that the higher NT of the
sera, the longer the virus is kept under control. However even with increased NT and
higher levels of anti-SFV IgG present in HI-(3), virus reactivation still occurred,
antibody alone was not able to bring about sterilising immunity.
In immunocompetent mice the immune response to SFV rapidly clears infectious
virus, this decrease is paralleled by the decreased levels of virus RNA. When
quantified by q-PCR, virus RNA copies dropped by 2.5 logio from 1 week post¬
infection to 3 weeks post-infection. After this point virus RNA copies did not drop
below the limit of detection of the assay. This corresponds with data from Donnelly
et al examining long-term effects of SFV infection, where viral RNA was shown to
for up to 90 days by PCR (Donnelly, 1997a). Work done on another alphavirus, SV
has shown persistence of viral RNA and long term CNS inflammation (Levine &
Griffin, 1992; Tyor, 1992c). A persistent low turnover of LCMV and MHV also
occurs after acute infection, they are kept in check by antibody response but the
immune response is unable to completely clear the virus (Lin, 1999; Ciurea, 1999b).
Following the development of the sensitive q-PCR to measure virus copies it would
be interesting to extend study of SFV persistence to determine if virus RNA is
eventually cleared and if so at what time point.
SFV infected BALB/c mice had similar levels of virus RNA at PID 21 as SCID mice
that received passive antibody transfers and showed similar kinetics of infectious
virus clearance, this suggests that antibody alone is the main mechanism of virus
clearance used in immunocompetent mice. Other data (Chapter 3 & 4) have shown
that the presence ofCD8+ T-cells and IFNy can speed up this process, but do not
have an effect on the overall decrease in virus RNA in the CNS.
Antibody is generally thought to mediate virus clearance by three mechanisms.
Neutralisation, blocking virus binding or entry to target cells; virus opsonisation, the
uptake of virus by phagocytes via Fc receptors and complement activation. Another
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mechanism has been suggested (Levine, 1991), specifically in the CNS, which is
separate from virus neutralisation, where antibody interacts with virus antigen on the
infected cell and can affect virus transcription. This novel mechanism has been put
forward for a number of viruses. In rabies infection a mAb was found to inhibit
RNA transcription in tissue culture, possibly by uptake of the antibody-antigen
complex by the cell (Dietzschold, 1992b). In SV infection in rat neuronal culture the
addition ofmAb to envelope protein E2, which can be detected on neuronal surfaces,
decreased cytopathic vacuoles and rough ER associated with virion production and
stopped viral replication (Levine, 1991; Despres, 1995). However such viral
modulation does not always favour the host. This is the case with measles virus.
The application of mAb to measles hemagglutinin in neuronal culture reduced
measles virus gene expression by 80% in 6 days reducing both intracellular viral
structural proteins and virus specific transcription. As always protection in vitro
does not necessarily translate into protection in vivo, as there are heterogeneous cell
types present in the CNS and far more systems interacting than in a homogenous
tissue culture flask. In vivo, mAb initially protects against acute encephalopathy in
newborn Lewis rats, these same animals go on to develop antibody induced acute
measles encephalitis (Liebert, 1990; Schneider-Schaulies, 1992). The exact
mechanism of how antibody inhibits virus transcription or gene expression is not
fully understood. The efficacy of antibody alone in clearing virus is conflicting,
measles virus persists in the face of a specific antibody response, antibody clears
infectious SV but virus RNA is still detectable and in animals infected with rabies,
clearance of infectious virus and virus RNA occurs. If antibody is able to restrict
neuronal virus replication in SFV infection, as suggested in SV, it is not sufficient to
suppress all virus replication in the CNS. It could be that antibody is insufficient to
completely stop virus replication or the actions of antibody are restricted to particular
cell types. Further investigation into the cell types that harbour persistent infection
following passive antibody transfer is needed to address these questions.
In this chapter the system ofHI serum transfer used demonstrated that antibody alone
is not sufficient to achieve sterilising immunity in SFV infection; a reservoir of virus
persists either as whole virus or intracellular virus genomes that can reactivate after
antibody has been cleared from the system. It is possible that a much longer transfer
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of serum could prevent viral reactivation, as seen in SV, but it cannot be ruled out
that remaining antibody was inhibiting replicating virus. In wild type mice, low
levels of virus RNA are still detectable after infection and long term antibody
production and raised white cell counts are seen following SFV infection (Parsons &
Webb, 1982h). It seems a likely possibility that this is due to virus persistence at a
low level that is kept under control by an enduring immune response to the virus.
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Summary of findings
Chapter 3 - The role of CD4+ and CD8+ T-cells in SFV
infection
• Mice lacking CD4+ T-cells are unable to make a complete antibody
response to SFV
• Mice lacking CD4+ T-cells are unable to clear infectious virus or virus
RNA from the brain
• Mice lacking CD8+ T-cells show no difference in their ability to clear
infectious virus from the brain compared to wild-type mice
• Mice lacking CD8+ T-cells are significantly slower at clearing of SFV
RNA from the brain compared to wild-type mice
• CD8+ T-cells are sufficient to mediate the demyelinating lesions observed
in SFV infected SCID mice that receive T-cells by adoptive transfer
• SFV can successfully infect cells in the CNS of C57B1/6 mice
Chapter 4 - The role of selected CD8+ T-ceii mediators in SFV
infection
• IFNyR"/_mice show no difference in their ability to clear infectious virus
from the brain as compared to wild-type mice
• IFNyR"'" mice have slower clearance of SFV RNA from the brain as
compared to wild-type mice
• IFNy is not required for the development of demyelinating brain lesions in
SFV infected mice
• Recombinant IFNy transiently protects SFV infected IFNa/pR"7" mice
• Neither perforin nor Fas are required for clearance of infectious virus or
viral RNA from the brain
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• SFV infected Faslpr mice have increased CNS demyelination compared to
wild-type mice
Chapter 5 - The role of antibody in clearance of SFV from the
CNS
• Immunocompetent mice slowly clear SFV RNA from the brain but it was
not established whether sterilising immunity is achieved
• HI SFV serum transfer to SFV infected SCID mice clears infectious virus
from the brain
• HI SFV serum transfer to SFV infected SCID mice lowers virus RNA
levels to those comparable with infected immunocompetent (BALB/c) mice
• HI SFV serum transfers are not sufficient to bring about sterilising
immunity in SFV infected SCID mice
Discussion
This thesis has examined the contributions of different components of the acquired
immune response to clearance of both infectious SFV and SFV RNA from the CNS
of infected mice and examined whether the immune response, specifically the
antibody response, can bring about sterilising immunity. CNS demyelination
observed following SFV infection has an immune-mediated aetiology (Fazakerley &
Webb, 1987) and the role of components of the acquired immune response in
inducing the pathological changes (demyelination and microcystic changes) observed
following infection were investigated.
The use of q-PCR for the first time, allowed the accurate detection and quantitation
of SFV RNA at low levels. Q-PCR although not more sensitive than standard PCR,
the generation of a melting curve authenticates the presence of the specific amplicon
and the use of the absolute standard curve allows quantification of virus RNA levels
and comparison between samples not achievable with standard PCR (Bustin, 2000).
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A limitation of q-PCR is that detection of virus RNA does not necessarily indicate
the presence of replicating viral genomes, and consequently care must be taken when
interpreting q-PCR data. Data from q-PCR complements virology techniques, such
as plaque assay (for infectious virus). An important consideration in interpreting
infectivity assay data, such as plaque assays, is that these assays inevitably involve
homogenisation of tissues which can result in antibody neutralisation of infectious
virus at the time of the assay. Viral persistence is an outcome of several CNS viral
infections and q-PCR is a useful tool in determining the level of virus clearance.
This study demonstrates a novel use of this technique in studying alphaviruses
persistence.
A role for CD8+ T-cells in immune mediated pathology in the
CNS
CD8+ T-cells migrate into the CNS in response to infection as demonstrated by the
phenotyping of CNS lymphocytes in chapter 3. This thesis demonstrates by the
transfer of activated CD8+ T-cells to SFV infected SCID mice that CD8+T-cells are
sufficient to mediate demyelinating lesions present in SFV infected brains. A
previous study examining the role of CD8+ T-cells in this process used antibody to
deplete CD8+ T-cells (Subak-Sharpe, 1993), however this depletion was transient.
The system used here is an improvement on these depletion studies as SCID mice
have no B or T lymphocytes and a pure population of CD8+ T-cells was transferred
(97%). The results shown here compliment and agree with the finding of Subak-
Sharpe; antibody depletion of CD8+ T-cells prevents demyelination in SFV infected
immunocompetent mice (Subak-Sharpe, 1993) and adoptive transfer of highly
purified population ofCD8+ T-cells induced demyelination in SFV SCID mice. The
adoptive transfer also substantiates the Morris et al. study where CD8+ T-cells are
found at sites of demyelination in SFV infection (Morris, 1997).
The role of CD8+ T-cells in causing immunopathological changes is well established
in other CNS virus infections. Neurotropic MHV infection of SCID mice results in
persistent infection without demyelination, however the transfer of CD8+ T-cells is
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sufficient to initiate demyelination (Murray, 1998b). CD8+ T-cells generated in the
response to Borna disease virus mediate fatal neuronal destruction and brain tissue
loss (Bilzer & Stitz, 1994; Hausmann, 2001) and IC injection of LCMV induces fatal
meningitis caused by anti-viral CD8+ T-cells (Baenziger, 1986c; Dixon, 1987a).
CD8+ T-cells are key effectors in virus clearance and activated T-cells are able to
cross the BBB. The lytic capacity of CD8+ T-cells makes them effective at clearing
virus, as the only way to completely clear a virus infection from tissues is by removal
of infected cells. However, this characteristic makes these cells dangerous in the
CNS, as exemplified by the fatal encephalitis induced by CD8+ T-cells in LCMV
infection.
There is a fine balance between virus clearance and the development of
immunopathological changes in the CNS. While a strong CD8+ T-cell response can
clear virus, if viral clearance is not executed rapidly, virus can spread further within
the CNS and more extensive CNS tissue damage (viral lysis or immune mediated)
can occur through direct cell lysis and bystander activation. For example, following
TMEV infection differing efficiencies of antigen presentation to CD8+ T-cells in
resistant and susceptible mice determines the rate at which virus is cleared and
whether CNS damage will occur (Dethlefs, 1997a).
Once CD8+ T-cells are active in the CNS, their response can be regulated, as shown
by the down-regulation of CD8+ T-cell activity during the transition from acute to
chronic MHV infection. It is not known what causes this down-regulation of the
CD8+ T-cell response but it serves to limit the on-going demyelinating disease
(Stohlman, 2002b).
It was not possible to establish what CD8+ T-cell mechanism(s) caused the
demyelinating lesions observed in SFV infection. IFNy was not necessary for
demyelination, and due to the background strain of the perforin and Fas deficient
mice (C57B1/6) which did not develop demyelination; it was not possible to conclude
if these mediators contributed to demyelination in susceptible mouse strains. The
effector mechanisms involved in demyelination could be perhaps determined by
transfer of CD8+ T-cells from perforin and Fas deficient mice to SFV infected SCID
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mice. However, this would require crossing the currently available perforin and Fas
deficient mice (on the C57B1/6 background) onto a BALB/c background.
The data shows that CD8+ T-cells are sufficient to mediate demyelinating lesions in
SFV infection. The antibody transfer in SCID mice can reduce infectious virus to
undetectable and virus RNA loads to very low and CD8+ T-cells are not required to
reduce infectious virus to undetectable and virus RNA loads to very low in
immunocompetent mice. The CD8+ T-cell mediated demyelination is a clear
example of immunopathology however, whether this response is necessary for
complete eradication of the virus remains unclear.
The use of non-cytolytic mechanism by CD8+ T-cells to
contribute to virus RNA clearance in the CNS
By using mice genetically deficient in CD8+ T-cells and IFNy, it was successfully
demonstrated that both these effectors contribute to the clearance of virus RNA from
the CNS. There was no difference in infectious virus clearance between the
knockout mice and wild-type mice, however, the use of q-PCR allowed more subtle
differences in virus titres to be observed. The results in this thesis indicate that IFNy
plays a key role in the anti-SFV CD8+ T-cell response and that non-cytolytic
mechanisms are involved in clearance of virus RNA from the brain.
CD8+ T-cells can recognise early viral proteins produced intracellularly before virus
budding occurs. This recognition allows an early anti-viral response which can result
in killing of infected cells or in the release of pro-inflammatory cytokines, notably
IFNy. IFNy can induce an antiviral state so preventing further viral infection and
restricting virus replication. CD8+ T-cell's ability to recognise viral infection early
and to non-lytically restrict viral replication (by use of IFNy) makes them valuable in
viral CNS infection.
The roles of CD8+ T-cells and IFNy in virus RNA clearance are supported by studies
on SV infection, where CD8a mice were also found to clear virus RNA at a slower
rate (Kimura & Griffin, 2000). The ability of IFNy to control virus replication was
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studied using a SV construct expressing IFNy, which could clear virus from spinal
cord neurons and certain areas of the brain in SCID mice (Binder & Griffin, 2001a).
The importance of non-cytolytic, anti-virus factors of CD8+ T-cells has been
demonstrated in other CNS virus infections. Persistent LCMV infection requires
IFNy secretion in order to clear virus (Tishon, 1993). Infectious MHV is not cleared
from the brains of mice deficient in IFNy, they also have increased clinical signs and
higher mortality rates than wild-type mice, consistent with persistent infection. Virus
antigen was found almost exclusively in oligodendroglia in MHV infected IFNyR7"
mice, demonstrating that IFNy alone restricts virus replication in this cell type (Parra,
1999d). The neuronal replication of VSV in vitro and in vivo is restricted by IFNy
induced nitric oxide synthase induction (Komatsu, 1996b).
CD8+ T-cells contribute to SFV clearance in the CNS and the use of non-cytolytic
mechanisms by CD8+ T-cell in the CNS seems prudent in the presence of a non¬
renewable cell population, as it allows antiviral function of CD8+ T-cells to be
utilised whilst limiting direct pathology through lytic mediators. Lytic mediators do
not appear to have an important role in the clearance of SFV from the CNS, as the
absence ofperforin and Fas mediated cell lysis did not affect SFV clearance from the
brain. Antibody although crucial, is not the only mediator that affects virus
clearance. However, it was not established if CD8+ T-cell secretion of IFNy is
essential for complete virus clearance or if it increases the rate at which virus is
cleared.
It is known that IFNy can contribute to virus clearance; however, this is the first
study to demonstrate that mice lacking IFNy have significantly slower clearance of
alphavirus RNA from the CNS than wild type mice. It was also demonstrated that
CD8+ T-cells are the main source of IFNy, as CD8a mice also had significantly
slower clearance of virus RNA.
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Is sterilising immunity ever achieved following CNS virus
infection?
The question of whether sterilising immunity occurs in CNS virus infection was
addressed in this thesis using two methods. In the first experiment a series of
transfers ofHI SFV serum to SFV infected SCID mice were carried out to examine
the extent to which antibody alone can clear SFV from the CNS. Previous studies
examining the role of antibody in viral CNS clearance have used a maximum of three
antibody transfers. The advantage of giving six transfers was that it maintained a
high titre of neutralizing antibody in the SFV infected SCID mice over a longer
period and so was more representative of the enduring immune response seen in
immunocompetent mice. It was demonstrated that antibody alone was sufficient to
protect mice in SFV infection and to clear infectious virus. However, sterilising
immunity was not achieved by HI transfers to SFV infected SCID mice, as virus
RNA was still detectable in brain tissue at all time points, and more critically, when
antibody titres were allowed to decline, infectious virus was once again detectable.
Antibody was capable of reducing virus RNA levels in the CNS in SFV infected
SCID mice to those comparable with immunocompetent mice. Leading on from this
observation, a second experiment investigated whether all virus RNA is cleared from
the CNS of immunocompetent mice. At 12 weeks post-infection virus RNA was
detectable in immunocompetent BALB/c mice. This raises the possibility that
sterilising immunity may not be achieved in immunocompetent mice or may take
much longer (many months) to be achieved after infectious virus is last detected.
This theory is supported by data from other studies with SFV. Not only was SFV
RNA detected by PCR in the CNS for up to 90 days post-infection in
immunocompetent mice (Donnelly, 1997b), but persistently raised white cell counts
and immunoglobulin titres have been detected in the cerebrospinal fluid up to PID 61
(Parsons & Webb, 1982a; Parsons & Webb, 1982d). This supports the concept that
SFV persists in the CNS; a continued immune response to the pathogen may keep
virus levels at the threshold of detection. In another study suppression of the
immune response to SFV in immunocompetent mice by cyclophosphamide (a
chemotherapeutic drug which is cytotoxic to rapidly proliferating cells such as
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lymphocytes) administration at 80 weeks post-infection resulted in infectious virus
detection in the CNS. No infectious virus was detectable in control mice that did not
receive cyclophosphamide. This suggests that over a year after SFV inoculation
virus infection is being controlled rather than eliminated by the immune response
(Fazakerley, 1985). A similar slow rate of virus clearance occurs with the related
alphavirus SV. Virus RNA was detectable by PCR at 6 months post-infection and
anti-SV plasma cells, which continually secrete antibody, were detected 1 year post¬
infection (Tyor, 1992a).
The terminally differentiated cells and specialised immune system of the CNS makes
complete virus clearance difficult and therefore the outcome of infection of the CNS
with RNA viruses is frequently persistent infection. Possible mechanisms of virus
persistence for RNA viruses include infection of immunospecialised sites (CNS),
non-lytic replication cycles and antigen expression in the thymus (resulting in
tolerance induction). Neo-natal LCMV infection, results in thymic expression of
viral antigens during T-cell development and virus specific T-cells are deleted; in the
absence of specific immunity persistence occurs. In diseases associated with late
complications ofmeasles infection, subacute sclerosing pan-encephalitis and measles
inclusion-body encephalitis, virus particles cannot be isolated due to restricted
replication of the virus in the CNS, but viral persistence occurs. Transcription of
viral genes involved in budding and maturation are reduced but genes for replication
and transcription are maintained (Ahmed & Chen, 1999). Even in the face of a
specific immune response virus can persist, in the case ofMHV infection a strong
acute response which clears infectious virus, but antibody secreting plasma cells are
still detectable at 90 days PI, viral antigen one year PI and virus RNA two years PI
(Knobler, 1982b; Fleming, 1995; Stohlman, 2002a), additionally, demyelinating
disease also occurs months following infection indicating persistent infection.
It appears that virus persistence is a trade off for the protection of neurons. For
sterilising immunity to be achieved, all replicating virus needs to cleared from all
infected cells. The most efficient was to achieve this is to kill infected cells but in
the CNS this is not an option as the destruction of irreplaceable key neurons can have
fatal consequences. In general CNS virus infections are limited and often result in
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persistence rather than clearance of infection. There are a number of factors which
contribute to this situation. The immune response as a whole in the CNS is less
efficient than in peripheral tissues, because there are no lymphoid organs, limited
access for leukocytes, antibody and complement, and limited MHC I expression.
Furthermore, neurons are protected from immune-mediated damage by several
mechanisms including; the absence ofMHC expression, an ability to prevent
perforin- mediated damage and that they do not easily undergo apoptosis compared
to renewable nerve cells, such as the neurons of the olfactory bulb.
It has been suggested that the continued presence of antigen serves to benefit the host
through the continued stimulation of the immune response and the maintenance of
memory. Low quantities of antigen can stimulate and help maintain the memory
response of B and T lymphocytes resulting in more rapid clearance if subsequent
infections should occur (Klenerman, 1997).
To demonstrate if antibody is necessary to control persistent infection the selective
depletion of B-cells by murine anti-CD20 antibody could be used. CD20 is a marker
found on all mature B-cells. This system has been shown to be effective in the
treatment of antibody- mediated autoimmune disorders in humans using Rituximab
(human anti-CD20 antibody). Anti-CD20 treatment has been shown to deplete B-
cells by both AICD and by directly stimulating apoptosis, however the efficacy of
anti-CD20 on all B-cell populations has not been proved (Silverman, 2006).
Immunocompetent mice would be infected with SFV and left for 6 months. The B-
cell population would then be ablated many months post-infection by antibody
administration. Mice would now be sampled for the presence of infectious virus. To
ensure the complete elimination of B-cells and antibodies cyclophosphamide could
also be administered in conjunction with anti-CD20, as this would inhibit
lymphocyte function and prevent clonal expansion of existing lymphocytes. If
infectious virus was recoverable after the B-cells had been depleted this would
demonstrate that SFV does persist and that infectious virus is controlled in the long-
term by antibody.
Whether sterilising immunity can be induced following SFV infection remains to be
answered. The data shown here and in previous studies suggests that sterilising
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immunity is not achieved, however further evidence is need to answer this question
conclusively.
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